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Sea Change: A Marine Knowledge, Research & Innovation Strategy for Ireland
Sea Change—A Marine Knowledge, Research & Innovation Strategy for Ireland 2007-2013—was launched in
early 2007 and was the outcome of extensive analysis and consultation with government departments, state
agencies, industry and the third-level sector.  It outlines a vision for the development of Ireland’s marine sector
and sets clear objectives aimed at achieving this vision, namely to:
1. Assist existing, and largely indigenous, marine sub-sectors to improve their overall competitiveness 
and engage in activity that adds value to their outputs by utilising knowledge and technology arising 
from research. 
2. Build new research capacity and capability and utilise fundamental knowledge and technology to 
create new marine-related commercial opportunities and companies. 
3. Inform public policy, governance and regulation by applying the knowledge derived from marine 
research and monitoring. 
4. Increase the marine sector’s competitiveness and stimulate the commercialisation of the marine 
resource in a manner that ensures its sustainability and protects marine biodiversity and ecosystems. 
5. Strengthen the economic, social and cultural base of marine dependant regional/rural communities. 
The Sea Change strategy was developed as an integral part of the government’s Strategy for Science, Technology
and Innovation (SSTI) and the Marine Institute as the lead implementation agency is working within SSTI 
policy and with government departments and agencies to deliver on the Strategy.  
The Marine Institute managed Marine Research Sub-Programme, one of eight sub-programmes within the
Science, Technology and Innovation (STI) Programme of the National Development Plan 2007—2013, targets
funding to meet the objectives of the Sea Change strategy.
Over the lifetime of Sea Change, funding will be provided for:
• Project-Based Awards
o Strategic Research Projects
o Applied Research Projects
o Demonstration Projects
o Desk/Feasibility Studies
• Researcher Awards
o Strategic Research Appointments
o Research Capacity/Competency Building
o Post-Doctoral Fellowships
o PhD Scholarships
• Industry-Led Research Awards
o Company Awards
o Collaborative Awards
• Infrastructure Awards
o Infrastructure Acquisition
o Access to Infrastructure
The Marine Institute is the national agency which has the following functions:
“to undertake, to co-ordinate, to promote and to assist in marine research and development and to provide
such services related to research and development that, in the opinion of the Institute, will promote 
economic development and create employment and protect the marine environment” 
Marine Institute Act 1991.
Further copies of this publication can be obtained from: 
Marine Institute, Rinville, Oranmore, Co. Galway, Ireland or www.marine.ie
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1. Executive Summary
1.1. Background
Since the Irish monitoring program was set up in 2001 azaspiracids (AZAs) have been detected 
in shellfish above the regulatory limit every year with the exception of 2004 (Figure 1). The 
SouthWest coast of Ireland is especially prone to the onsets of AZA events. Over this period a 
number of poisoning incidents associated with this toxin group have occurred, all related to Irish 
shellfish (Table 1). In 2003 the Marine Institute was awarded funding for a research project named 
ASTOX. This project was very successful in producing a range of reference materials (RMs), which 
are essential for accurate detection and monitoring, and which up to this point were unavailable. 
The project also examined the toxicity of AZAs, primarily using in vitro cell assays but some in vivo 
studies were also performed. Functional assays based on lymphocyte T (Jurkat) and Caco-2 cells 
were developed and both indicated that AZAs are cytotoxic. A study on medaka fish embryos found 
AZAs to be teratogenic, while mouse studies revealed multiple organ damage. Although much was 
learned about the toxicity of AZAs, the mode of action still remained elusive. Additional questions 
remained regarding the causative organism, effects of exposure to combined groups of toxins, oral 
toxicity and bioavailability.
1.2. Project aims
The overall aims of the ASTOX 2 project were to strengthen knowledge on the causative organism 
and toxicity of AZAs. The project aims were grouped into three areas: ecology, chemical support 
and toxicology.
The project was designed to investigate the primary causative organism(s) and address the trophic 
transfer of AZAs through the marine food web. The identification and monitoring of the producing 
organism(s) using molecular probes would enable more effective management of shellfish production 
zones (warning system for onset of blooms). 
Chemical support outcomes were to include the provision of purified AZA analogues for the 
preparation of RMs (to ensure sustainable supplies for monitoring laboratories) and for toxicological 
assessment. Suitably contaminated feed was additionally to be prepared for the in vivo studies. 
Validated methods of analysis were to be developed for the analysis of phytoplankton and animal 
tissues and to explore stability, metabolism and bioavailability. 
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The toxicological studies were aimed at answering four major questions:
 • What are the molecular targets of AZAs in mammalian cells i.e., the mode of action at 
molecular level?
 • What is the pharmacokinetic behaviour of AZAs?
 • What are the relative toxicities of AZAs? 
 • What are the possible consequences of the co-occurrence of AZAs with other lipophilic 
shellfish toxins?
The project incorporated the use of in vitro (Jurkat T lymphocytle cell) and in vivo (mouse and pig) 
assays to try and answer these questions. Information from these toxicity studies was necessary to 
underpin or revise the current risk assessments.
1.3. Producing organism(s) and culturing
1.3.1. Identification of new and related Azadinium species
In 2007, whilst on a survey in the North Sea, Alfred Wegener Institute scientists discovered a small 
(10–15 µm in length) photosynthetic thecate dinoflagellate, subsequently named Azadinium spinosum, 
that was found to produce AZA1 and -2. Over the course of the ASTOX 2 project eight additional 
Azadinium species (A. obesum, A. poporum, A. polongum, two varieties of A. caudatum, A. dalianense and 
three other species (yet to be named)) were identified, in addition to a related species Amphidoma 
languida. Yet another Azadinium species was discovered by an Italian research group off the coast of 
Naples subsequently named Azadinium dexteroporum.
Thus currently there are 11 species (three of which are not yet formally described), reflecting a rapidly 
increasing body of knowledge on the diversity of this genus, considering the short interval since this 
first identification of Azadinium. Some of the species are available as multiple strains. It is noteworthy 
that multiple strains of the type A. spinosum from different locations have consistently been found to 
produce AZA1, -2 and -33. The next two species, including A. poporum, have initially been described 
as non-toxigenic, as none of the known AZAs were found. However, with the recent detection of 
new AZAs in two species, including A. poporum, it became evident that the species diversity within 
this group is also reflected by a high chemical diversity, with AZA production even found in the 
related genus Amphidoma. In particular, A. poporum turned out to be a rich source of different AZA 
compounds, but with a large variability of AZA-profile among different strains.
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1.3.2. Quantitative analysis of A. spinosum
A. spinosum cells were collected from bioreactor cultures, using centrifugation or filtration. 
Different extraction procedures were evaluated for formation of methyl-ester artefacts, yield, and 
matrix effects. Filtration of cultures using glass-fibre filters led to increased formation of methyl-
esters. Hence centrifugation is recommended for recovery of cells. The type of extraction solvent 
(methanol, acetone, acetonitrile) did not significantly affect the yield of AZAs so long as the organic 
content was 80% or higher. However, the use of methanol led to increased formation of methyl-
ester artefacts. AZA1 recovery over two successive extractions was 100% at 95% confidence level 
for acetone and methanol. In standard addition experiments, no significant matrix effects were 
observed in extracts of A. spinosum or A. obesum up to sample intake of 4.5×109 µm3. Moreover, 
experiments carried out to clarify the formation and structure of methylated AZA analogues, led to 
the description of two new AZAs and the correction of the chemical structures of AZA29–32.
1.3.3. Nutritional and environmental parameters affecting toxin production
An in depth study on the environmental parameters affecting toxin growth and toxin production of 
A. spinosum was performed. Growth rate and maximum cell concentration were highest at 35 psu, at 
temperatures between 18 to 22 °C, and with aeration. Concerning AZA cell quota, the most significant 
effect was observed at low temperature; the AZA cell quota was more than 20 times higher at 10 °C 
(220 fg/cell) than at temperatures between 18 and 26 °C. High irradiance also enhanced (but to a lesser 
degree) cell quotas. Low K modified medium concentration (0.5 Kmod) improved AZA cell quota 
while higher concentration (2 Kmod) improved maximal cell concentration in the photobioreactor. 
1.3.4. Bulk culturing
Continuous pilot scale culturing was carried out to evaluate the feasibility of AZA production using A. 
spinosum cultures. Algae were harvested using tangential flow filtration or continuous centrifugation. 
AZAs were extracted using solid phase extraction (SPE) procedures, and subsequently purified.  
When coupling two stirred photobioreactors in series, cell concentrations reached 190,000 and 
210,000 cells/mL at steady state in bioreactor 1 and 2, respectively. The AZA cell quota decreased as 
the dilution rate increased from 0.15 to 0.3 per day, with optimum toxin production at 0.25 per day. 
After optimisation, SPE procedures allowed for the recovery of 79 ± 9% of AZAs (AZA1, -2, -33 
and -34). 
Harvesting of A. poporum cultures was also performed. Approximately 300 L of each strain was 
grown to high density (>100,000 cells/mL) in 5 L flasks using gentle aeration. Lipophilic toxins were 
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harvested by adding HP-20 to cultures where cells had been lysed by acetone addition (7% final 
concentration). HP-20 was subsequently collected, dried, and extracted with 100% acetone to get a 
crude extract containing the previously undescribed toxins AZA36 and -37. 
1.4. Molecular probes
A molecular probe was developed specifically for the detection and discrimination of A. spinosum, A. 
obesum and A. poporum. Good correlation was observed between results from the molecular probe 
analysis of seawater and the results of chemical analysis of shellfish samples. This probe will serve as 
a very useful tool in the effective monitoring of AZA producing organisms in seawater samples.  
1.5. Trophic transfer and metabolism
1.5.1. Vector species
Preliminary studies with copepods found that these plankton grazers ingested minor amounts 
of A. spinosum and almost no AZA accumulation was found. Of the protistan grazers that were 
investigated the large ciliate Favella ehrenbergii showed substantial toxin accumulation.
1.5.2. Trophic transfer – toxin accumulation and biotransformation
Two separate experiments were performed, involving the feeding of Mytilis edulis on A. spinosum 
both at the MI and at Ifremer. The original algal toxins AZA1 and -2, as well as mussel metabolites 
AZA3 to 12, -17, -19, -21 and -23 were found during these trials. After as little as 6 h, AZA contents 
in mussels reached the EU regulatory limit (160 µg/kg), and metabolites were observed in all 
conditions at ~25% of the total AZA content. This increased to 50% after 24 h, and continued to 
increase until the end of the studies. AZA17 and -19 were found to be the main metabolites, with 
AZA17 concentrations estimated to be in the same order of magnitude as that of the main algal 
toxin, AZA1. A previous study showed that AZA3, -4, -6 and -9 are formed when shellfish are 
cooked due to the chemical conversion (thermally driven) of AZA17, -21, -19 and -23 respectively.
1.5.3. Dissolved AZAs
Experiments were performed to determine whether dissolved AZAs released from decaying blooms 
of A. spinosum could be relevant for the shellfish industry; human health; or play a role in ecological 
interactions with other aquatic organisms (e.g., bivalve larvae, plankton, fish embryos). In the study, 
two levels of cellular concentrations were investigated using lysed A. spinosum cells and the results 
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compared with those using live A. spinosum cells. The conditions corresponded to a bloom of 
1×105 cells/mL of A. spinosum and a more realistic scenario of a bloom of 1×104 cells/mL. The study 
showed that dissolved AZAs were bioavailable for mussels and that AZA accumulation may reach 
concentrations above the regulatory limit and thus might be considered as a food safety issue. 
Additional experiments to assess the ability of mussels to produce AZA metabolites by exposure to 
semi-purified AZA resulted in formation of metabolites, however, the conversion efficiency and the 
recovery were too low to justify using this procedure for preparative isolation.
1.5.4. Effects of A. spinosum on feeding behaviour and physiology
A study was designed to compare the feeding behaviour of mussels fed toxic and non-toxic diets of 
A. spinosum and Isochrysis aff. galbana (T-Iso), respectively. Physiological factors such as feeding time 
activity (FTA), clearance rate (CR), filtration rate (TFR) and absorption rate (AR) were followed to 
confirm the negative effect of A. spinosum on mussels. 
A. spinosum had a significant effect on mussel feeding behaviour compared to T-Iso: CR was lower 
by a factor of 6, FTA by a factor of 5, TFR by a factor of 3 and AR even decreased to negative values 
for the last day of exposure. Furthermore, direct feeding with A. spinosum revealed slightly increased 
mussel mortality and negative effects on the thickness of mussel digestive gland tubules compared 
to the non-toxic diet. These results show a negative effect of A. spinosum on blue mussel feeding 
activity and indicate a possible regulation of AZA uptake by decreasing filtration and increasing 
pseudofaeces production. 
1.6. Isolation and reference materials
1.6.1. Isolation from shellfish (Mytilus edulis)
Research into analytical methods, chemistry, metabolism and toxicology of AZAs has been severely 
constrained by the scarcity of high-purity AZAs. Consequently, since their discovery, considerable 
efforts have been made to develop methods to isolate AZAs in sufficient amounts and purities 
for toxicological studies, in addition to the preparation of calibrant RMs. A seven-step procedure, 
involving a series of partitioning and column chromatography steps, was improved (compared with 
previously reported procedures) for the isolation of AZAs. Recoveries increased 2-fold (to ~52%) 
compared to the method employed in the ASTOX project and led to the isolation of 12 AZA 
analogues (seven of which were fully characterized for the first time).
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1.6.2. Isolation from phytoplankton
The preparative isolation procedure developed for shellfish was optimised for algal extracts (A. 
spinosum and A. poporum), such that only four steps were necessary to obtain purified AZA1 and -2. 
A purification efficiency of ~70% was achieved, and isolation from 1,200 L of culture yielded 9.3 mg 
of AZA1 and 2.2 mg of AZA2 (purities >95%). This work demonstrated the feasibility of sustainably 
producing AZA1 and -2 from A. spinosum cultures. In addition to AZA1 and -2, sufficent amounts of 
AZA33, -34, -36 and -37 were isolated for structural determination by NMR and toxicity assays.
Purity and structural determination were performed by LC-MS/MS, LC-UVD and NMR. Overall 16 
AZA analogues were purified. 
1.6.3. Reference materials (RMs) and proportions in shellfish
Calibrant RMs were prepared for each analogue and subsequently used for identification and accurate 
quantitation in cooked Mytilus edulis shellfish extracts. AZA1, -2, -3 and -6 were found to be the most 
relevant toxins in terms of proportions. Very high levels of AZA3 (2.5-fold that of AZA1) and -6 (2.5-
fold that of AZA2) were found in some samples. This finding is significant considering the EU stipulates 
that raw shellfish be analysed, with only AZA1, -2 and -3 being regulated for, which means that levels of 
AZA equivalents may be underestimated in shellfish under current monitoring practices. 
1.6.4. Certified reference materials (CRMs) 
A number of CRMs are currently available from the NRCC that were produced as part of the 
ASTOX project. Stocks isolated as part of the ASTOX 2 project will ensure the supplies of AZA 
calibrants will be sustained.
1.7. Toxicity
1.7.1. In vivo
1.7.1.1. Pig feeding study
Pigs are often used in toxicology studies because they have similar anatomical and physiological 
characteristics to humans, including the cardiovascular, urinary, integumentary and digestive systems. Two 
trials were performed whereby mini-pigs were fed AZA1, -2 and -3 contaminated feed at a dosage of 
~350 µg/kg (i.e., 120 g of feed with an AZA concentration of 23 µg/g (144 times the regulatory limit) fed 
to an 8 kg pig). During the trials, no sickness (diarrhea, vomiting, etc) was noticed, however, the following 
was observed:
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 • Pigs were slightly drowsy after 24 h compared with the control
 • Analysis of blood samples revealed AZA concentrations peaked ~4 h after feeding
 • Histology showed some cell damage to the duodenum villi, jejunum, ileum, colon, and 
liver
 • Enzyme expression characteristic of liver damage was observed in haematology
 • Prolonged food retention (compared to control) possibly due to reduced GI tract 
mobility
 • Chemical analysis of mini pig samples showed wide distribution of AZAs throughout the 
body, thus, AZAs were absorbed from the feed across the intestine
 • Phase 2 metabolism is likely to play a significant role as only 14% of administered AZAs 
were accounted for
1.7.1.2. Mouse intraperitoneal (ip) study
The current regulatory limits are based on the initial mouse studies (ip) performed by Satake et al 
(1998) and Ofuji et al (1999) which indicated higher toxicity for AZA2 and -3 relative to AZA1. The 
study was repeated producing similar results for AZA2 (117 µg/kg) and -3 (164 µg/kg) but a lower 
LD50 (higher toxicity) for AZA1 (74 µg/kg). In parallel, the LD50 was determined for AZA6 (100 µg/
kg) for the first time.
Chemical analysis of the tissues revealed wide distribution with similar distribution profiles for each 
toxin. Higher recoveries were observed for AZA1 and -2 (~15–37%) while only 2–15% of AZA3 
could be accounted for possibly due to the greater instability of this compound. 
1.7.1.3. Mouse oral study
Limited data was previously available on the oral toxicity of AZAs with studies only performed on 
AZA1 which showed that the GI tract, liver, spleen and thymus are the main organs affected. A study 
was performed for AZA1, -2 and -3 and the results were very similiar to those obtained in the ip study.
Chemical analysis of the tissues revealed wide distribution of toxin. Higher recoveries were observed 
for AZA1 and -2 (~4–19%) while lower recoveries were obtained for AZA3 (2–8%) after 24 h.
NDP Marine Research Sub-Programme 2007-2013   
8
1.7.1.4. Combined toxicities (mouse oral)
AZAs have been shown to co-occur with other toxin groups (OA group toxins in Ireland and YTX 
in Norway), therefore it was important to investigate whether exposure to combinations of these 
toxins could have additive, synergistic or antagonistic effects.
Oral mouse studies demonstrated no additive or synergistic effect on lethality or absorption into 
the body when administered in combination with OA. Similar results were obtained in a separate 
experiment examining combinations of AZA1 and YTX. The results indicate that combinations of 
these toxin groups in shellfish does not present an increased risk for consumers.
1.7.2. In vitro
1.7.2.1. Mode of action studies
A series of screening experiments were performed whereby the effects of AZA1 towards various 
ion channels were directly monitored. A distinct and significant inhibition of the hERG (a gene that 
codes for an ion channel protein) potassium channel was observed. Further exploration of this 
phenomenon demonstrated that AZA1–3 were open state blockers of hERG potassium channels. 
These channels are best known for their contribution to the electrical activity that co-ordinates 
the heart’s beating, but are additionally transcriptionally expressed in a broad array of other cell/
tissue types including the brain, liver, kidney, breast, pancreas and colon. Considering that the 
concentration of AZA necessary to inhibit hERG channels (IC50 range: 640–840 nM) are at least 
two orders of magnitude higher than those capable of causing cytotoxicity and cytoskeletal effects, 
it is likely that yet another target and mechanism of action exists for AZAs. 
1.7.2.2. Cytotoxicity and apoptosis
Multiple human cell lines (Jurkat T lymphocytes, Caco-2 intestinal cells, and BE(2)-M17 
neuroblastoma cells) were used to characterize cytotoxicity and pathways of apoptosis. Cytotoxicity 
experiments were consistent with the published literature showing that AZA1 was cytotoxic 
in both a concentration and time-dependent manner to each cell type tested, with mean EC50 
values ranging between 1.1 and 7.4 nM. Despite the absence of morphological changes indicating 
apoptosis, caspase-3/7 activity was higher in all cell types treated with AZA1. Furthermore, in 
T lymphocytes, the most sensitive cell type, the activities of the initiator caspases-2 and -10 and 
concentrations of intracellular cytochrome c were elevated. DNA fragmentation was also observed 
for T lymphocytes exposed to AZA1, -2, and -3. Collectively, the data confirm that AZA1 is highly 
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cytotoxic to multiple cell types and that cells exposed to AZA1 undergo atypical apoptosis, possibly 
in conjunction with necrotic cytotoxicity.
1.7.2.3. Structure activity relationships (SARs)
The Jurkat T lymphocyte cell assay was used to assess SARs for the AZA analogues purified over 
the course of the project. Using this model relative potencies after are: AZA2 > AZA6 > AZA34 ≈ 
37-epi-AZA1 > AZA8 ≈ AZA3 > AZA1 > AZA4 ≈ AZA9 > AZA5 ≈ AZA10 > AZA33 ≈ AZA36 > 
AZA37 > AZA26.
The results indicate AZA potency is gained by methylation of C8 and/or C22 (AZA2, -6) while 
AZA potency is reduced by C3 and/or C23 hydroxylation (AZA4, -5). AZA33 (AZA1 missing 
A/B/C rings) was significantly less potent than AZA1 (~5-fold), whereas AZA34 (AZA1 missing C4/
C5 alkene) was 5.5-fold more potent than AZA1. Similarly, 37-epi-AZA1 was 5.1-fold more potent. 
Semi-synthetic hydrogenated AZA1 analogues, 7,8-deuterohydroAZA1 and 4,5,7,8-tetrahydroAZA1, 
were also tested. Both compounds were found to be approximately equipotent to AZA1 suggesting 
that the C4/C5 alkene and the C7/C8 olefin bonds do not contribute to the toxicological activity. 
1.8. Scientific publication output
To date this project has led to the publication of 32 peer reviewed papers (with more than 7 
additional manuscripts in preparation), 3 book chapters and 72 presentations at national and 
international conferences.
1.9. Recommendations summary
1.9.1. Benefits to the Industry
 • Improved monitoring and forecasting becomes possible with the development of a 
molecular probe and the isolation of purified stocks of AZAs for CRMs
 • Toxicity and cooking studies indicate current regulatory limit is sufficiently low and the 
EFSA recommendation to reduce the limit may be unwarranted
 • Feeding and vector studies peformed in ASTOX 2 will contribute towards developing 
mitigation strategies
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1.9.2. Recommendations to regulators
 • Introduce a cooking step in the legislated method to more accurately reflect toxin 
profiles (due to heat induced toxin conversions)
 • Include AZA6 in legislation (high levels were detected in some cooked Mytilus edulis 
tissues)
 • Review current regulatory limit based on all the information gathered in the ASTOX 2 
project, with a revision of the TEFs for AZA2 and -3 based on oral and mouse ip studies
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2. Introduction
2.1. History of AZA research
Azaspiracid poisoning (AZP) was first reported in 1995 when several people in the Netherlands 
became ill after eating contaminated shellfish harvested in Ireland.1 Contaminated mussels from this 
and subsequent incidents were sent to Tohoku University in Japan where the causative toxins AZA1, 
-2 and -3 were isolated and characterized.2,3 In a study using two male ddY mice, an ip lethal dose of 
purified AZA1 of 200 µg/kg bw was reported2, while the lethal doses for AZA2 and -3 were 110 and 
140 µg/kg bw, respectively.3 In 2002, AZA1–3 were introduced into EU biotoxin legislation with the 
limit being set at 160 µg/kg.4
The Irish national monitoring program was set up in 2001, and since that time, the detection of 
AZAs in shellfish samples has led to significant protracted shellfish farm closures with severe 
economic consequences for the industry5 (Figure 1). To date, seven human AZP events have been 
confirmed (Table 1), but it is quite possible, due to the similarity of symptoms observed for people 
with DSP or other types of food poisoning (e.g., bacterial enteritis), that many more undocumented 
events may have occurred. Coincidently, each of the confirmed AZP events have been traced to 
contaminated Irish shellfish (Mytilus edulis). AZAs have been detected in other European countries6, 
Morocco7, North8 and South America9, Japan10 and elsewhere (Figure 2).
In 2003 the Marine Institute received National Development Plan (NDP 2003–2006) funding for 
a three year project on AZAs named ASTOX. The primary aims of the project were to purify 
sufficient amounts of AZA1–3 to produce CRMs to aid in the monitoring of these toxins and to 
further study the toxicological effects. Through collaborations with other international research 
teams the project aims were achieved; successful isolations of AZA1–3 from shellfish, enabling the 
production of CRMs and some in vitro toxicity testing.11 Over the course of the project 8.4 mg of 
AZA1, 0.9 mg of AZA2 and 1.3 mg of AZA3 were isolated. The majority of this material was used 
for the preparation of calibrant CRMs – a first for this toxin group.12 A number of tissue CRMs 
were also prepared for the first time.13–16 The availability of CRMs is essential to ensure accurate 
results are being produced by monitoring laboratories. Other findings from the project included 
information on shellfish distribution, toxin ratios and the effects of cooking.17,18 
The toxicological studies focused mainly on cell based assays with the development of lymphocyte 
T (Jurkat) and Caco-2 cell assays. Caco-2 cells are often used as a model for studying intestinal drug 
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transport19 and/or TEER20, and were putatively chosen as an in vitro model to parallel the extensive 
intestinal effects that AZAs are known to have on mammals when tested in vivo.21–24 Two of the 
ASTOX related studies suggested that AZA1 had little or no effect on Caco-2 cells11,25, whereas 
one separate investigation found AZA1 to be somewhat cytotoxic.26 Despite these different findings 
regarding cytotoxic endpoints, monolayers of Caco-2 cells exposed to AZA1 have shown significant 
reductions in TEER assays when exposed to low concentrations of AZA1 (i.e., 5 nM)11 suggesting 
altered permeability and/or cellular function. The Jurkat T lymphocyte assay was shown to be 
particularly sensitive to AZAs demonstrating the time- and concentration-dependent effects as well 
as differences in AZA analogue potencies.11,27 This assay supported the original mouse ip studies in 
terms of the relative toxicities of AZA1, -2 and -3.11 
To date, no effects (of AZAs) other than gastro-intestinal disorder have been described in humans. 
However, a number of studies on animals (within the ASTOX project and by other research groups) 
suggest that there is a potential for sub-acute effects. An early study by Ito et al.24, on chronic 
exposure of mice to AZA suggested that more tumors were observed in AZA-exposed mice 
compared to the control population. Unfortunately, the study was not considered conclusive as 
the number of animals used was quite low and there was no clear dose-response relationship (i.e., 
more lung tumors were observed at the lower dose of 20 µg/kg twice weekly (3/10 mice) than at 
the higher dose of 50 µg/kg twice weekly (1/10 mice)). Still, 9 out of 10 mice at the higher dose level 
were sacrificed during the study due to extreme weakness and the lung tumor that was observed at 
the highest dose level was the earliest tumor observed (the other two tumors being observed at the 
lower dose level during the period of recovery post exposure). Hence a tumorigenic effect of AZAs 
cannot be completely ruled out at this stage. The study by Colman et al.28, even though only based 
on a single dose exposure, also showed strong sub-acute effects on embryonic development of 
Japanese medaka fish. This study suggests a teratogenic potential of AZAs at sub-acute levels in this 
model and transfer across the placental barrier in pregnant women should be considered a hazard 
that needs to be investigated further. This hazard appears of particular importance in light of the 
facile uptake observed for AZA1 across the intestinal barrier in small rodents.29 Initial observations 
of AZA-exposed mice had also suggested that AZA should be considered a neurotoxin as 
symptoms had included jumping behaviour.30 An additional indication of neurotoxicity was found by 
Kulagina et al.31 who detected effects of AZA1 on neuronal cells. Hence, further confirmation of 
neurotoxic effects should be made once the mechanism(s) of action is (are) clarified in case sub-
acute effects in humans may be caused.
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In 2008, based on all the information gathered, another risk assessment was performed by EFSA 
who suggested a lowering of the regulatory limit.32 Up to this point, little information on the 
oral toxicity, bioavailability and mode of action of AZAs was available. Furthermore, uncertainty 
remained regarding the causative organism and the effects of exposure to combined groups of 
toxins. For such studies large amounts (mg quantities) of purified toxins would be required. Apart 
from AZA1–3, numerous other analogues were identified in the ASTOX project33, however, due 
to time limitations their significance had not been established. In 2009, funding was provided by the 
NDP (2007–2013) for another three year project on AZAs, named ASTOX 2, which was to address 
these outstanding issues.
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● Site closure (≥ 160 µg/kg)
Figure 1. Closure of Irish shellfish harvesting sites due to AZAs from 2002–2013.
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2.2. ASTOX 2 project design
The project was divided into 10 work packages (WPs) (Table 2, Figure 3). Two of the WPs dealt 
with project management and dissemination (WP1 and 10). WP 2 dealt with bulk culturing of the 
producing organism and involved Ifremer, the Marine Institute (MI) and the Alfred Wegener Institute 
(AWI). Confirmation of the causative organism and development of molecular probes was covered 
in WP3 involving the MI and AWI. WP 4 led by AWI and Ifremer encompassed trophic transfer of 
A. spinosum. WP5 focused on the isolation of AZAs and involved the MI, the Norwegian Veterinary 
Institute (NVI) and the National Research Council, Canada (NRCC). The remaining WPs (6–9) dealt 
with the toxicological aspects – in vivo and in vitro testing with subsequent analysis of tissues for 
metabolites and involved the MI, Norwegian School of Veterinary Science (NSVS), the University 
of Michigan (UM) and the Centre for Coastal Environmental Health and Biomolecular Research 
(NOAA). Additional collaborators included Queen’s University Belfast (QUB) and the Univerisy of 
Trieste.
WP 1 
Project 
Management
WP 10 
Integration and 
dissemination
WP 2
Bulk culturing
WP 3 
Confirmation of 
AZA producer(s)
WP 4 
Trophic transfer
WP 5
AZAs isolation
WP 7
Prep. of animal 
feed
WP 8
Mouse and pig 
toxicity studies
WP 6
Analytical method 
validation
WP 9
Cell based 
assays/mode of 
action
Figure 3. ASTOX 2 work package (WP) tasks. 
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3. AZA producing phytoplankton
3.1. Introduction
For many years following the identification of AZAs the source remained elusive. The seasonal 
accumulation of these toxins in shellfish, particularly mussels (Mytilus edulis) and the structural 
homologies with other known lipophilic phycotoxins, pointed towards a dinoflagellate producer. 
Protoperidinium crassipes had been reported as the producer38, however this organism was later found 
not to produce these toxins in the laboratory39 and is more likely a vector of the producing organism.
In 2007, during a cruise on the research vessel Poseidon in the North Sea the causative organism 
was discovered from the NorthEast coast of Scotland, provisionally named as 3D9, and the strain 
isolated had been described as a new species in a new genus.40 This organism, a small (10–15 µm in 
length) armoured dinoflagellate named A. spinosum was shown to produce AZA1 and -2 (2–20 fg/cell 
AZA1) in culture and effectively identified as de novo producer of AZAs.41 
3.2. Azadinium spinosum
Following the discovery of A. spinosum further isolation of Azadinium-like species was performed 
on plankton samples collected during a cruise to coastal waters of the southern North Sea along 
the Danish coast. A large number of crude cultures from these stations were established by use 
of serial dilution and screened for the presence of Azadinium-like dinoflagellates and AZAs. Four 
new isolates could be grown as clonal cultures. All cultures were carefully analysed morphologically 
(light and electron microscope), with respect to their DNA sequences (18S and 28S rDNA, internal 
transcribed spacer (ITS) and cytochrome oxidase I (COI)), phylogenetically and chemically (for 
the detection of AZAs). One isolate (UTHE2) was found to contain AZAs. Subsequent electron 
microscopic examination confirmed this strain to be A. spinosum showing the characteristic 
Kofoidean plate pattern for the genus Azadinium (po, x, 4 ,´ 6´ ,´ 6C, 5(?)S, 6´´ ,´ 2´´´´) and exactly 
resembling the A. spinosum described by Tillmann et al. (2009).40
In August 2009, shellfish samples of blue mussel (Mytilus edulis) from the SouthWest of Ireland were 
analysed using LC-MS/MS and found to be above the regulatory limit (0.16 µg/g AZA equivalents) 
for AZAs. Water samples from this area were collected and the armoured dinoflagellate A. spinosum 
was isolated, cultured and shown to produce AZA toxins. This was the first strain of A. spinosum 
isolated from Irish waters.42 Molecular phylogenetic analysis of the LSU rDNA gene shows that the 
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Irish A. spinosum was identical to the other two available A. spinosum strains from Scotland (3D9)40 
and Denmark (UTHE2).43,44 The toxin concentration of the Irish strain was found to be ~15–25 fg/cell 
AZA1 and ~1–5 fg/cell AZA2.
In 2011 another A. spinosum isolate was discovered from a coastal station off the Shetland Islands (on 
the research vessel Heincke) that displayed similar characteristics to other A. spinosum isolates.45 
3.3. Discovery of several new Azadinium and related 
species
The first isolation and description of A. spinosum as a source of AZA toxins stimulated further 
isolation and characterization of Azadinium-like organisms. The description of A. spinosum in 2009 
was soon followed by the discovery of a second species of the genus, now described as Azadinium 
obesum.46 This species was isolated from the same water sample collected from the NorthEast coast 
of Scotland, indicating co-occurrence with A. spinosum. Intensive chemical analysis by LC-MS/MS, 
however, failed to detect known AZAs or potential analogues in A. obesum.46,47
Further Azadinium like isolates were collected from Danish coastal waters that did not contain any 
of the known AZAs. The isolates resembled Azadinium sp. in terms of size, shape and swimming 
pattern, however, the morphological differences, DNA sequences and phylogenetic analysis 
indicated a new species subsequently named Azadinium poporum.43 Subsequent surveys around 
Korea48 and China49 led to the isolation of additional A. poporum strains, some of which produced 
known and novel AZAs (Table 3). Considerable differences in the ITS and 28 S gene sequences 
were observed between the Asian and European strains. In an LSU/ITS tree, all available strains of 
A. poporum comprised 3 well supported clades. The first clade included multiple strains originating 
from the coast of China, as well as a Korean strain. The second clade included strains from the East 
China Sea and South China Sea, and the third consisted of strains from Europe. Therefore there is a 
considerable cryptic diversity within A. poporum with sympatric occurrence of two distinct ribotypes 
in China.
Another isolate from Irish coastal water samples turned out to represent a yet un-described new 
species, to be placed in the genus Amphidoma. Interestingly, this species, although with a distinctively 
different plate pattern to Azadinium, show some clear similarities (e.g., the configuration of the 
apical pore complex, the number and arrangement of sulcal plates) that indicate a close phylogenetic 
relationship between the genera Azadinium and Amphidoma. This morphological evaluation was 
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confirmed by a detailed sequence-based phylogenetic study. LC-MS/MS analysis showed that 
Amphidoma languida produced two novel AZAs; AZA38 and -39.47
Another species collected from the NorthEast coast of Scotland, was named Azadinium caudatum. 
Both sequence and morphometric data clearly showed that the species occurred with two distinct 
varieties, var. caudatum and var. margalefii, that are easily distinguished by the different shapes of 
the antapical projection.50 A. caudatum is easily distinguished from other species of Azadinium by 
light microscopy due to its larger size; characteristic triangular shape; and clearly visible antapical 
projection. The basic plate pattern is the same as other Azadinium species, nevertheless there are a 
couple of minor morphological differences visible at SEM level. LC-MS/MS analysis of the two strains 
(var. caudatum and var. margalefii) did not show any evidence of AZA production.51 
During the 2011 expedition on the research vessel Heincke another Azadinium was isolated from 
a coastal station off the Shetland Islands. This isolate was described as a new species, Azadinium 
polongum. By light microscopy, it was very similar to A. spinosum, A. obesum and A. poporum. Similar 
to A. spinosum, A. polongum also had an antapical spine (Figure 4) making diffrentiation by light 
microscopy very difficult. A distinctive morphological feature (but only visible at the SEM level) of 
A. polongum is the shape of the pore plate (elongated) which differs from other Azadinium species 
(round to slightly ellipsoid pore plate). Detailed LC-MS/MS analysis showed that A. polongum does 
not produce any known AZAs in measureable amounts.45
The most recently described species A. dalianese was isolated from Chinese coastal waters. This 
species is clearly different from all other species of Azadinum by having a reduced number of apical 
and epithecal intercalary plates. No known AZAs could be detected.52
By using high resolution light microscopy during an expedition on the research vessel Merian to 
Greenland and Iceland, the presence of Azadinium on a few stations in the Irminger Sea between 
Greenland and Iceland and on a few coastal stations of Western Iceland could be shown (Figure 4). 
Among those, a number of new species were identified, which currently are being described 
taxonomically. Together with the records of Azadinium from the Shetland Islands, these observations 
clearly show the presence of the genus in cold water and Sub-Arctic areas.
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A. spinosum A. obesum A.  poporum A. polongum A. caudatum
var. margalefii
Amphidoma
languida
A. caudatum
var. caudatum
iAZA1, -2, -33 , -34 No known AZAs
AZA2, -11, -36, -37, 
-40, -41 No known AZAs No known AZAs AZA38, -39
A. dalianense
No known AZAs
A. species # 1 A. species # 2 A. species # 3
No known AZAs No known AZAs No known AZAs
Ireland, Scotland, 
Shetland Is, Denmark
Scotland, Denmark, Korea, 
China
Shetland Is Scotland Ireland
China Greenland, Iceland Greenland, Iceland Greenland, Iceland
Currently  no 
isolates
Figure 4. Light (colour) and electron (black and white) microscope pictures of the Azadinium and 
related species detailing location of strain isolation and toxins identified.
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Table 3. Summary of Azadinium species and AZA producers identified to date.
Species Strain Origin AZAs AZA cell quota
Azadinium spinosum 3D9 Scotland 2007 AZA1, -2, -33, -34 ~20 fg
UTH E2 Denmark 2008 AZA1, -2, -33, -34 ~20 fg
SM2 Ireland 2009 AZA1, -2, -33, -34 ~20 fg
SHET F6 Shetland Is. 2011 AZA1, -2, -33, -34 ~20 fg
Azadinium obesum 2E10 Scotland 2010 none -
Azadinium poporum UTH D4
UTH C5
UTH C8
Denmark 2008 AZA37 ~10 fg
HJ2010 Korea 2010 AZA36 ~2 fg
G25 Bohai Sea 2007 AZA36 1–2 fg
G42 East China Sea 2011 AZA2 n.a.
G64 East China Sea 2011 AZA2 8–23 fg
G60 East China Sea 2011 - -
G66 East China Sea 2011 AZA11 2–8 fg
G68 South China Sea 
2011
AZA2 2–5 fg
16 new strains South China
East China Sea
Yellow Sea
AZA2; AZA11
AZA36; AZA40
AZA41, none
0.2–8 fg
10 new strains Argentinian coast AZA2 2–5 fg
Azadinium caudatum
var margalefii
AC1
AC2
Scotland 2011 - -
Azadinium polongum SHET B2 Shetland 2011 - -
Amphidoma languida SM1 Ireland 2009 AZA38
AZA39
~10 fg 
Merian 2A11 Greenland
Iceland 2012
AZA38
AZA39
~10 fg 
Azadinium 
dexteroporum53
Mediterranean Naples AZA?
AZA?
2–4 fg 
Merian 1D12 Greenland
Iceland 2012
- -
Azadinium dalianense AZH02 China 2012 - -
Azadinium species #1 Merian 48A, 
4B11, A2D11
Greenland, Iceland - -
Azadinium species #2 Merian 3D6 Greenland, Iceland - -
Azadinium species #3 Merian 1C6 Greenland, Iceland - -
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Although the number of available strains of the genus Azadinium is still low, the results up to 
now support the view that toxin production is a stable characteristic of the species A. spinosum. 
However, for A. poporum, both AZA-producing strains as well as strains without any detectable 
AZAs have been reported49,54, indicating the presence of intraspecific variability in toxin production. 
It is clear that different species of the genus do co-occur.43,55 The increasing diversity of the genus 
and the co-existence of toxigenic and non-toxigenic species in the same water mass, complicate all 
attempts to identify/quantitate the source organism of AZAs by routine monitoring programmes 
using light microscopy. Thus molecular probes able to discriminate toxic A. spinosum from other 
similar species are required. 
3.4. Morphology, taxonomy and phylogeny
Detailed studies revealed morphological details potentially important to elucidate the taxonomic 
position of the genus Azadinium within the higher order system of dinoflagellates. These include 
the description of the plate overlap pattern46,56, which was shown to be particular in some aspects 
among dinoflagellates. The identified type of growth bands (the way thecal plates grow and increase 
in size) for A. spinosum has been found to be typical for the order gonyaulacales (Figure 5). Finally, 
the cell division type of A. spinosum was identified.57 Cells divide by sharing the thecal plates, which is 
characteristic of the gonyaulacales (Figure 6).
Figure 5. A. spinosum. “Growth bands“ are restricted to overlapping plate margins (typical for 
Gonyaulacales) and do not occur on any plate margin (as in Peridiniales).
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Figure 6. A. spinosum. Cell division type is desmoschisis. Plates are shared between sister cells. This 
type of cell division is common among Gonyaulacales.
Morphological criteria used to separate Peridiniales and Gonyaulacales indicate that the genus 
Azadinium has more affinities to Gonyaulacales. Phylogeny, however, showed that the genus 
Azadinium is closely related to the Prorocentrales, Gymnodiniales and Peridiniales, and is clearly 
separated from the Gonyaulacales. The ordinal position is therefore not fully clarified and requires 
more information on the phylogeny of potentially related genera. 
Morphology and pigment profiles of the new species of the genus Amphidoma and the genus 
Azadinium revealed increasing evidence for a close relationship that led to including Azadinium and 
Amphidoma in the family Amphidomataceae.55
Using transmission electron microscopy the ultrastructures of three Azadinium sp. (A. spinosum, A. 
obesum and A. poporum) were investigated and found to be quite common for dinoflagellates (Figure 
7). Ultrastructural differences included the lack of stalked pyrenoids in A. obesum and an “apical 
striated complex’’, that had never been observed in A. spinosum. Intracellular bacteria are missing 
and thus - for A. spinosum - not involved in toxin production. 
Interestingly, in A. poporum two types of pyrenoids (stalked pyrenoids, internal pyrenoids) may be 
simultaneously present, together with starch grains located in the plasma (Figure 8).
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Figure 7. TEM of A. spinosum. 
C=chloroplast, N=nucleus, 
n=nucleolus, P=pyrenoid. 
Figure 8. TEM of A. poporum (cross section). 
Ipy=internal pyrenoid, pgy=stalked pyrenoid, 
S=starch. 
3.5. Development of a molecular probe
3.5.1. Azadinium 28s rRNA probes 
Ribosomal RNA probes specific for representatives of the genus Azadinium (A. spinosum, A. obesum 
and A. poporum) were designed for fast and reliable characterisation, identification and numeration 
of these Azadinium species. The probes are ~17–18 base pair oligonucleotide sequences which 
are specific for D1D2 region of the LSU (28S rRNA) of the target algae. They are applied in two 
methods of detection – standard Fluorescence InSitu Hybridisation (FISH) and Catalysed Reported 
Deposition - Fluorescence InSitu Hybridisation (CARD-FISH), as well as Real Time qPCR.58
3.5.2. CARD FISH 
The probes bind efficiently to a specific sequence of the rDNA of the target cells. They are labelled 
with a fluorescent dye, which emits a signal that can be detected via epifluorescent microscopy. 
The cells are stained with DAPI as a positive stain for intact cell identification (Figure 9). In addition 
to applying target specific probes, negative controls are performed to differentiate between a 
background and a positive signal (Figure 10). The probes hybridise with the cells of target Azadinium 
species giving a bright signal. 
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Figure 9. DAPI Citifluor stained cells of A. 
spinosum on a 1.2 µm polycarbonate filter 
(Isopore, Millipore, USA) at 10× magnification.
 
Figure 10. A. spinosum cells showing bright 
positive signal after CARD FISH at 10× 
magnification (same field as DAPI staining).
 
3.5.3. Quantitative real time PCR 
TaqMan®MGB probe and primer sets (assays) were designed for the three Azadinium species as in 
the case of CARD FISH. The designed primer sets were first tested with the SYBR Green qPCR 
approach to determine if a specific PCR amplicon was formed and to evaluate the efficiency of the 
assay. After the standard curves for all sets were made, the TaqMan MGB probes were applied. 
The primer and probe sets gave good standard curves, with an efficiency ranging ~95–105%. The 
standard curves, for later quantitation approaches were made using dilution series of known 
concentrations of the DNA extracts corresponding to exact cell numbers of unialgal cultures 
(Figure 11). 
Figure 11. The real time measurements of the fluorescence plotted against the number of cycles. 
DNA extracts of A. spinosum starting with 10 ng per well diluted 1:10. The standard curve is 
obtained from this graph.
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All three qPCR assays form products with their target sequences in efficient reactions and bind 
specifically to the target species (A. spinosum, A. obesum and A. poporum). 
3.5.4.  The role of qPCR in the detection of Azadinium species in routine monitoring 
programmes 
The three qPCR assays developed were further optimised and their effectiveness evaluated 
when implemented in detecting target Azadinium DNA in field samples submitted to the Irish 
phytoplankton monitoring programme. The parameters of the assay optimised included extraction 
(volume, centrifuging, filtration, extraction kits, cell disruption, lysis incubation) and analysis (probe-
primer concentration, annealing temperature). The introduction of controls to distinguish between 
true positives and true negatives from false positives and false negatives have also been implemented 
into the method (controls include extraction efficiency and recovery, inhibition, contamination and 
quantitation (cells/L)).
Identification and enumeration of Azadinium down to species level is difficult by light microscopy 
due to their small size and morphological characteristics. The use of the qPCR methodology as a 
tool in identifying the presence of and distinguishing between species within the genus provided 
valuable information on AZA events observed in Ireland during 2012 and 2013, particularly in Killary 
Harbour and the SouthWest. In all cases where corresponding phytoplankton samples were taken 
at the time of the event, the presence of A. spinosum DNA was detected by qPCR. Figure 12 shows 
the concentration levels of A. spinosum (cells/L) in phytoplankton samples and how they related to 
AZA equivalent concentrations (µg/g) detected in Mytilus edulis during June–August 2013. Initial 
observations from this event and other AZA events observed in the period 2012–2013 indicate 
A. spinosum can bloom rapidly, with subsequent rapid intoxification and accumulation of AZAs in 
mussels. The results also show that there is a rapid decline in cell densities following the inital bloom.
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Figure 12. AZA concentrations in M. edulis and A. spinosum cells/L (qPCR) from Killary Outer 
July–August 2013.
A survey of Irish coastal waters for blooms of A. spinosum was undertaken in August 2012 aboard 
the Celtic Voyager (Figure 13). Chlorophyll max and depth layer samples (fractionated in the particle 
size range 3–20 µm and collected on 3 µm TSTP filters) were analysed for the presence of A. 
spinosum by qPCR. Surface layer samples collected from the majority of the stations contained A. 
spinosum DNA, and to a slightly lesser extent in the chlorophyll max layers. A. spinosum DNA was 
present in just under half of the stations in the depth layer.
Figure 13. Survey samples collected during August 2012. 
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4. Bulk culture of producing organism
4.1. Introduction
The main sources of marine algal toxins for purification purposes are the producing organisms 
in culture or harvested from natural blooms (e.g., okadaic acid group toxins59, brevetoxins60, 
saxitoxins61, yessotoxins62 and pectenotoxins63); from contaminated shellfish12,64; or from bulk 
extraction of environmentally contaminated HP-20 resin.65 Isolation from bulk cultures of the 
producing organism is preferred; as extracts are considerably purer than shellfish extracts; and their 
availability is not dependent on the occurrence of natural toxic episodes. Purification of phycotoxins 
for the preparation of calibration standards is essential to sustain phycotoxin monitoring in food.66 
This has become particularly important as micro-algal lipophilic toxins in contaminated shellfish are 
now monitored in Europe using LC-MS/MS as a reference method.67 
4.2. Validation of extraction and analysis methods
A. spinosum cells were collected from bioreactor cultures, using centrifugation or filtration. Different 
extraction procedures were evaluated for the formation of methyl-ester artefacts, yield, and 
matrix effects.68 Filtration of cultures using glass-fibre filters led to an increase in the formation of 
methyl-esters. Hence centrifugation is recommended for recovery of cells. The type of extraction 
solvent (methanol, acetone, acetonitrile) did not significantly affect the yield of AZAs so long as the 
organic content was 80% or higher. However, the use of methanol as an extraction solvent led to an 
increase in the formation of methyl-ester artefacts. AZA1 recovery over two successive extractions 
was 100% at 95% confidence level for acetone and methanol. In standard addition experiments 
no significant matrix effects were observed in extracts of A. spinosum or A. obesum up to sample 
intake of 4.5×109 µm3. Moreover, experiments carried out to clarify the formation and structure 
of methylated AZA analogues, led to the description of two new AZAs and the correction of the 
chemical structures of AZA29–32.
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10 mL of A. spinosum culture.
Centrifugation: 2,500 g, 4 °C, 20 min.
Supernatant: add 2 mL DCM and vortex for 1 min. Pellet: add 500 µL solvent and transfer to eppendorf (1.5 mL). 
Vortex: 1 min, sonicate 10 min. Centrifuge: 15,000 g, 4 °C, 10 min.
Transfer the organic phase into a glass 
tube and evaporate. Repeat 3 times.
Add another 500 µL of solvent to 
pellet and homogenise. Centrifuge. 
Repeat 3 times. 
Transfer supernatant into 
glass tube and evaporate.
Reconstitute in 0.5 or 1 mL MeOH/H2O 9/1 v/v.
Filter and transfer into HPLC vial and analyse by LC-MS/MS.
Figure 14. Sample preparation scheme for AZA extractions from A. spinosum.
No significant matrix effects were observed during LC-MS/MS analysis with acetone or methanol 
under the conditions tested.
Based on results of this study, the following procedures are recommended for the analysis of AZA1 
and -2 in A. spinosum:
 • Sample and immediately separate the cells from the culture media by centrifugation
• Extract AZAs with acetone 
 • Two to three successive extractions are suggested to ensure high extraction yield 
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Figure 15. AZA chromatograms using an isocratic elution: A) A. spinosum after extraction with 
acetone, B) A. spinosum after extraction with methanol, C) partial methylated sample of AZA1 and 
-2, D) total methylated sample of AZA1 and -2, E) AZA1 standard after a storage experiment and 
F) AZA2 standard after a storage experiment. AZA1X and -2X are AZA1 and –2 methyl-esters, 
AZA30 and -32 are the AZA1 and -2 methyl hemiketals. 
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Figure 16. Mass spectra of A) AZA1, B) AZA1X (AZA1 methyl ester) and C) AZA30 (AZA1 
methyl hemiketal). 
4.3. Environmental parameters affecting growth and toxin 
production
A. spinosum was found to grow in a wide range of conditions: from 10 to 26 °C; 30 to 40 psu; 50 to 
400 µmol/m2/s and with or without aeration. The highest growth rate and/or cell concentration was 
obtained at 35 psu, from 18 to 22 °C and with aeration. AZA cell quota was significantly affected 
by low temperature; 20-fold higher at 10 °C (220 fg/cell) than at temperatures between 18 and 
26 °C. Likewise, but to a lesser degree, AZA cell quota was enhanced at high irradiance in the 
photobioreactor and using aeration. A. spinosum growth rate and AZA cell quota were found to 
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be slightly different with all media tested. However, low K modified medium concentration 
(0.5 Kmod) improved AZA cell quota whilst a higher concentration (2 Kmod) improved maximal 
cell concentration in the photobioreactor. 
These experiments on the effects of environmental and nutritional factors on A. spinosum69 
expanded our knowledge on its culture and facilitated growth of the organism in pilot scale 
photobioreactors for AZA1 and -2 production.70 Furthermore, it gave an initial insight into factors 
that could impact natural blooms. 
However, further studies using factorial plan designs are now required to determine the optimum 
parameters for AZA production using A. spinosum in continuous cultures. Such studies will help 
to determine the effect of nutrient limitations on growth, AZA toxin production and A. spinosum 
biochemical composition. Its small size, ability to grow in continuous cultures and the large 
differences observed under different environmental and nutritional conditions may render this 
organism an appropriate model for the elucidation of the genes involved in toxinogenesis. 
Figure 17. Growth kinetics of A) temperature (10 to 26 °C), B) salinity (30 to 40 psu), C) photon 
flux density (50 to 250 µmol/m2/s) and D) with and without aeration. The arrows indicate at which 
day samples were taken for AZA analysis and * the day used to calculate growth rates (end of the 
linear growth phase).69
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4.4. Bulk culture of phytoplankton
4.4.1. A. spinosum
Continuous pilot scale culturing was performed to evaluate the feasibility of AZA production 
using A. spinosum cultures. Algae were harvested using tangential flow filtration or continuous 
centrifugation.70 AZAs were extracted using SPE procedures, and subsequently purified. When 
coupling two stirred photobioreactors in series, cell concentrations reached 190,000 and 
210,000 cells/mL at steady state in bioreactors 1 and 2, respectively. The AZA cell quota decreased 
as the dilution rate increased from 0.15 to 0.3 per day, with optimum toxin production at 
0.25 per day. After optimization, SPE procedures allowed for the recovery of 79 ± 9% of AZAs. The 
preparative isolation procedure previously developed for shellfish was optimized for algal extracts, 
such that only four steps were necessary to obtain purified AZA1 and -2. A purification efficiency 
of more than 70% was achieved, and isolation from 1,200 L of culture yielded 9.3 mg of AZA1 and 
2.2 mg of AZA2 of >95% purity (see also section 6.3). This work demonstrated the feasibility of 
sustainably producing AZA1 and -2 from A. spinosum cultures.
Figure 18. Schematic representation of A. spinosum production using photobioreactors in series.
This study70 was the first performed on A. spinosum production in pilot scale photobioreactors 
(Figure 18). It demonstrated the ability of this small and fragile dinoflagellate to grow in this type of 
reactor. The effect of dilution rate on AZA cell quota and toxin production outline the secondary 
metabolite character of AZAs. A dilution rate of 0.25 per day was found to yield the highest 
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volume-specific toxin production per day. Two bioreactors coupled in series at higher dilution rates 
allowed for an AZA production rate of 475 µg/day (19 µg/day/L). Under these conditions ~3 mg of 
AZAs were obtained in crude extracts over 12 days (8 days of culture, 1 day of filtration and 3 days 
of extractions). 
The production of large volumes of A. spinosum required the development of rapid procedures to 
concentrate and harvest algal cells for optimal toxin recovery. Both continuous centrifugation and 
tangential flow filtration were successfully applied to concentrate A. spinosum cultures. A simple 
and efficient procedure of extraction allowed for the retrieval of toxins from both the retentate 
and the permeate; providing a crude A. spinosum extract rich in AZAs and low in interfering matrix 
components.
This work showed that despite slow growth rates and low maximum cell concentrations, culturing 
in photobioreactors is a viable biotechnological approach to the production of toxins, with 
applications in research and operational food safety surveillance programs. Furthermore, metabolite 
production in chemostat bioreactors is stable and predictable, and there is the possibility to 
influence secondary metabolite production by using different culture conditions.
4.4.2. A. poporum
Culturing and harvesting of A. poporum cultures were performed on a smaller scale. Approximately 
300 L of each strain were grown to a high density (>100,000 cells/mL) in 5 L flasks using gentle 
aeration (Figure 19). Toxins were harvested by adding HP-20 resin to the cultures following cell lysis 
(by the addition of acetone). The HP-20 resin was subsequently collected, dried, and extracted with 
100% acetone providing a crude toxin extract ready for purification (see section 6.3.2).
Figure 19. Mass culturing of A. poporum to collect toxins for structural elucidation and toxicity 
tests.
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5. Trophic transfer of AZAs
5.1. Introduction
Due to observational deficiencies in toxic plankton (especially in detecting Azadinium species) and toxin 
monitoring programmes it had been difficult to draw a clear correlation between the detection of AZAs 
in bivalve shellfish and the occurrence of Azadinium blooms. In addition, there is also the possibility 
of alternative AZA sources (i.e., cryptic AZA-producing species) or toxin vectors, e.g., transfer via 
the pelagic food web. For a number of toxic algae, grazing within the plankton community is generally 
viewed as the initial pathway through which algal toxins become vectored into pelagic food webs. 
Subsequent accumulation and trophic transfer can intoxicate higher-trophic-level consumers such as fish, 
sea birds, and marine mammals.71 For algal toxins accumulating in mussels, three transfer routes must 
be taken into account: (i) AZAs could accumulate in bivalve shellfish following feeding upon AZA bound 
to suspended particulates; (ii) via plankton vectors (e.g., copepods, tintinnids or other microplankton 
grazers) that have fed upon toxigenic Azadinium cells and (iii) direct uptake of the causative organism. 
5.2. Planktonic food webs
AZAs can be present in plankton larger than the known producing species. In addition to AZA 
detection in the heterotrophic dinoflagellate Protoperidinium crassipes38 (with an AZA cell quota of 
~1.5 pg per cell), a second grazer species, Favella ehrenbergii, collected from field samples was also 
found to contain AZAs (~0.7 pg/cell).41 In addition to the detection of AZAs in grazer species data 
was collected on AZAs in various plankton size fractions. During a research cruise on the research 
vessel Poseidon in 2007,  AZA1 was detected over the entire North Sea in plankton samples 
collected with a plankton net (20 µm), which would not retain the small species of Azadinium.41 The 
AZAs were mostly evenly distributed among three size fractions (20–55 µm, 50–200 µm and 
>200 µm) prepared from the net tows. At two stations (which had the highest amount of AZAs 
in net-samples) the majority were found in the 50–200 µm fractions (corresponding to a high 
abundance of F. ehrenbergii). However subsequent size fractionation of these samples revealed that 
>90% of the AZAs were found in the 3–8 µm and 8–10 µm fractions, which clearly corresponded 
to the size class of the identified AZA producing species. It is important to note that in quantitative 
terms, AZA found in larger size fractions were orders of magnitude lower. Although it is difficult to 
directly compare Niskin bottle samples and net tows, absolute AZA amounts in the small fractions 
(assumed to be due to A. spinosum) were ~2- to 3-fold higher than the low pg/L range estimated in 
net tow samples (assumed to be the result of trophic transfer).
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Similar results were obtained on the subsequent cruise in Danish coastal areas of the North Sea.44 
AZA1 was present in a number of net tow (20 µm) samples (in the range of 50 pg per net tow), albeit 
in low amounts, with only traces found in the >200 µm fraction. AZA1 concentrations measured in 
the small size fractions (<20 µm), however, were much higher with maximum concentrations of 
~2 ng/L AZA1. This is roughly 5-fold higher than amounts found in the corresponding net tow samples. 
These results are indicative of negligible trophic transfer, at least under this particular field situation. 
5.3.  Vector species
5.3.1. Feeding experiments with copepods 
Preliminary and yet unpublished experiments with copepods indicated a minor grazing impact and 
negligible AZA accumulation in this important group of plankton grazers. During a cruise on the 
research vessel Heincke in 2011, cultured A. spinosum was added to both field plankton samples 
and copepods (various species). After 24 h no substantial grazing in copepods nor significant AZA 
accumulation in larger size fractions was detected.
5.3.2. Potential protistan grazers
A number of potential protistan predators (Amphidinium crassum, Polykrikos kofoidii, Gyrodinium 
dominans, Oxyrrhis marina, Peridiniella danica and Favella ehrenbergii) were established in culture and 
tested for their potential to ingest and grow when A. spinosum was provided as a food source. 
Certain grazers such as Polykrikos kofoidii and Amphidinum crassum failed to ingest A. spinosum, most 
probably because of prey size limitation (for P. kofoidii) or due to their peduncle feeding mode (for 
A. crassum). In contrast, laboratory cultures of Favella ehrenbergii clearly ingested A. spinosum (Figure 
20) and started to grow (Figure 21). Toxin accumulation was substantial (Figure 22), however, 
growth was limited in the presence of just A. spinosum. 
Peridiniella dania, a small heterotrophic thecate dinoflagellate, has been identified as a promising 
potential grazer (Figure 23) but quantitative grazing experiments have not yet been performed. For 
other small heterotrophic dinoflagellates such as Oxyrrhis marina and Gyrodinium dominans, ingestion 
of A. spinosum was observed, but only rarely, with no positive growth (Figure 24). 
The swimming behaviour of Azadinium may play a role in grazer interactions. Direct observations 
under the microscope show that Azadinium can escape by sudden jumps when attacked by these small 
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dinoflagellates. However, ingestion of Azadinium by these predators rapidly decreased from initial 
higher values even when immobilised prey was offered as food. Hence, it is likely that factors other 
than motility are involved. Clearly much more detailed studies are required to test the hypothesis that 
AZAs and/or other chemical compounds are involved in grazing interactions of Azadinium.
Figure 20. Favella ehrenbergii that has been feeding on A. spinosum for 16 h. Left: brightfield; right: 
epifluorescence showing red auto-florescence of ingested Azadinium.
Figure 21. Change of Favella ehrenbergii density when starved (open circles) or fed with A. spinosum 
(black circles). Grey bar indicates the decline of A. spinosum from initial 3,000 cells/mL to complete 
food depletion.
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Figure 22. Feeding experiment of Favella ehrenbergii using A. spinosum as food. Initial AZA cell quota 
(AZA1 and -2) in A. spinosum (left) and final AZA cell quota in Favella (right). Bar height represents 
triplicate mean ± 1 SD. Toxin content of Favella would correspond to toxins accumulated from 
the uptake of 485 A. spinosum cells. The presence/absence of AZA degradation or decomposition 
analogues known from mussels could not be estimated due to the low number of Favella available in 
this experiment.
Figure 23. The heterotrophic thecate dinoflagellate Peridiniella danica in A) ventral view and B) 
dorsal view. C) A lugol-fixed cell ingesting a cell of A. spinosum (arrow). D) P. danica with remains of 
two ingested cells of A. spinosum still visible in food vacuoles.
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Figure 24. Change in cell density of the heterotrophc dinoflagellate grazers Gyrodinium dominans 
(A) and Oxyrrhis marina (B) when starved (grey circles), or fed with A. spinosum (red squares), or fed 
with Dunaliella salina (green squares). Symbols represent triplicate mean ± 1 SD. 
Whereas these preliminary experiments do not contradict the possibility of vectoral transfer of 
AZAs to bivalves, they do not provide strong support for this mechanism. Generally, predator-prey 
interactions are known to be species-specific and this may be even more important for toxic species 
where specific chemical compounds might play a role.71,72 Furthermore certain plankton predators 
have been shown to be extremely selective in their prey preferences.73 The scant data that are 
available thus far do not support a view of a universal and rapid spread of AZAs among planktonic 
grazers; but may be indicative that certain (specialized) grazers such as Favella ehrenbergii may play 
an important role in food web transfer of Azadinium and AZAs. More detailed investigations and 
experiments are needed to clarify this issue.
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5.4. Trophic transfer – accumulation, detoxification and 
biotransformation
A number of feeding studies were performed over the course of the project with mussels being fed 
A. spinosum. In the preliminary study42 a 24 h feeding trial of blue mussels (Mytilus edulis) using an algal 
suspension of the Irish A. spinosum culture at different cell densities demonstrated that A. spinosum is 
filtered, consumed and digested directly by mussels. LC-MS/MS analysis had shown that AZAs were 
accumulating in the shellfish hepatopancreas. The toxins AZA1 and -2 were detected in the shellfish 
together with the AZA3, -6, -17 and -19 analogues, suggesting that AZA1 and -2 are metabolised in 
the shellfish within the first 24 h after ingestion of the algae. The levels of AZA17 detected in the 
shellfish hepatopancreas were equivalent to the levels of AZA1, but in the remainder tissues, the 
levels of AZA17 were 4 to 5-fold higher than that of AZA1. Only small quantities of AZA3 and -19 
were present, with negligible amounts of AZA6 detected after the 24 h period. These results are 
proof of a direct toxin transfer of AZA toxins from A. spinosum by feeding Mytilus edulis without the 
need for a vector species. Mussels will actively filter, ingest, accumulate and bioconvert AZA toxins 
readily into other AZA analogues as shown in Figure 25.
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Figure 25. Mussels which feed on A. spinosum metabolise AZA1 and -2 to produce other AZA 
analogues.
In a follow up study adult mussels were continuously exposed to A. spinosum over 1 week in 160 L 
cylindrical conical tanks.74 Three different diets were tested for contamination: 5,000, 10,000 cells/
mL of A. spinosum and a mixture of 5,000 cells/mL of A. spinosum with 5,000 cells/mL of Isochrysis 
aff. galbana (T-Iso, CCAP 927/14). During the subsequent period of detoxification (2 weeks), 
contaminated mussels were continuously fed with 5,000 cells/mL of T-Iso. 
Kinetics of accumulation, detoxification and biotransformation were evaluated, as well as the toxin 
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distribution and the effect of A. spinosum on mussel digestive gland tubules. Mytilus edulis fed on A. 
spinosum in the three tested conditions. The original algal toxins AZA1 and -2, as well as mussel 
metabolites AZA3 to 12, -17, -19, -21 and -23 were found during these trials. After 6 h, AZA 
contents in mussels reached the EU regulatory limit, and metabolites were observed in all conditions 
at ~25% of the total AZA content. This fraction exceeded 50% after 24 h, and continued to increase 
until the end of the study. AZA17 and -19 were found to be the main metabolites, with AZA17 
concentrations estimated in the same order of magnitude as that of the main algal toxin, AZA1.
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Table 4. Temporal variation in the proportion of AZA toxins (%), and AZA toxin concentrations 
(µg/kg and µg/kg AZA1 TEQ) in whole mussels over time for diet 1 (5,000 cells/mL of A. spinosum). 
Highlighted in grey are the toxin proportions related to AZA1 and yellow to AZA2. TEFAZA17 = 1.4 
(as AZA17 transforms into -3 after cooking); TEFAZA19=TEFAZA6=1 (as AZA19 transforms into -6 after 
cooking, and TEFAZA6 is estimated the same as TEFAZA1).
Algal AZAs
(%)
AZA1 57.9 39.5 35.3 41.5 35.1 31.7 25.8 22.9 29.3
AZA2 17.4 15.0 15.6 16.4 14.5 14.0 14.8 12.0 11.7
 Algal AZAs (µg/kg) 283.1 169.5 169.1 248.3 308.9 218.7 120.6 94.5 105.1
AZAs 
metabolites
(%)
AZA3 0.3 0.6 0.6 0.5 0.7 0.8 0.7 0.7 0.7
AZA4 0.0 0.0 0.2 0.5 2.0 2.5 2.3 5.2 7.3
AZA5 0.0 0.7 1.1 1.1 1.5 1.9 1.8 3.9 5.3
AZA6 0.8 2.1 1.9 1.8 2.3 2.5 2.4 3.6 2.8
AZA7, -8 2.9 2.6 1.7 2.0 2.9 2.7 1.7 1.6 1.9
AZA9 0.0 0.0 0.0 0.0 0.2 0.3 0.4 0.8 1.2
AZA10 0.0 0.0 0.3 0.4 0.5 0.6 0.6 1.1 1.5
AZA11,-12 0.4 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3
AZA17 16.7 32.3 35.4 28.2 29.8 31.0 36.8 33.8 25.5
AZA19 3.6 6.9 7.4 6.4 6.9 7.8 8.5 9.0 7.5
AZA21 0.0 0.0 0.3 0.8 2.8 3.2 3.4 4.3 4.4
AZA23 0.0 0.0 0.0 0.1 0.4 0.5 0.6 0.7 0.8
 AZAs metabolites (µg/kg) 93.0 141.0 163.3 180.7 313.9 258.9 176.6 176.7 151.5
 AZA total (µg/kg) 376.1 310.5 332.4 429.0 622.8 477.7 297.2 271.2 256.6
 Regulated AZAs (AZA1–3)
 (µg/kg AZA1 TEQ) 336.9 209.3 213.5 307.8 387.2 277.4 158.7 123.3 131.7
 AZA1, -2, -3, -6, -17 and -19 
 (µg/kg AZA1 TEQ) 441.6 377.6 409.4 512.5 704.5 534.2 344.3 285.9 249.6
This study74 confirmed the findings of the previous feeding study that was performed earlier in the 
project.42 It further showed that blue mussels can accumulate AZAs to levels above the regulatory 
limit in less than 6 h. Detoxification was slow (half life ~11 days); with detoxification rates in the 
same order as other lipophilic toxins.
NDP Marine Research Sub-Programme 2007-2013   
47
5.5. Accumulation of AZAs from the dissolved phase
Another study performed over the course of the project investigated whether mussels were capable 
of accumulating dissolved AZA1 and -2.75 The toxin profiles of these mussels at 24 h were compared 
with profiles of those exposed to live or lysed A. spinosum. The possibility of preparative production 
of AZA metabolites by exposing mussels to semi-purified AZA1 was also assessed.
Mussels were exposed to similar concentrations of AZAs: dissolved AZA1 and -2 (crude extract) 
at 7.5 and 0.75 µg/L, dissolved AZA1 and -2 (7.5 µg/L) in combination with T-Iso, and lysed and live 
A. spinosum cells at 1×105 and 1×104 cells/mL. Subsequently, the mussels were dissected (digestive 
glands, gills and remaining flesh) and analysed. Mussels (whole flesh) accumulated AZAs above the 
regulatory limit except at the lower levels of dissolved AZAs. The toxin profile of the mussels varied 
significantly with treatment (Figure 26). The gills contained 42–46% and the digestive glands 23–24% 
of the total toxin load using dissolved AZAs, compared to 3–12% and 75–90%, respectively, in 
mussels exposed to live A. spinosum. 
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Figure 26. LC-MS/MS comparison of metabolite profiles in mussel tissues after exposure to 
dissolved AZAs (7.5 µg/mL): A) DGs, B) Gills, and C) RF and after exposure to live A. spinosum cells 
(1×105 cells/mL): D) DG, E) Gills, and F) RF.  
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23%
42%
35%
Dissolved AZAs 7.5 µg.L-1
DG Gills RF
63%19%
18%
Lysed A. spinosum
100 000 cell.mL-1 
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11%
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24%
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Dissolved AZAs  
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Figure 27. Total AZA tissue distribution in mussels (DG,     , RF,      , and Gills     ) after 24 h of 
exposure to dissolved AZAs, live A. spinosum or lysed A. spinosum at different concentrations.
The results show that dissolved AZAs were bioavailable for mussels and that AZA accumulation 
may reach concentrations above the regulatory limit and thus might be considered as a food safety 
issue. However, differences observed in the distribution of toxins in the shellfish depended on 
whether the shellfish were exposed to dissolved AZAs or to live or lysed A. spinosum (Figure 27). 
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This finding tended to decrease the importance of dissolved AZAs as a source of contamination 
relevant for human health as the AZA distribution found in situ reflect results observed with live A. 
spinosum. This differing AZA distribution between tissues indicates that AZA uptake can occur in 
the digestive gland during feeding and also through the gills during respiratory and filtration activities 
in the presence of dissolved AZAs. This last observation raises questions as to the mechanisms 
involved in the uptake of AZAs through the gills and about the potential for subsequent re-
distribution to other organs. The bioavailability of dissolved AZAs shown for mussels also raises 
questions regarding possible effects on other aquatic organisms. 
An additional experiment on the preparative production of AZA metabolites by exposure of 
mussels to semi-purified AZA1 resulted in formation of AZA1 metabolites in mussels (AZA17 
(16.5%) and AZA3 (1.7%) after 4 days), but the conversion efficiency and the recovery was too low 
to justify using this procedure for preparative isolation (Table 5). Hence, further studies should 
investigate these losses and the existence of unknown metabolic transformations in mussels and 
seawater. 
Table 5. AZA budget after exposure of mussels to semi-purified AZA1.
Amount (µg)
Recoveryb (%)
AZA1 AZA17 AZA3 Total AZAsa
Dissolved AZA (day 0) 98.4 - - 98.4 100
Dissolved AZA (day 1) 55.1 1.0 1.1 57.2 58.1
Dissolved AZA (day 2.5) 37.8 1.7 1.7 41.2 41.9
Dissolved AZA (day 4) 26.3 2.3 2.0 30.6 31.1
Mussels (day 4) 10.3 16.8 1.6 28.7 29.2
Total recovered 36.6 19.1 3.6 59.3 60.3
aTotal AZAs = AZA1 + AZA3 + AZA17
bRecovery (%) = (Total AZAs / AZA1 (day0)) × 100
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5.6. Effect of A. spinosum on the feeding behaviour of 
mussels
In order to determine whether A. spinosum has adverse effects on mussels, feeding experiments 
were performed76 as detailed below.
 • Mussels were first exposed to a non-toxic diet (T-Iso) for 4 days (20,000 cells/mL). After 
this period, mussels were fed A. spinosum (5,000 cells/mL) for another 4 days
 • AZA accumulation and biotransformation in mussels were followed using LC-MS/MS
 • Individual assessment of mussel feeding time activity (FTA), clearance rate (CR), filtration 
rate (TFR), absorption rate (AR), faeces (Fs) and pseudofaeces (Ps) production were 
carried out on mussels fed either toxic (A. spinosum) or non-toxic diets
Fast AZA biotransformation was observed; with AZA1 and -2 metabolites found after 3 h (Table 
6). 73% of the AZAs were found in the hepatopancreas. AZA17 reached a maximum proportion of 
35% and AZA19 reached 6% after two days of contamination. Other AZAs found were AZA3–10 
and AZA21, with proportions below 3% for each analogue. However, although fast initial toxin 
accumulation was observed (regulatory limit reached after 6 h), the rate of uptake stabilised with 
little or no increase in concentration levels over a longer time period.
Table 6. AZA accumulation and biotransformation in mussels fed A. spinosum. 
%
Time (days) 0.125 0.25 0.5 1 2 3 4
AZA1 66.9 65.5 51.0 47.5 38.6 40.2 45.1
AZA2 14.3 15.1 13.4 15.0 15.6 14.8 14.1
AZA3 0.0 0.0 0.0 0.5 0.6 0.7 0.6
AZA4 0.0 0.0 0.0 0.3 0.2 0.6 0.3
AZA5 0.0 0.0 0.0 0.3 0.9 0.6 0.8
AZA6 0.0 0.0 0.1 0.1 0.1 0.1 0.1
AZA7–10 2.5 2.6 4.1 2.2 1.8 2.2 2.2
AZA17 13.7 14.0 26.7 29.2 35.0 33.1 29.4
AZA19 2.5 2.7 4.6 4.9 5.9 5.8 5.2
AZA21 0.0 0.0 0.0 0.1 1.3 2.1 2.2
µg/kg AZAs 123.7 242.8 180.3 225.6 173.3 250.4 161.2
µg/kg 
TEQ
AZA1–3 114.7 225.2 135.6 169.7 116.9 169.5 115.2
AZA1–3, -6, -17, -19 137.3 270.8 181.9 231.9 165.0 235.7 156.6
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A. spinosum had a significant effect on mussel feeding behaviour compared to T-Iso: CR was lower 
by a factor of 6, FTA by a factor of 5, TFR by a factor of 3 and AR even decreased to negative values 
for the last day of exposure. The feeding studies performed showed a negative effect of A. spinosum 
on the shellfish in terms of mortality rates (were higher), thickness of digestive tubules (reduced, 
Figure 28) and on feeding responses and a possible regulation of AZA uptake by decreasing filtration 
and increasing pseudofaeces production. Consequently, additional experiments are required to 
explain why AZA concentrations in mussels can get so high (>8,000 µg/kg) in Irish waters compared 
to the “low” concentration found in these laboratory experiments (200 µg/kg). 
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Figure 28. Evolution of the digestive gland tubule thickness (µm) in toxic (A. spinosum) and non-
toxic control (T-Iso) diets during contamination (days 2 and 7) and at the end of the detoxification 
period (day 21). The error bars represent the standard deviation (n ≥150 digestive tubules). Values 
with different letters are statistically different (P < 0.05).
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6. Isolation of AZAs
6.1. Introduction
The scarcity of high purity AZAs was a severe constraint on AZA research activity. Purification of 
these compounds is necessary:
1) To enable the preparation of CRMs which are essential to ensure monitoring laboratories can 
produce accurate results;
2) For use in toxicology studies so that regulators can implement appropriate closure limits, and;
3) To understand the chemistry of these compounds and their behaviour in biological 
environments.
The initial isolation of AZA1 was performed with contaminated mussel tissue (20 kg whole flesh) 
from Killary Harbour, Ireland, and involved 7 purification steps yielding 2 mg of AZA1.2 AZA2–5 were 
subsequently isolated from contaminated whole flesh using a procedure which included additional 
clean up steps (8 steps in total).3,77 Purification in both studies was guided by LC-MS/MS and MBA.
Further AZA1, -2 and -3 isolations performed as part of the ASTOX project11 employed a modified 
7-step procedure with recoveries of ~23% reported.12 Purification was guided by LC-MS/MS and 
ultra violet (UV) detection (210 nm). 
Up to this point, all the AZA isolation procedures used acidic mobile phases. In 2008, a study 
evaluating the stability of AZAs at various pH values found that significant degradation (due to the 
formation of re-arrangement isomers) occurred even under slightly acidic conditions in solution. 
Under neutral and slightly alkaline conditions, AZAs were more stable.78
In 2009 isolation of AZA2 from a marine sponge collected in Japan was reported. Purification was 
performed using 7 clean up steps without using acidic or inorganic additives in the mobile phase.10 
6.2. Isolation from shellfish
Sufficient supplies of contaminated Mytilus edulis tissue, collected from Bruckless, Donegal during 
the AZA outbreak in 2005 were available for isolation purposes. Efforts were made to improve on 
the previously reported isolation methods. 
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Initially the effect of extraction solvent was investigated. Small scale tests with methanol and ethanol 
showed that both solvents were equivalent in terms of extraction efficiency. Ethanol was chosen 
primarily to minimize the formation of methyl derivatives, which can be significant when methanol is 
used as extractant.33,68
Freeze-drying of shellfish prior to extraction had been successfully employed in the isolation of 
pinnatoxins from Australian oysters.79 This has many advantages: such as avoiding the necessity of 
water-miscible extraction solvents; complete control of extractant composition; and low water 
content in the extract (thus minimising difficulties during evaporation and potential toxin stability 
problems). The effect of freeze-drying the mussel hepatopancreas prior to extraction of AZAs was 
therefore explored. Higher extraction efficiencies were achieved for the freeze-dried samples after the 
first and second extractions, with 12% and 2% more AZAs being extracted respectively. No difference 
was observed in clean-up efficiency (94.2% for both freeze-dried and wet tissues), but the extracts 
from the freeze-dried samples evaporated more quickly with little or no foaming in the subsequent 
vacuum-evaporation step. The subsequent two liquid-liquid partitioning steps resulted in only minor 
losses of toxin (~95% recovery) with an overall clean up efficiency of 67% (Table 7). The next step in 
the isolation procedure used in the ASTOX project was elution on a silica column which employed 
acidic mobile phases.11 Previous studies have shown that AZAs are unstable in acidic environments, but 
that shellfish tissue appears to have a protective effect.78 As the sample at this stage of the isolation 
was still quite crude, and there appeared to be no degradation of the AZAs during small-scale trials, 
it was deemed appropriate to use acetic acid in the eluent at this point of the procedure. Of all the 
steps, silica gel chromatography (step 4) gave the greatest efficiency in terms of clean up (93%) and 
recovery (~95%) (Table 7).
In the next chromatography step, on sephadex LH20, the AZAs eluted together after ~64 min and 
were collected in 11 fractions. A clean-up efficiency of 66% was achieved with a recovery of 85%. 
In the subsequent flash chromatography step, previous isolation procedures used an acidic mobile 
phase with a RP-8 stationary phase.11,12 However, the sample is significanly cleaner at this point so 
there is a risk of acid-promoted degradation of AZAs during storage or evaporation. The use of 
triethylamine proved to be a safer alternative, with the toxins being stable whilst stored in the freezer 
as a dry sample (after evaporation of the mobile phase containing 0.1% triethylamine).
A comparison between RP-8 and phenyl-hexyl (which proved effectual by Ueoka et al in the 
isolation of AZA2 from a marine sponge10) stationary phases was additionally performed. Both 
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phases performed similarly in terms of clean-up efficiency and recovery however the phenyl-hexyl 
proved to be much more efficient at separating the AZA analogues than the RP-8 stationary phase 
(Table 7). Separation of the AZA analogues at this stage in the procedure improved recoveries and 
purities in the final semi-preparative HPLC step (step 7), so the phenyl-hexyl stationary phase was 
chosen for flash chromatography. This step resulted in a clean-up of 64% and a recovery of ~90%.
Final clean-up was performed using semi-preparative chromatography (C8 or C18) with UV detection 
(210 nm). An acidic mobile phase was previously used for this step11,12 but to prevent any stability 
issues, a neutral mobile phase was chosen. Acceptable chromatography was obtained for AZA1 
and -2 using the neutral mobile phase, but broad, fronting peaks were observed for those analogues 
which lack a methyl group at the C22 position e.g., AZA3 and -6. Fractions from the semi-preparative 
HPLC purification were diluted with water and recovered on SPE cartridges to remove any buffer 
trace contaminants introduced via the LC eluents. This also reduced the water content and volume 
of the AZA fractions prior to evaporation. This SPE recovery resulted in very little loss of toxin, with 
recoveries of >95% being achieved, and greatly facilitated evaporation of the purified AZA-fractions to 
dryness. 
Overall recoveries improved 2-fold from ~23% in the ASTOX project12 to ~52% for this work64 
(Table 7). 
Table 7. Batch summary table for purification of AZA1–3 and AZA6 from Mytilus edulis.
Step 
No
Step AZA1 
(mg)
AZA2 
(mg)
AZA3 
(mg)
AZA6 
(mg)
Weight 
(g)
Subsampling (HP) 14.1 4.0 4.8 0.78 505.0
1 1st crude extract 14.0 3.9 4.7 0.77 26.9
2 1st partitioning 13.3 3.7 4.4 0.73 23.9
3 2nd partitioning 12.6 3.5 4.2 0.69 8.9
4 Silica gel 11.9 3.3 4.0 0.65 0.6
5 LH20 10.1 2.8 3.4 0.55 0.2
6 Flash (phenyl-hexyl)* 9.2 2.5 2.4 0.49 -
7 Prep HPLC (C8/C18) 7.3 1.7 2.0 0.30 -
% Recovery 52 43 43 38
% Purity >95 >95 >95 >95
* AZA1–3 and AZA6 were separated from each other in this step. 
Using this method 11 AZAs (AZA1–10)64,80 and 37-epi-AZA181 were purified and their structures 
confirmed by NMR (Table 11).
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6.3. Isolation from phytoplankton
Marine biotoxins are ideally isolated from cultures of the producing organism due to the initial 
extract being significantly cleaner than from shellfish, and therefore requiring fewer purification 
steps.59–61 Once the causative organism was identified40 significant efforts (see Section 4) were 
successfully made as part of ASTOX 2 to bulk culture the A. spinosum. 
6.3.1. Isolation from A. spinosum
The A. spinosum extracts obtained using HP-20 were considerably purer (Table 8) than the shellfish 
extracts (Table 7). Hence, it was expected that fewer purification steps would be required. As with 
the isolation from shellfish, the crude extract was initially partitioned between ethyl acetate and 
1 M sodium chloride. The step resulted in a clean-up of 57% and a recovery of 90%. The sample was 
further purified by chromatography on a silica gel column giving a very high efficiency in terms of 
clean up (87%) and recovery (~91%, Table 8).
Table 8. Batch summary table for purification of AZA1 and -2 from A. spinosum.
Step 
No
Step AZA1
(mg)
AZA2
(mg)
Weight
(g)
Purity 
(%)†
HP-20 resin extract 12.5 3.2 3.04 0.5
1 Partitioning 11.2 3.0 1.32 1.1
2 Silica gel 10.2 2.8 0.17 7.6
3 Flash (phenyl-hexyl)* 9.7 2.4 0.01 >90
4 Prep HPLC (C8/C18) 9.3 2.2 - >95
% Recovery (steps 1–4) 75 70
*AZA1 and -2 were separated from each other in this step 
†For total AZA1 + AZA2, based on w/w
The third step was flash chromatography using a phenyl-hexyl stationary phase and a weakly alkaline 
mobile phase, resulting in separation of AZA1 and -2. This step resulted in the highest clean-up 
(93%) and recovery (95%) (Table 8).
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Final purification was achieved by semi preparative HPLC using a neutral mobile phase. Fractions 
were collected based on UV detection (210 nm) to facilitate removal of non-AZA components. This 
step resulted in recoveries of ~93%. 
Finally, SPE cartridges were used to remove buffer remaining in the sample, as well as to reduce the 
water content in, and volume of, the AZA fractions prior to evaporation, and as an additional final 
clean-up step to remove trace contaminants introduced via the LC eluents. The 1H NMR spectra of 
AZA1 and -2 were compared to published NMR data and found to be identical. Examination of the 
spectra indicated purities of >95%. Six successive culture lots (1,200 L harvested in total) enabled 
the recovery of 9.3 mg of purified AZA1 and 2.2 mg of purified AZA2.
Overall recoveries (steps 1–4) were 75% for AZA1 and 70% for AZA2. This recovery is a significant 
improvement compared to isolations from shellfish with recoveries increasing by a factor of ~1.5. 
Furthermore, the procedure is easier to perform with two less clean-up steps after extraction 
being required to achieve sufficient purities (Figure 29).
6.3.2. Isolation from A. poporum
Two strains (North sea and Korean) of A. poporum were bulk cultured (see section 4.4.2) for 
purification using the procedure described in section 6.3.1. From the pellet produced from 
the North Sea strain, an AZA with a m/z of 858 (and a fragment m/z of 348) was purified and 
subsequently named AZA36 (Table 9).
Table 9. Batch summary table for purification of AZA36.
Step
No
Step AZA36
(mg)
Weight
(g)
Purity 
(%)†
HP-20 resin extract 1.70 1.03 0.2
1 Silica gel 1.60 0.25 0.6
2 Flash (phenyl-hexyl) 1.57 0.01 20.0
3 Prep HPLC (C18) 1.28 - >95
% Recovery (steps 1–3) 75
† based on w/w
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From the pellet produced from the Korean strain, an AZA with a m/z of 846 (and a fragment m/z of 
348) was purified and subsequently named AZA37 (Table 10).
Table 10. Batch summary table for purification of AZA37.
Step
No
Step AZA37
(mg)
Weight
(g)
Purity
(%)†
HP-20 resin extract 1.30 8.30 <0.1
1 Ethyl acetate partitioning 1.20 0.74 0.2
2 Silica gel 1.05 0.18 0.6
3 Flash (phenyl-hexyl) 0.92 <0.01 40.0
4 Prep HPLC (C18) 0.89 - >95
% Recovery (steps 1–4) 69
† based on w/w
Six AZAs (AZA1 and -270, AZA33 and -3482 and AZA36 and -3783) were purified using this method. 
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6.4. Purity assessment
An LC-MS scan was performed in the range m/z 100–1000, followed by LC-MS/MS (SIM) analysis 
for all the known AZA analogues as well as for any additional masses picked up in the MS scan. The 
sample was also analyzed using the LC-PDA semi-preparative method to ensure that no additional 
peaks were observed in the UV trace. To determine whether strongly retained compounds, such as 
phthalates, were present in the sample, isocratic LC-PDA was performed. NMR analysis had shown 
the presence of a phthalate in some fractions that was detectable by LC-PDA (λmax 205, 225 and 
275 nm). The contaminant was conveniently removed by partitioning with hexane. Once samples 
were sufficiently pure (LC-MS/MS and LC-PDA), they were prepared for NMR spectroscopy. The 
1H NMR spectra of AZA1–3 were compared to published NMR data and found to be essentially 
identical, and examination of the spectra indicated purities of >95%. 
Figure 30. 1H NMR spectrum of AZA1 in CD3OD.
6.5. Minor analogues and novel AZAs
Over the course of ASTOX up to 30 AZA analogues were identified in shellfish extracts.33 Further 
studies revealed how many of these analogues are formed – via metabolism.75,84 Apart from AZA1–
3, other known and novel analogues (13) were isolated to determine their relevance in terms of 
food safety, but also to study SARs. 
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AZA4–10 were isolated from shellfish in sufficient quantities to enable structural determination 
by NMR, the preparation of reference standards and for toxicity testing. Structures for AZA6–10, 
previously proposed by LC-MS/MS, were confirmed by NMR spectroscopy. The relative toxicities of 
these analogues are detailed in Table 11.
The development of an LC-MS/MS method for lipophilic toxin analysis using a neutral mobile phase 
led to the discovery of unidentified isomers of AZA1, -2 and -3 in tissue and calibrant CRMs.15 These 
isomers were resolved using a neutral eluent, but co-eluted with the parent toxin under acidic85 and 
basic86 conditions. The proportion of these isomers for AZA1–3 in the tissue CRM ranged from 
2–15% of their parent analogues. This finding is significant due to the potential of these isomers 
to interfere with the accuracy of analytical results. These isomers were found to be C37 epimers 
following the isolation of 37-epi-AZA1 (from shellfish) and subsequent structural elucidation using 
LC-MS/MS and NMR81 (Table 11). Studies revealed that the epimers are spontaneous epimerization 
products whose formation is accelerated with the application of heat and most likely exist for all the 
AZA analogues. Interestingly, toxicity assessment using the Jurkat T lymphocyte cell assay indicated 
that the epimers are more toxic than the parent analogues81 (Table 11).
An additional compound was isolated from shellfish with a mass of 823 Da, which had previously 
been proposed as dehydro AZA1 by Rehmann et al.33 The compound, named AZA26, was found not 
to be dehydro AZA1 but instead had a ketone functionality at C23.87 Very low levels were detected 
in shellfish and it is not considered of relevance to human health, however, the fact that it was found 
to be significantly less toxic than AZA1 (Table 11) is of interest in terms of structure activity.
LC-MS/MS analysis of A. spinosum extracts revealed the presence of other AZA analogues with 
masses of 715 and 815 Da, subsequently named AZA33 and -34, respectively. Sufficient quantities 
were available in bulk cultures of the A. spinosum to enable isolation for NMR structural elucidation 
and toxicity testing.82 Both compounds were found to differ from AZA1 at the carboxyl end of the 
molecule (Table 11) and although they were not found in shellfish at significant levels their structural 
and toxicity differences provided valuable information.82 
A further two previously unknown compounds were isolated from a bulk culture of A. poporum and 
were named AZA36 and -37. These compounds differed in that they lacked a methyl group at C39 
compared to all the other isolated AZAs and that they have a 3-hydroxy substitution, that so far 
had only been observed in shellfish metabolites of AZA1 and -2, (Table 11). Toxicity testing revealed 
that both AZAs were less toxic than AZA1, with a relative potency of 0.33 for AZA36 and 0.16 for 
AZA37 in comparison to AZA1.83
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In total, 16 AZA analogues were purified in ASTOX 2 from shellfish and phytoplankton, 11 of which 
were fully characterised by LC-MS/MS and NMR for the first time. 
Table 11. Structural variants of AZAs, their protonated masses, origin and toxicity.
Left hand side (LHS) Right hand side (RHS)
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b
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H
H
HO
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O
O
H
H
O
HN
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R5
OH
OR3
1
2
1 3
7
19 21
20
8
22
23
30
39
A
B
C D E
F
G
H
I
37
 Type§ R1 7,8 R2 R3 R4 R5 R6 [M+H]
+ Origin Status
Toxicity 
(Jurkat) 
EC50
AZA1 a1 H Δ H H CH3 H CH3 842.5 A. spinosum phycotoxin 1.1
37-epi-
AZA1 a1 H Δ H H CH3 H CH3 842.5 A. spinosum phycotoxin 0.2
AZA2 a1 H Δ CH3 H CH3 H CH3 856.5 A. spinosum phycotoxin 0.3
AZA3 a1 H Δ H H H H CH3 828.5 shellfish metabolite 0.6
AZA4 a1 OH Δ H H H H CH3 844.5 shellfish metabolite 2.0
AZA5 a1 H Δ H H H OH CH3 844.5 shellfish metabolite 3.0
AZA6 a1 H Δ CH3 H H H CH3 842.5 shellfish metabolite 0.2
AZA7 a1 OH Δ H H CH3 H CH3 858.5 shellfish metabolite -
AZA8 a1 H Δ H H CH3 OH CH3 858.5 shellfish metabolite 0.3
AZA9 a1 OH Δ CH3 H H H CH3 858.5 shellfish metabolite 1.9
AZA10 a1 H Δ CH3 H H OH CH3 858.5 shellfish metabolite 3.1
AZA26 a2 H Δ H - - - - 824.5 shellfish metabolite 36.6
AZA33 b1 - Δ - H CH3 H CH3 716.5 A. spinosum phycotoxin 5.2
AZA34 c1 - Δ - H CH3 H CH3 816.5 A. spinosum phycotoxin 0.2
AZA36 a1 OH Δ CH3 H CH3 H H 858.5 A. poporum phycotoxin 5.0
AZA37 a1 OH - H H CH3 H H 846.5 A. poporum phycotoxin 6.3
§ The type refers to variations of the LHS and RHS parts of the molecule. 
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6.6. Structure confirmation/elucidation
6.6.1. LC-MS/MS spectra
CID mass spectra of AZAs are characterized by specific fragmentations of the molecule, which are 
followed by several water losses. The molecular ion usually cleaves off up to six molecules of water 
(group 1 fragments). The smallest cleavage (apart from a water loss) is caused by a retro Diels Alder 
(RDA) reaction of ring A (A-ring cleavage), where the bonds between C6 and the ether bridge and 
between C9 and C10 are cleaved. This results in the loss of C1–C9 with its substituents, followed 
by several water losses resulting in the group 2 fragments. The second fragmentation of the carbon 
skeleton is the C-ring cleavage, where the bonds between C15 and C16 as well as the bond between 
C17 and the ether bridge of the C-ring are cleaved. The remaining fragment, with its water losses, 
gives the group 3 fragments. By the C-ring cleavage, the C1–C15 part of the molecule is eliminated. 
The group 4 fragments are formed by the E-ring cleavage (RDA), where C1–C23 is eliminated. 
Before identification of the AZA-producing organisms, all published AZAs had diagnostic 
substituents located at C1–C23, and all shared the remaining m/z 362 fragment. The 39-desmethyl 
AZA variants form m/z 348 as the major ion in the group 4 fragments. Other fragmentations of less 
diagnostic value are the cleavage between C27 and C28 resulting in the group-5 fragments, with m/z 
262/248 and the G-ring cleavage giving the group-6 fragments with m/z 168/154.47–49 
Apart from these general fragmentation patterns, a specific fragmentation pathway exists for 
3-hydroxy-AZAs, which can be observed within the molecular ion cluster. In addition to the 
subsequent water losses from the pseudo-molecular ion, which is common among all AZAs, 
3-hydroxy-AZAs also eliminate CO2 followed by several water losses. The fragments resulting from 
the CO2 elimination are not very abundant (typically they make up to ~20% of the highest peak), but 
are clearly visible. Another fragmentation pathway unique for 3-hydroxy-AZAs is the elimination of 
a 78 Da fragment equivalent to C2H6O3, which probably is caused by a cleavage between C2 and C3 
combined with one water loss. Like the CO2 elimination, this fragmentation pathway is not dominant, 
but the combination of a CO2 cleavage and a 78 Da-elimination is characteristic for 3-hydroxy-AZAs.
The only differences in the LC-MS/MS spectra between the parent analogue and its 37-epimer were 
minor changes to the ratio of the RDA (m/z 672/654 and 462) fragment ions.81
The mass spectrum of the AZA33 showed typical AZA type structure water loss fragments (m/z 
698 and 680). Additionally a fragment peak for the m/z 362 and 462 ions indicated that the amine 
end of the AZA1 compound was present. No RDA fragment was present, suggesting that the A ring 
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system of AZA1 was different in AZA33. AZA34 also displayed water loss fragments (m/z 798 and 
780), a RDA fragment, in addition to the typical m/z 362 and 462 ions.82
AZA36 and AZA37 display the same group fragments as the other AZAs, except that all fragments 
are shifted m/z 14 lower masses, because of the missing methyl group at C39, i.e., m/z 658 instead of 
m/z 672 for group 2, m/z 448 instead of m/z 462 for group 3, m/z 348 instead of m/z 362 for group 
4, etc. It is also noteworthy that the saturation of the 7,8 doublebond in ring A of AZA37 results 
in a different fragmentation of ring A: instead of the fragment m/z 658 a bigger fragment m/z 686 is 
formed.83 This modified fragmentation pathway will help to identify structural characteristics of new 
AZAs by LC-MS/MS.
The mass spectrum of AZA26 showed typical AZA type structure water loss (m/z 806 and 788) 
and RDA (m/z 672) fragments. Additionally a fragment peak for the m/z 362 and 462 ions indicated 
that the amine end of the AZA compound was present.87 
6.6.2. NMR studies
AZAs consist of chains of carbon atoms substituted with hydrogen atoms with and connected with 
ether links and an amino link. The 1H and 13C nuclei are particularly amenable to NMR spectroscopy, 
and it is this method, supplemented by LC-MS/MS, that has primarily been used for AZA structure 
determination. The structure of AZA1 was established in this way and full 1H and 13C NMR 
assignments were reported in 1998.2 Subsequent isolation of two other AZAs led to structural 
elucidation of AZA2 and -3 and presentation of their full 1H- and 13C NMR assignments.3 AZA4 and 
AZA5 are hydroxylated analogues and were isolated in smaller amounts, such that only 1H NMR was 
obtained.77 It should be noted that these NMR studies did not reveal the absolute stereochemistry 
of the AZAs, nor even their complete relative stereochemistries. From 2000, the first syntheses of 
AZA substructures began to be reported. This synthetic activity88–91 eventually led to the definition 
of the absolute stereochemistry of AZAs, which is not accessible from normal NMR analyses.
Establishing the 2- and 3-dimensional structures of complex molecules by NMR spectroscopy 
requires the presence of useful through-bond 1H–1H and 1H–13C connectivities, through-space 1H–1H 
NoE interactions, and coupling constant information. In complex organic molecules, some of these 
correlations can be absent or hard to observe due to overlapping signals or unfavourable coupling 
constants, preventing full structure determination from NMR spectra alone. A series of synthetic 
studies by Nicolaou et al revealed that the originally proposed structure of AZA1 was incorrect, and 
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eventually established the absolute stereochemistry and correct structures of AZA1–3 as shown in 
Table 11.88–91 The structures of the remaining AZAs have been revised accordingly (Table 11), with a 
consequent re-assignment of the original NMR assignments for resonances associated with C7 and C9.
AZA6 was isolated and its structure, proposed originally from MS data, was established by NMR.64 
AZA7–10 have also been isolated, and their structures originally proposed from MS studies, were 
confirmed by NMR80 (Table 11). However, NMR analysis of AZA2687 showed a different structure 
to that originally proposed from MS studies.33 Most of the remaining AZAs (i.e., AZA11–23 and 
AZA29–32) have not yet been characterised by NMR, and their structures therefore remain tentative. 
Additional structural information was derived for AZA17, -19, -21 and -23 following the discovery that 
these AZAs convert to analogues with established structures (AZA3, -6, -4, and -9 respectively).84
6.6.3. Characterisation reactions 
In addition to NMR a number of different approaches were used to support structural hypotheses. 
All AZAs have a carboxyl group at the C1 position. Treatment of a sample with diazomethane, 
which specifically reacts with a carboxyl moiety to produce the methyl ester, was used to confirm 
the presence of the carboxyl group for some AZAs.47 This method has also been used to confirm 
the identity of AZA methyl derivatives.64,68 In addition, derivatisation of the free carboxyl group on 
AZAs with 9-anthryldiazomethane (ADAM)92 was used to differentiate between methyl esters of 
AZAs and methyl ketals.68
The presence of a diol at C21–C22 can also be confirmed by reaction with sodium periodate, 
which cleaves the cis diol on AZAs to produce a lactone derivative containing only C21–C40 with 
appended functional groups. This method was used to support structural evidence for dehydro-
AZA333 and for structural confirmation (C21–C40) of AZA664 and AZA33 and -34.82
6.6.4. Relative molar response study
Reference standards were prepared for the majority of the isolated analogues. Accurate quantitation 
of these standards by qNMR facilitated their use in relative molar response studies. The molar 
responses of AZA4–10 were assessed against AZA1. A number of LC-MS/MS experiments were 
performed. Only slight differences were observed between the gradient and isocratic results in SIM 
mode with the isocratic conditions giving somewhat higher results. The response factor of AZA6 
matched most closely that of AZA1 under isocratic conditions in both SIM and SRM modes. All the 
other hydroxylated analogues gave lower response factors, in particular for AZA7 and -9 (Table 12). 
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Table 12. Results for AZA analogue relative molar response (to AZA1) by LC-MS/MS using acidic 
HPLC conditions.
AZA SIM SRM isocratic SRM gradient
isocratic gradient Water 
loss
RDA 462 362 Water 
loss
RDA 462 362
37-epi-AZA1 0.93 - 0.88 0.91 0.75 1.1 0.86 0.91 0.75 1.1
4 0.88 0.75 0.80 0.81 0.86 0.96 0.96 1.03
5 0.77 0.70 0.55 0.47 0.47 0.61 0.54 0.53
6 0.95 0.93 1.06 1.21 1.17 1.05 1.21 1.13
7 0.45 0.40 0.37 0.33 0.37 0.40 0.37 0.40
8 0.84 0.81 0.58 0.41 0.47 0.59 0.47 0.51
9 0.53 0.49 0.45 0.48 0.61 0.50 0.53 0.68
10 0.69 0.67 0.47 0.46 0.49 0.48 0.49 0.51
33 0.97 1.03 1.05 0.80 0.90 1.03 0.77 0.91
34 1.05 1.01 1.17 0.39 0.87 1.22 0.41 0.90
6.6.5. Toxicity testing
The analogues were assessed for toxicity using the Jurkat T lymphocyte cell assay. Issues with 
impurities for AZA7 due to the presence of other AZA contaminants prevented it from being 
subjected to the Jurkat cell assay. All other AZA analogues tested were cytotoxic to Jurkat T 
lymphocyte cells in a time- and concentration-dependent manner. However, there were distinctive 
differences in the relative potencies of each analogue as determined by their respective EC50 values 
(Table 11). Relative to AZA1 (used to normalize all potencies based on EC50 values) the potency 
order was: 
AZA2 > AZA6 > AZA34 ≈ 37-epi-AZA1 > AZA8 ≈ AZA3 > AZA1 > AZA4 ≈ AZA9 > AZA5 ≈ 
AZA10 > AZA33 ≈ AZA36 > AZA37 > AZA26.
The results indicate AZA potency is gained by methylation of C8 and/or C22 (AZA2, -6) while AZA 
potency is reduced by C3 and/or C23 hydroxylation (AZA4, -5). The A. poporum toxins (AZA36 and 
-37) that each have a hydroxyl group at C3, and lack a methyl group at C39, were found to be less toxic.
AZA33 (AZA1 missing A/B/C rings) was less potent than AZA1 (~5-fold), whereas AZA34 (AZA1 
missing C4/C5 alkene) was 5.5-fold more potent. Similarly, 37-epi-AZA1 was 5.1-fold more potent 
than AZA1. 
Semi-synthetic hydrogenated AZA1 analogues, 4,5-dihydroAZA1 and 4,5,7,8-tetrahydroAZA1, were 
also tested. Both compounds were found to be approximately equipotent to AZA1 suggesting that 
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the C4/C5 alkene and the C7/C8 olefin bonds are not necessary for toxicological activity (see also 
section 11.6).
Interestingly AZA26 was the least potent (~30–40-fold less toxic) of all the analogues tested. This 
compound differs from the other analogues by having a ketone functionality at C23 and lacking the 
C20–21 diol. These results suggest that it is this middle part of the molecule which confers the 
potency. However, a previous study by Ito et al11 in which truncated analogues were synthesised 
and tested in mice for toxic effects concluded that the whole molecule was necessary for toxicity. 
One of the truncated analogues contained the diol at C20–21 and the methyl group at C23 but 
lacked the F, G, H and I rings and it exhibited no measurable toxicity. The same study also found 
that altering the orientation of the functional groups from C1–C20 (in the AZA1 structure) had a 
significant effect – resulting in little or no toxicity. 
6.6.6. Proportions of AZA analogues
To determine the proportions of the analogues (relative to AZA1), raw shellfish contaminated with 
AZAs were cooked so that AZA3, -4, -6 and -9 could be determined. These analogues are heat 
induced decarboxylation products of AZA17, -21, -19 and -23 respectively.84 The analysis of cooked 
shellfish reflects what is typically ingested by the consumer. Additional differences have been reported 
between the analysis of raw and cooked shellfish in terms of concentration levels.17 Figure 31 shows 
that AZA1–3 and -6 are the predominant toxins. The levels of the remaining analogues relative to 
AZA1 are low, with AZA5 comprising ~7% while AZA4, AZA7–10, AZA33 and -34 are all below 3%. 
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Figure 31. Proportions of AZA2–10, AZA33 and -34 relative to AZA1 in cooked shellfish (n=20).
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Table 13. Distribution of purified AZAs to project partners. 
Compound Amount (mg) Sent to Purpose
AZA1 1.70 UM Jurkat T lymp. cell assay
AZA2 0.43 UM Jurkat T lymp. cell assay
AZA3 0.40 UM Jurkat T lymp. cell assay
AZA4–10, 37-epi-AZA1, 
AZA33 and -34
~0.05 UM Jurkat T lymp. cell assay
AZA1 0.27 NSVS ip mouse study (LD50)
AZA2 0.15 NSVS ip mouse study (LD50)
AZA3 0.23 NSVS ip mouse study (LD50)
AZA6 0.22 NSVS ip mouse study (LD50)
AZA1 1.5 University of Trieste Oral mouse study
AZA2 1.5 University of Trieste Oral mouse study
AZA3 1.5 University of Trieste Oral mouse study
AZA1 3.5 NRCC CRMs
AZA2 3.5 NRCC CRMs
AZA3 3.5 NRCC CRMs
AZA1 0.22 NVI ELISA
AZA2 0.01 NVI ELISA
AZA3 0.01 NVI ELISA
AZA6 0.003 NVI ELISA
AZA1 2.0 Perkin Elmer Tritiation
AZA1 0.22 MI Mussel feeding
AZA2 0.28 MI Mussel feeding
AZA3 0.13 MI Mussel feeding
AZA6 0.015 MI Mussel feeding
AZA1 2.1 QUB Antibody work
AZA2–10 ~0.005 QUB Antibody work
Biotoxin monitoring programs within the EU only analyse raw shellfish and typically low levels of AZA3 
are detected in such samples.5 In cooked shellfish, levels of AZA3 and -6 ranged widely, probably due 
to the different rates of AZA1 and -2 metabolism (oxidation of methyl at C22 to produce the carboxy 
analogues AZA17 and -19 respectively) in the shellfish tested. These results highlight the degree to 
which AZA equivalents are underestimated in routine monitoring programs where uncooked shellfish 
are tested, and suggest that AZA6 should be included in the AZA regulation. Previously, levels of AZA 
analogues other than AZA1–3 were reported to comprise less than 5% of the total AZA equivalents33, 
however, this study indicates that the AZA analogues 4–10, as well as AZA33 and -34, comprise ~17% of 
the total AZA content with AZA6 being the most significant (~12%). Different toxin profiles have been 
reported from other countries whereby AZA2 is more predominant than AZA10,17,93,94, suggesting that 
shellfish from these locations are more likely to contain higher levels of AZA6 and -10, and to a lesser 
extent AZA9. In such circumstances these analogues may have greater significance.
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6.7. Analytical methods and CRMs
With the shift towards chemical monitoring methods (away from the MBA) for lipophilic toxins, 
including AZAs, it is important that appropriate RMs are available. RMs are essential for the 
development, validation and quality control of analytical methods66 and can generally be classified 
in two categories: pure standard RMs are necessary for instrument calibration while matrix RMs 
are designed to assess the performance of entire analytical methods, including: testing of extraction 
methods; assessing matrix effects; and evaluating the accuracy of measurement or determination steps. 
As part of the ASTOX project significant work was performed on the isolation and purification of AZAs 
for the preparation of AZA calibrant RMs.11 Work was also carried out by the NRCC in collaboration 
with the UK Food Safety Authority.95 These efforts led to the production of CRMs for AZA1, -2 and 
311, which are commercially available from the NRCC (Table 14).96 Certified values were assigned using 
qNMR97, with confirmation through a relative molar response study based on LC-FLD analysis following 
ADAM derivatisation.92 Isolation procedures for AZAs have been further improved to ensure continued 
supply of pure AZAs for production of calibrant CRMs.64 AZA matrix RMs were also developed as part 
of the ASTOX project.11 Studies were aimed at the production of homogeneous and stable materials, 
primarily prepared from mussel tissues. A variety of stabilisation techniques were studied, including 
gamma irradiation and freeze-drying.98,99 This extensive feasibility work led to the production and 
certification of a mussel matrix CRM with assigned values for AZA1–3.13 Certified values were assigned 
using direct analysis by LC-MS/MS, and confirmed by LC-FLD following ADAM derivatisation.92 Recently, 
as part of an international collaboration, a multi-toxin CRM containing AZAs was prepared as a freeze-
dried mussel powder14, and this has been utilised in method validation exercises.100 
Table 14. List of AZA CRMs available from the NRCC.
Product CRM type
Certified 
analyte Concentration Uncertainty
CRM-AZA1 Calibration solution AZA1 1.47 µmol/L 0.08
CRM-AZA2 Calibration solution AZA2 1.50 µmol/L 0.06
CRM-AZA3 Calibration solution AZA3 1.25 µmol/L 0.05
CRM-AZA-Mus
*
Mussel matrix 
(wet homogenate) AZA1 1.16 mg/kg 0.10
AZA2 0.273 mg/kg 0.024
AZA3 0.211 mg/kg 0.023
CRM-FDMT1
*
Mussel matrix 
(freeze-dried powder)
AZA1 4.07 mg/kg 0.26
AZA2 1.13 mgkg 0.07
AZA3 1.00 mgkg 0.06
* Certified values are traceable to the International System of Units (SI) through the use of NRCC CRMs.
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7. Mini pig study
7.1. Introduction
Little is known about the toxicokinetics and toxicodynamics of AZAs. To date, few animal trials 
have been carried out to assess the oral toxicity of AZAs and in all of the studies only mice have 
been used. These studies have shown AZA1 to cause extensive damage (Section 9). 
Pigs are often used in toxicology studies as they possess similar anatomic and physiological 
characteristics to humans; their cardiovascular, urinary, integumentary and digestive systems being 
similar. These animals were therefore chosen to further investigate the oral toxicity of these 
compounds.
7.2. Preparaton of pig feed
An initial (pilot) mini pig feeding trial was carried out in the NSVS using one mini pig. Feed was 
prepared using naturally contaminated Mytilus edulis tissue that was further concentrated using 
semi isolated AZA1, -2 and -3. It was necessary to prepare the feed using semi isolated AZAs as it 
was not possible to obtain AZA contaminated shellfish at high enough concentrations to allow for 
the direct mixing of shellfish with commercial pig feed. To obtain the semi isolated AZA material, 
AZAs were isolated from contaminated mussels using the first four steps of the isolation process 
(Figure 29). In order to ensure that the mini pigs would consume the feed, it was necessary for 
it to resemble the commercial feed as much as possible. High proportions of AZA contaminated 
hepatopancreas could make the feed unpalatable. 
The feed was prepared by adding semi-isolated AZA1, -2 and -3 to ~20 g of homogenised and sieved 
pig feed pellets. This was achieved by dissolving the AZAs in 20 mL of methanol in a round bottomed 
flask, adding the feed and removing the methanol on a rotary evaporator at room temperature. 
To this dried feed, an additional 90 g of dry pig feed was added and homogenized, followed by the 
addition of 22 mL of water. Using a 5 mL syringe, cylindrical rows of feed were extruded and cut 
into pellets using a scalpel. These were allowed to air dry overnight. Moisture content analysis was 
carried out on the pellets to ensure they were similar to the pig acclimatization feed. Four portions 
of feed (~1 g) were weighed out and placed in an oven at 104 °C for 24 h. The moisture content was 
determined to be 10.5±0.5%, which compares well to the moisture content (11%) of the commercial 
pig feed to which the pigs are acclimatised prior to the trial. The contaminated pig feed also had a 
similar appearance and texture to the uncontaminated pig feed (Figure 32).
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The mean AZA1, -2 and -3 combined concentration of the feed was 16.6 µg/g (Table 15). Sub-
samples (n=12) were analysed and the feed shown to be homogenous (Table 15). 
Table 15. AZA (AZA1–3) concentration in pig feed prepared for initial pig feeding trial.
AZA1 AZA2 AZA3
AZA 
Total
(No TEF)
AZA
Total 
(TEF)
Mean (µg/120g feed) 857.5 710.8 428.7 1997.1 2762.8
stdev 162.7 222.9
%CV 8.1 8.1
Figure 32. Pig feed pellets purchased from Special Dietary Services (left) and AZA1, -2 and -3 
contaminated pellets prepared in the MI (right).
The mini pig weight was ~8.3 kg, therefore the feed equated to 240.6 µg of AZA equivalents per kg of 
mini pig. EFSA base their exposure assessment on a 60 kg adult consuming a 400 g portion of shellfish. 
Based on the regulatory limit of 160 µg AZA1 equivalents/kg shellfish meat, a 60 kg adult would 
be exposed to 64 µg AZA1 equivalents in a single shellfish portion of 400 g. The mini pig received 
2,762.8 µg AZA1 equivalents in a 120 g food portion, which equates to a concentration of 23 µg/g (144 
times the EU regulatory limit). Once the contaminated feed was consummed the pig had access to 
AZA free feed and water until the end of the 24 h trial. Blood was sampled throughout the trial. 
The initial trial demonstrated that the technique for preparing the contaminated feed was suitable as 
all the feed was consumed. Analysis of tissues confirmed uptake and distribution of AZA1–3. 
Based on these results, it was decided to prepare the feed for the subsequent mini pig trial (using 
four mini pigs) at a level of 3,200 µg AZA equivalents. The feed was prepared as in the initial trial. 
Analysis of the feed was carried out by LC-MS/MS and shown to be homogenous (Table 16). 
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Table 16. AZA (AZA1–3) concentration in pig feed prepared for second pig feeding trial.
AZA1 AZA2 AZA3 AZA Total
Mean (µg/g) 17.1 4.6 3.0 24.7
stdev 1.7
%CV 6.8
The vacuum packed feed was forwarded to NSVS for the mini pig trial. Portions of the feed were also 
maintained frozen for future analysis if required. Each mini pig was dosed with 267 µg AZA1–3/kg pig 
(Table 17). 
Table 17. Dose rate of AZAs used in the second mini pig trial.
Pig
Pig weight 
(kg)
Feed weight 
(g)
AZA1
(µg)
AZA2 
(µg)
AZA3 
(µg)
Total
AZA1–3 
No TEF(µg)
Dose
µg AZA1–3/kg pig
1 9.0 97.4 1660.7 451.9 289.3 2401.9 266.9
2* 8.8 93.9 0.0 0.0 0.0 0.0 0.0
3 8.7 94.2 1606.1 437.1 279.8 2323.0 267.0
4 8.6 93.1 1587.4 432.0 276.5 2295.9 267.0
*Mini pig number 2 was used as the control.
In addition to AZA1, -2 and -3, the feed contained other AZA analogues (Figure 33) such that the 
concentration for AZA1–12 was 29.6 µg/g. 
Figure 33. Concentration of AZA analogues in pig feed.
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7.3. Toxicology study
In the first trial (pilot) no sickness (diarrhea, vomiting, etc) was observed in the one mini pig that 
was dosed (333 µg/kg). In the second trial three pigs and a control received the same dose. The only 
clinical observation was that the pigs were more sedate after 24 h compared with the control minipig.
Pathalogical changes were evaluated based on general histological descriptions on normal tissue 
structure and comparisons with the data from the pilot study, in addition to the histology in the 
control minipig. In general, the results showed that the second trial, in many aspects, was similar to the 
findings in the pilot study but there were also some differences. 
-Duodenum: The most obvious change was the presence of aggregates of multiple dark, round 
structures, interpreted as apoptotic bodies, in the lamina propria of the villi (Figure 34A, arrows). 
The apoptotic bodies seemed to be localised in large cells, probably macrophages. There were also an 
increased number of neutrophils in the lamina propria, some of which had disrupted nuclei, and thus a 
possible source for the apoptotic bodies. The epithelium was sitting on the basal lamina but on the villi 
the epithelial cells had vacuoles in the apical cytoplasm with eosinophilic round “bodies” (Figure 34C, 
arrowheads). There appeared to be a reduced number of goblet cells on the villi or the goblet cells 
were “empty”. The observed changes were noted in both trials. 
-Jejunum, ileum and colon: In the pilot study, the jejunum and ileum were unaffected. In the second 
trial, these segments displayed similar changes to those described for the duodenum. However, in the 
colon, the apoptotic bodies (Figure 34D, arrows) and increased number of neutrophils were localised 
in the outer lamina propria. In the ileum, the amount of apoptotic bodies in the lymphoid follicles 
also increased compared to the control but this needs confirmation (since there is ongoing apoptotic 
activity in these follicles in normal animals). 
-Stomach: In one animal, apoptotic bodies were found in the most distal part (pyloric part) of the 
outer lamina propria. The upper areas appeared to be normal.
-Liver: In the pilot minipig, the hepatocytes showed mild perilobular vacuolisation interpreted as 
hydropic degeneration. Liver sections were evaluated blind with changes recorded in 15 microscopic 
fields using a ×40 lens. The results showed that in the exposed minipigs (in the second trial), a 
multifocal distribution of hepatocytes with condensed, hypereosinophilic cytoplasm and dark, 
condensed nucleus was found (Figure 34F and H, asterisk). In the 15 fields, the number of cells varied 
between 3 and 47 in the three exposed animals. In the liver of the pilot, no such cells were recorded. 
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In the second trial, the hepatocytes of the exposed group also appeared to have large vesicular 
nuclei with more prominent nucleolus than in normal animals. The cells described are interpreted as 
multifocal, single cell degeneration/necrosis or apoptosis. Although differences were observed, the 
results from both studies indicated that the liver cells had been exposed to a harmful substance. 
-Spleen: In the second trial, changes were found that consisted of cell depletion and hemorrhages of 
the marginal zone with an increased number of neutrophils in the red pulp. Some of these cells showed 
apoptotic changes. In the pilot study observations consisted of a bloody marginal zone and ellipsoids. 
The ellipsoids did not contain erytrocytes in the second trial. 
-Lungs: In the lungs an increased number of neutrophils including apoptotic bodies, were found in the 
alveolar septa of the exposed animal.
-Pancreas: In one exposed animal, scattered single cells of the exocrine cells were rounded and 
small with a condensed nucleus, present inside a vacuole. This was interpreted as single cell death/
apoptosis.
In the other organs, histopathological changes were not noted or the possible changes need to be 
further investigated. 
The haematology/clinical chemistry analysis showed a moderate increase in the number of white 
blood cells of the exposed minipigs. The number of neutrophils increased after 4 h, and after 24 h 
the number increased by ~5-fold. The percentage of neutrophils (of all leucocytes) had increased 
from ~20 to 80%, while the number of lymphocytes lowered from ~60 to 20%.
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Figure 34. A/C) duodenum from exposed minipig, B) duodenum from control minipig, D) colon 
from exposed minipig, E) colon from control minipig, F/H) liver from exposed minipig, G) liver from 
control minipig.
The clinical chemistry analysis showed an increase in the level of several enzymes, especially AST, 
ALT, AP and GGT in the exposed minipigs compared to the controls (Figure 35). The data support 
the changes observed in the liver, as these enzymes are more or less specific for liver cell damage. 
However, damage to other tissues, such as the intestine, could also be a source for one or more 
of these enzymes. The increase in total bilirubin after 24 h in two of the exposed animals might 
indicate that the liver function is reduced. The reason for the marked increase in triglycerides in two 
of the exposed minipigs is not readily explained but some disturbance in the pancreatic function or 
hyperadrenocortisism (“stress”) might be possible causes.
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Figure 35. Levels of enzymes detected in minipig samples over the 24 h exposure period. (G3, was 
the animal with the hematoma).
7.4. Validation of method for pig feed tissue extraction 
and analysis 
7.4.1. LC-MS/MS matrix effects
Pig tissues that were free from AZAs were extracted and spiked with AZA standards. Different 
types (20) of pig tissues were extracted using a double methanolic extraction to investigate the 
extent of matrix effects using LC-MS/MS. Results for tissues that were found to give recoveries 
that were outside the limits of 100±15% were deemed to be enhanced or suppressed due to matrix 
effects. The tissues types that were worst effected by matrix effects (enhancement or suppression), 
were the buffy layer, brain tissue and jejunum (Figure 36). 
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Figure 36. LC-MS/MS matrix effects for AZA1, -2 and -3 in pig tissue extracts. 
7.4.2. Toxin extraction from animal tissues
Four different extraction methods were evaluated (Figure 37) using the brain tissue; a double 
methanolic extraction; double methanolic extraction with an ethyl acetate/water cleanup; double 
methanolic extraction with an SPE cleanup and an acetone extraction with an ethyl acetate/water 
cleanup. The acetone extraction with an ethyl acetate clean up proved to give the least amount 
of matrix interferences. This extraction technique also has the advantage of not producing AZA 
methyl derivatives.68 
The acetone extraction was then assessed for extraction efficiency. The first two extractions 
removed ~95% of AZA equivalents. 
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Figure 37. LC-MS/MS matrix effects for AZA1, -2 and -3 using different extraction techniques.
7.4.3. Toxin extraction from wet blood 
A method was developed for the extraction of AZA1 from spiked mouse plasma that yielded 
recoveries of ~100%. A similar method, employing acetonitrile followed by ethyl acetate extractions 
(three extractions; combining/drying supernatants) and a reverse-phase SPE clean-up was applied 
to AZA1 spiked mouse whole blood giving recoveries of ~100%. This method was used to extract 
AZAs from the minipig blood samples (see Section 7.5.2). 
Attempts to develop an extraction protocol for use with dried blood spots (i.e., blood spot cards), 
were only moderately successful, with maximum efficiencies of 50–70% achieved. Future efforts 
should investigate use of protein digests (e.g., pepsin), manipulation of physical variables (e.g., 
sonication), and tests of additional solvent systems.
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7.5. Tissue analysis
7.5.1. LC-MS/MS analysis
7.5.1.1. Initial trial
Triplicate analysis was performed on each tissue type (~2 g tissue) using a double acetone extraction 
with a triple ethyl acetate/water partition. The organic layer was dried under nitrogen and re-
suspended in methanol for LC-MS/MS analysis.
Twenty five tissue samples were analysed for fourteen AZA analogues, AZA1–12, AZA17 and -19. 
AZAs were found in many tissues of the mini pig indicating that AZAs entered the body and were 
absorbed into the blood stream. Interestingly, relatively small quantities (<0.75 ng/g) of the known 
AZA analogues were found in the faeces suggesting that absorption and metabolism had occurred. 
(Figure 38).
Figure 38. Concentration of AZAs in mini pig tissues from initial trial.
The mini pig in the initial trial displayed no AZA related symptoms (nausea, vomiting, diahorrea, 
etc). The information gathered from the trial was used to define the levels for the second trial and 
it was decided to use a triplicate dose at a higher AZA concentration, instead of three incremental 
doses.
NDP Marine Research Sub-Programme 2007-2013   
81
7.5.1.2. Second trial
The second mini pig trial used 4 mini pigs (3 dosed and one control). Due to complications with the 
catheter used for blood collection, Pig 3 did not consume the AZA contaminated feed as quickly as 
Pig 1 or Pig 4 (Pig 2 was the control).
AZAs were distributed throughout the tissues of the GI tract. After 24 h there was absorption of 
AZAs into the stomach (Figure 39) and to a lesser extent, the intestines (Figures 40 and 41). AZA1 
and -2 hydroxylates were found in the colon contents. These hydroxylates could be due to the 
alkaline conditions found in the small intestines and colon.
Figure 39. Concentration of AZAs in the feed and in the stomach (following 24 h).
AZAs found in other tissues indicate that AZAs have crossed the intestinal barrier, entered 
the bloodstream and have been transported throughout the body (Figure 41). The total AZA 
concentration recovered from the tissues was 14% of the administered dose. This indicates that the 
AZAs are metabolised or degraded in the process of digestion.
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Figure 40. Concentration of AZAs in the tissues of the GI tract.
Liver samples also showed a relatively high concentration of AZA1, -2 and -3 (~75 ng/g total), but 
interestingly, only showed very low concentrations of the other AZA analogues (Figure 41). 
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Figure 41. Concentration of AZAs in pig tissues from the second pig trial.
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The second trial contained animals dosed at the same level so it is possible to obtain information 
on the intra animal variability. Pig 1 and Pig 4 show good correlation for the majority of tissue types 
tested but due to the complications with Pig 3, there was a time delay with absorption of the AZAs. 
This can clearly be seen from the lower concentration of AZAs obtained (Figure 42). 
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Figure 42. Comparison of total AZA concentration in each of the four mini pigs per tissue.
7.5.2. Blood analysis
Complete, 24 h time course results were obtained from only two of three experimental animals 
due to sampling issues with the third. Interestingly, there was a clear difference between these two 
minipigs in the overall pattern of AZA uptake and elimination (Figure 43). One animal (Pig 1) showed 
a very rapid appearance of AZAs in the blood within 0.5 h (0.44 ng/mL AZA1–3), whereas the other 
(Pig 4) showed less than 20% of this amount (0.08 ng/mL AZA1–3) by the 1 h time point. Moreover, 
the highest AZA1–3 concentrations in the blood was attained within 3 h in the former, but not until 
2 h later (i.e., 5 h) in the latter minipig. Notably, the peak concentration in both animals was ~3- to 
4-fold higher than that recorded in the pilot study (from one pig). 
AZA1:AZA2 ratios were elevated initially (~5 to 6) compared to that measured in the contaminated 
feed (feed = 3.7) (Figure 43), suggesting that AZA1 was taken up faster into blood at the outset. 
Although the AZA1:AZA2 ratios declined to levels at or slightly below that in the feed as highest 
concentrations were reached, these ratios increased over the remainder of the experiment, 
indicating that either AZA2 was eliminated at a faster rate than AZA1, or AZA1 was remobilized 
into blood from other tissues. 
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Compared with the other two analogues, AZA3 entered the blood at levels far below its availability  
in the feed. In terms of elimination, both animals showed a generally consistent loss (albeit much 
slower than the uptake rate) of toxin after the highest levels were reached followed by a more 
gradual decline, with measurable levels of AZA remaining in the blood at the final 24 h time point 
(~2–3 ng/mL AZA1–3). 
The differences in AZA uptake observed between these two minipigs likely reflected inter-animal 
variability; however, the overall pattern for Pig 4 was most similar to that described for the pig used 
in the pilot study. 
Preliminary toxicokinetic/toxicodynamic modelling was performed, taking into consideration the 
exact dosage and starting ratios of the AZA analogues. Using a one compartment first order 
uptake/elimination model, it was estimated that the rate of AZA entry into the blood was ~10-fold 
the rate of toxin elimination, with a half-life of elimination from blood of ~12–24 h. 
Overall, AZAs are taken up into the minipig blood rapidly but at different rates:  AZA1 > AZA2 > 
AZA3. Importantly, this is the same order of relative potency (ip LD50) determined in the ASTOX 
2 project (in vivo mouse), implying that the most toxic analogue (AZA1) is taken up more rapidly 
and remains elevated longer in the bloodstream than less toxic AZA2 and -3. It remains to be 
determined whether this results in preferred delivery of AZA1 to other tissues and contributes to 
its higher relative potency.
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AZA in whole blood (Pig 4) AZA in whole blood (Pig 4)
Figure 43. Time course of individual AZAs and AZAtotal (left panel), and ratios of AZA analogues 
(right panel) in minipig blood following exposure to contaminated feed. Results are shown for 
animals G1 (top graphs) and G4 (bottom graphs).
7.6. Digestive simulation study
This study investigated what happens to AZAs when they are exposed to the chemical and physical 
conditions of the mammalian digestive system. The study was carried out by an in-vitro digestive 
simulation using AZA naturally contaminated mussels (Mytilus edulis), which mimics what is actually 
consumed as part of a meal. The investigation used the change in concentration of AZA1, -2 and 
-3 to indicate how AZAs change or degrade throughout the digestive process when they are 
consumed. The difference between cooked and uncooked mussel tissue was also investigated. 
Digestive simulated fluids (salivary, gastric and intestinal) were prepared in accordance with Naim et 
al, 2004.101
The three stage digestion simulation (salivary, gastric and intestinal) was monitored at eight time 
points and each time point was represented by three samples. To prepare the samples, aliquots of 
homogenised shellfish tissue (2 g) were weighed into 50 mL polypropylene centrifuge tubes. The 24 
samples to be cooked were placed in a closed centrifuge tube and placed in a water bath at 90 °C 
for 10 min.
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Three of each of the cooked and uncooked homogenates were extracted (double methanolic 
extraction) at t=0. Artificial saliva (AS) (2 mL at 37 ºC) was added to two of the 2 g portions of 
homogenised cooked and uncooked tissue samples and the samples slowly shaken for 1 min to 
simulate mastication. Simulated gastric juices (SGF) (16 mL) were then added to 18 homogenised 
cooked and uncooked tissue samples that had undergone the AS addition. These 36 samples were 
then placed in an incubated shaker for 1 hour at 37 ºC with gentle shaking. After 1 hour, three 
cooked and uncooked samples were removed. The remaining 30 samples were left to incubate at 
37 ºC for another 1 h to mimic an overall 2 h gastric simulation. The pH was adjusted to 8 for 
twelve of the remaining samples with 2 M NaOH. The simulated intestinal fluids (SIF) were added 
and allowed to incubate at 37 ºC for 4 h with three samples being removed for analysis every h.
Once the allotted time for each sample was reached, the reaction was stopped by placing 
the sample in an ice bath. The sample was centrifuged at 4500 rpm for 5 min at 4 ºC and the 
supernatant decanted into a centrifuge tube. The pH was adjusted to 7 and extracted three times 
with 5 mL portions of ethyl acetate. The ethyl acetate layers were combined and dried under 
nitrogen. The samples were re-suspended in methanol (10 mL) and analysed by LC-MS/MS. The 
pellets that remained after centrifugation were extracted by double methanolic extraction before 
analysis by LC-MS/MS.
Figure 44. Schematic of the procedure for the digestive simulation.
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The samples were extracted in triplicate at t=0 after cooking by double methanolic extraction. No 
changes were observed in the AZA1 and -2 concentrations between the cooked and uncooked 
tissues, while the levels of AZA3 increased by a factor of 3.6 from 0.06 µg/g to 0.22 µg/g. This 
increase is due to the heat induced decarboxylation of AZA17.84
7.6.1. Effects of gastric juices on AZA concentrations in uncooked mussels
AZA1 levels in the uncooked tissue decreased from 0.80 µg/g in the pellet to ~0.29 µg/g (Figure 45), 
while 36% remained in the tissue. This represents the portion that would be excreted. A further 
38.6% is bioaccessible (i.e., it is available for absorption) and the remaining 25.4% may be degraded, 
transformed or lost through some other means. AZA2 behaved similarly with 43.7% remaining in 
the pellet (Figure 45). Only 30% was present in the supernatant (representing the portion that was 
bioaccessible). 26% of AZA2 is transformed/broken down by the digestive process. 46% of AZA3 
(Figure 45) was found in the pellet, while ~54% was extracted from the supernatant.
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Figure 45. Concentration of AZA1, -2 and -3 remaining in the pellet (blue) and the supernatant 
digestive fluids (pink) at various time points throughout the digestive simulation using uncooked 
shellfish tissue.
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7.6.2. Effects of gastric juices on AZA concentrations in cooked mussels
Following completion of the digestive simulation on the cooked tissues ~90% of AZA1, -2 and 
-3 remained in the undigested tissue (pellet) (Figure 46). A possible hypothesis for this is that 
thermal denaturation of the proteins in the mussel tissue had occurred. As proteins are heated, the 
hydrogen bonds responsible for the native state of the protein can be disrupted, i.e., the tertiary 
structure of the protein is disrupted. An interaction between the amino and carboxyl groups during 
heat denaturation might diminish the lyophobic or polar properties of natural protein, whereas 
an unfolding of the peptide chains by surface denaturation might expose lyophobic groups to the 
surface, which in the native state, are buried in the interior.102 AZAs are lipophilic and weakly bound 
to a 45 kDa protein, it is possible therefore that AZAs are held in the tissue when cooked.103
It is difficult to make assumptions on the bioavailability of a toxin based on in vitro testing because 
the relationship between bioaccessibility and bioavailability is unclear. However, the bioaccessibility 
of AZAs, as demonstrated by in vitro testing, can be used as a maximum value (worse case scenario) 
for bioavailability. This study demonstrates that the bioaccessibility of AZAs is greater in uncooked 
shellfish. Ultimately, processing of mussels involving a heating step may lead to an increase in toxin 
levels due to interconversion of analogues of AZA and loss of water, but this heating may also 
render the AZAs less toxic due to inaccessibility. As a result, this may have implications for the 
recent evaluation of the current regulatory limit. 
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Figure 46. Concentration of AZA1, -2 and -3 remaining in the pellet (blue) and the supernatant 
digestive fluids (pink) at various time points throughout the digestive simulation using cooked shellfish 
tissue.
7.6.3. Effect of duration of cooking on availability of AZAs
The heat study was carried out on 2 g aliquots of raw mussel tissue naturally contaminated with AZA1, 
-2 and -3. The tissue aliquots were exposed to between 1 and 10 min of heating at 90 °C. At each of 
the time points the reactions were stopped by cooling the samples in an ice bath. These were then 
subjected to a full digestive simulation, i.e., the tissues were exposed to simulated saliva for 
1 min, followed by gastric juice for 2 h and pancreatic intestinal juices for 4 h. After the allotted time all 
samples were cooled in an ice bath, followed by separation of the digestion fluids from the remaining 
pellet by centrifugation. Extraction of the pellet was performed immediately. 
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Following a cooking time of 2 min, <90% of AZA1 and -2 remain in the pellet (Figure 47). The pellet 
represents the meat that would remain in the intestines and be excreted i.e., any AZAs contained 
in this portion would not be available for absorption in the body. This indicates that after 2 min of 
cooking at 90 °C, there is a reduction in the bioaccessability of AZA1 and -2. Similarly, the graph 
for AZA3 (Figure 47) indicates a reduction in bioavailabilty after cooking. Figure 47 also shows an 
increase in AZA3 due to the cooking process due to heat induced decarboxylation of AZA17.84 
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Figure 47. Concentration of AZA1, -2 and -3 remaining in the pellet (blue) and the supernatant 
digestive fluids (pink) at various time points throughout the heat study.
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8. Mouse ip study
8.1. Introduction
Mice exposed to mussel extracts containing AZA via ip injection exhibited “neurotoxin-like” 
symptoms characterized by sluggishness, respiratory difficulties, spasms, progressive paralysis, and 
death within 20–90 min.1,30,104
The ip minimum lethal dose of partially purified AZA1 was originally determined to be 150 µg/kg104, 
while from the first purified AZA1 a lethal dose was identified to be 200 µg/kg.2 The ip minimum 
lethal doses of AZA2 and -3 were 110 and 140 µg/kg, respectively3, suggesting higher potency 
relative to AZA1. These results have since been used for TEF determination and application for 
regulatory purposes.32 
The more polar AZA4 and -5 (hydroxylated versions of AZA3) were less potent with lethal dose 
values of 470 and <1,000 µg/kg, respectively.77
Ip injection of mice with a lethal dose (>150 µg/kg) caused swelling of the stomach and liver 
concurrent with reduction in size/weight of the thymus and spleen.105 There was vacuole formation 
and fatty acid accumulation in the hepatocytes, parenchymal cell pyknosis in the pancreas, dead 
lymphocyte debris in the thymus and spleen, and erosion and bleeding in the stomach. The 
pathological changes induced by AZA were stated to be unique from those induced by diarrhetic, 
paralytic and amnesic shellfish poisoning toxins.105 This was an important observation at the time 
before the AZAs were identified as a new toxin class. 
8.2. Toxicology study – AZA1, -2, -3 and -6
The LD50 of AZA1, -2, -3 and -6 toxins was estimated by using both response surface analysis and 
survival analysis. Female NMRI mice were acclimatised for a week prior to the trial. Experiments 
were performed at the NSVS. Mice between 15 and 22 g were used and given adjusted dosages for 
20 g mice. The first level dose was administered to 3 mice, second level to 5, third level to 7 and 
fourth level to 9 mice.106 Between each dosage level the numbers of dead and live mice were used 
for adjustment of the dose for the next step.
NDP Marine Research Sub-Programme 2007-2013   
92
Clinical observations showed distinct symptoms; jumping, cramps and heavy breathing 3–5 min prior 
to death at the highest dosages. At the lower doses the animals survived but appeared to be ill; 
sweating and moving slowly, before recovering again. 
AZA1 gave an unsuspected result in that the lethality dosage described in the literature had to be 
reduced (from 200 µg/kg bw to 74 µg/kg bw). The initial dosage for AZA2 was set at 110 µg/kg bw 
and the LD50 was found to be 117 µg/kg bw. The starting dosage for AZA3 was 140 µg/kg bw with 
the LD50 determined to be 164 µg/kg bw (Table 18).
Table 18. Data on ip LD50 on NMRI-female mice and comparison with data currently applied.
Compound
*Present New study
LD50 (µg/kg) TEF LD50 (µg/kg) TEF
AZA1 200 1.0 74 1.0
AZA2 110 1.8 117 0.6
AZA3 140 1.4 164 0.5
AZA6 - - 100 0.7
*Satake et al2 (using 2 male ddY mice) for AZA1. Ofuji et al3 for AZA2 and -3. 
To confirm the results for AZA1 the experiment was repeated using male mice (Table 19).
Table 19. Data on ip LD50 on NMRI-male mice for AZA1. 
Compound 
New study
LD50 (µg/kg) TEF
AZA1 75 1.0
8.3. Pathology
A range of organs were collected in formaldehyde, either at time of death, the next day (for mice 
that died during the night) or after 24 h (for mice that survived for 24 h). Pathological changes 
were evaluated in HE-stained paraffin section. Control mice were used to verify that the changes 
observed were associated with exposure to AZAs. The pathological changes were similar for both 
AZA1 and -6.
-Liver: In the liver, single-cell necrosis (apoptosis) was observed in single cells multifocally or in small 
groups of cells. A few neutrophils were detected in relation to the necroses (Figure 48). There were 
a reduced number of mitotic figures in the liver tissue of mice exposed to AZA1 or -6.
NDP Marine Research Sub-Programme 2007-2013   
93
Figure 48. A) Liver, control. Mitotic cell bottow left, × 40 and B) Liver, AZA6. Apoptosis: cells 
with apoptotic nuclei.
-Thymus: An increased number of apoptotic bodies were observed in all areas of the thymus. In the 
controls, some apoptosis occured, but significantly less than in AZA exposed animals (Figure 49).
Figure 49. A) Thymus, control. Low apoptotic activity, × 40 and B) Thymus, AZA6. Many apoptotic 
cells (arrows).
-Spleen: In the lymphoid tissues of the spleen, an increased level of apoptotic activity was observed 
(Figure 50).
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Figure 50. A) Spleen, control. Normal lymphoid tissue, × 10 and B) Spleen, AZA6. Increased 
apoptosis (arrows).
-Intestine (duodenum, jejunum): In lymphoid tissues and in the lamina propria, exposure to AZAs 
resulted in some increased apoptosis. There was also single-cell necrosis/apoptosis in epithelial cells, 
both in the tips of villi and in crypts/glands deep in the mucosa. Additionally, there was accumulation 
of dead cells and possibly neutrophils in the crypt abscesses (Figure 51).
 
Figure 51. A) Duodenum, AZA1. Cryptabscesses, × 40 and B) Duodenum, AZA6. Apoptosis of 
epithelial cells.
Heart muscle, lungs, kidney, skin, skelatal muscle, stomach and brain did not show any obvious 
changes in mice exposed to AZA1 or -6 by ip.
8.4. Tissue analysis (LC-MS/MS)
The tissue samples were doubly extracted with 100% methanol. Organs (~0.2 g) were extracted 
with methanol (1 mL) initially by mashing with a steel rod followed by vortex mixing for 1 min. 
Samples were centrifuged at 3,000 g for 5 min and the extracts decanted into pre-weighed 
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centrifuge tubes. The remaining pellet was extracted a second time as described above. The extract 
was combined with the extract from the first extraction, with the weight of the extract and 
centrifuge tube being recorded. Extracts were filtered through a glass pipette plugged with cotton 
wool into HPLC vials for analysis by LC-MS/MS. Matrix effects were assessed on two instruments; 
a Waters 2795 coupled to a Micromass time of flight (QTof) Ultima using an acidic mobile phase 
in both isocratic and gradient modes; and on a Waters 2695 coupled to a Micromass triple stage 
quadrapole (TSQ) using the same acidic gradient method employed on the QTof. Previous studies 
have shown that matrix effects can differ between instruments.85 Both matrix suppression and 
enhancement were observed depending on the tissue type, with the most significant interferences 
occurring on the TSQ instrument (Figure 52). The least amount of interferences were obtained 
using the isocratic method on the QTof. Hence this method was used to quantitate the toxin 
concentrations in the various tissues.
AZAs were detected in all tissues, with low levels recorded in the brain, urine and some of the 
feaces samples. The highest levels were detected in the lung, liver, spleen and kidney (Figure 53). 
Recoveries ranged from 12–37%, with the exception of AZA3 (2.8 µg dose, mouse still alive 
following 24 h) which gave a recovery of 2%. This may be due to the fact that AZA3 is significantly 
less stable than AZA1 and -212 and may therefore be more prone to metabolic processes. 
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Figure 52. Matrix effects observed for AZA1, -2 and -3 in mouse tissues (SSR 10).
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#condition of mouse (live or dead) following 24 h. 
* % of toxin detected in tissues relative to dose amount.
Figure 53. Distribution of toxins in mouse (ip) tissues.
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9. Mouse oral study
9.1. Introduction
Due to the lack of purified AZAs, limited studies on their acute oral toxicity have been performed. 
Previous studies focused only on AZA1. These studies found that the GI tract, liver, spleen and 
thymus were the main organs affected.21–24,29,107
In the original studies, crude extracts of AZA1 (>900 µg/kg) were given orally to mice via gastric 
intubation.105 Mice receiving moderate oral doses of AZA1 (100–300 µg/kg) generally display little 
to no signs of toxicity.22,23 However, mice surviving higher doses (420–780 µg/kg) developed dose- 
and time-dependent signs and symptoms of toxicity (i.e., depression and reduced movement) but 
without indications of diarrhea. After 24 h, all surviving mice were greatly depressed and did not 
move from sternal recumbency (i.e., remained lying down on chest).29 Similarly, many mice receiving 
low (20 or 50 µg/kg), repeated (>30) doses of AZA1 exhibited extreme weakness that necessitated 
them being sacrificed in order to prevent further suffering. Repeated doses of 1 or 5 µg/kg did not 
induce weakness or illness.24 
At 6 times the ip injected dose that induced 100% mortality, all mice survived with no clinical signs 
after 24 h. Subsequent studies using purified material have further detailed the effects of AZA1 on 
mice following oral exposure.21–23,29 Studies by Ito et al.21 using male ICR mice orally administered 
single doses of AZA1 ranging from 300 to 900 µg/kg demonstrated the lethal nature of AZA1, 
whereby all mice receiving 900 µg/kg AZA1 had to be sacrificed prior to the end of the 24 h 
experiment. Although there was not a clear dose-response, likely due to insufficient experimental 
replicates, an approximate oral minimum lethal dose with purified AZA1 was estimated at 
500 µg/kg. Similarly, separate studies by Aasen et al.22 and Aune et al.29 using female NMRI mice 
demonstrated that doses of 100–540 µg/kg were insufficient to kill any of the tested animals but 
doses above 600 µg/kg resulted in some mortality. The experimentally determined LD10 and LD50 
levels (with 95% confidence intervals) were 570 (435–735) and 775 (596–1,055) µg/kg, respectively.29 
In another series of in vivo exposure studies, mice were orally administered low, repeated doses of 
AZA1 (1–50 µg/kg) and then monitored for recovery.24 Ten percent of the mice survived the 40 
repeated injections at the highest dose (50 µg/kg), as the other 90% were sacrificed due to extreme 
weakness, and 30% of the mice in the 20 µg/kg treatment group were also sacrificed early. 
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In separate experiments, severe injuries were induced by two repeated doses of 250, 300, 350, or 
450 µg/kg, two days apart, and recovery was monitored for up to 90 days. Of the 16 mice receiving 
450 µg/kg, 11 died prior to the second dose, suggesting a revised minimum oral lethal dose of 
<450 µg/kg. In fact, some mice died at 250 and 300 µg/kg, but only two replicate mice were available 
for each dose. 
The most common pathological effect of AZA1 following oral exposure is degradation of the lining 
surrounding the upper small intestine.21,22,24,29 Single dose studies in mice examined 24 h following 
oral intubation of AZA1 (100–300 µg/kg) clearly demonstrated shortened villia, elongated crypts, 
and exfoliation of epithelial layer in villi along the lumen of the duodenum.22 In addition, there were 
indications of edema, hyperemia, infiltration of neutrophils (>5-fold more than controls), and single 
cell necrosis/apoptosis with apoptotic bodies in the lamina propria.22,29 These pathological effects 
were dose-dependent but were completely healed after 7 days recovery. 
Similarly, Ito et al.21 observed sporadic degeneration and erosion of the small intestinal microvilli, 
vacuole degeneration in epithelial cells, and atrophy of the lamina propria at 4 h following exposure 
to 300 µg/kg AZA1. Higher doses of AZA1 (500–700 µg/kg) revealed progressive intestinal erosion 
at 8 h and continued atrophy of the lamina propria at 24 h. However, at 24 h there were fewer 
degenerating epithelial cells in the microvilli, suggesting some signs of recovery. Compared to mice 
orally exposed to OA, the damage elicited by AZA1 was slower in onset with much longer times 
required for recovery.21 
Despite known uptake and systemic distribution of AZA1 following oral exposure, only limited and 
less severe histopathological changes were observed in other internal organs/tissues. The stomach, 
which has consistently been shown to contain the highest AZA concentrations following oral 
exposure22, was pathologically normal. However, there was a dramatic increase in food retention 
suggesting localized constipation.22,29 Moderate doses of AZA1 (100–300 µg/kg) resulted in the liver 
being abnormally pale in coloration29, which may be the result of fatty acid droplet accumulation.21 
Higher doses (500–700 µg/kg) increased liver weight by 38%. There were time- and dose-dependent 
effects on the number of necrotic lymphocytes in the thymus, spleen, and the Peyer’s patches 
of the small intestine, which was supported by quantitation of the number of non-granulocytes 
(lymphocytes, monocytes, macrophages) in the spleen. AZA1 treatments of 600 and 700 µg/
kg resulted in a 33% decrease in the number of non-granulocytes, which were primarily T and B 
lymphocytes.21 There were no reported histological changes associated with the kidney, heart, lung, 
and brain.21,22,29 
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9.2. Toxicology study – AZA1, -2, -3 
9.2.1. Experimental method
Female CD-1 mice (18–20 g) were acclimatized for 2 weeks prior to the trial. Experiments were 
carried out at the University of Trieste. AZA1, -2 and -3, dissolved in PBS pH 7.0 containing 1.8 % 
ethanol, were administered by gavage to groups of 8 mice fasted for 3 h (administered volume: 
10 mL/kg) at the following dose ranges: 135–1,100 µg/kg for AZA1; 300–1,100 µg/kg for AZA2 and 
-3. Control mice were administered with the vehicle alone (10 mL/kg). Signs of toxicity and lethality 
were recorded for 24 h (time of sacrifice), and up to 14 days for subgroups of surviving mice. After 
24 h, animals were weighed and anesthetized by ip injection of tiletamine/zolazepam (Zoletil®; 
Milan, Italy; 20 mg/kg) and xylazine (Virbac, Milan, Italy; 5 mg/kg). Blood samples were collected 
from the abdominal aorta for hematochemical determinations (AST; ALT; GLDH; CPK; creatinine; 
sodium ions; potassium ions; calcium ions; chloride ions; inorganic phosphate (Pi)). Animals were 
then exsanguinated and the main organs were removed and fixed in neutral buffered 10% formalin 
for the histological evaluation. Similarly, animals that died during the observation period were 
immediately weighed and necropsied; the main organs and tissues were removed and fixed for the 
histological evaluation, while blood was collected for hematological analyses. The LD50 values based 
on 24 h mortality data, were calculated according to the Finney method108 at a 95% CL.
9.2.2. Lethality
At 24 h, lethality was noted starting at 230 µg/kg (2/16 mice; AZA1), 500 µg/kg (3/16 mice, AZA2) 
and 650 µg/kg (1/16 mice, AZA3). Furthermore, only 8 mice administered with AZA1 (300–850 µg/
kg) died between 24 and 48 h (Tables 20–22). At 24 h, the LD50 values were 443 µg/kg (95% CL: 
350–561 µg/kg), 626 µg/kg (95% CL: 430–911 µg/kg) and 875 µg/kg (95% CL: 757–1,010 µg/kg), 
respectively. The toxic potency is AZA1 > AZA2 > AZA3 and TEFs, based on LD50, are 1.0 (AZA1), 
0.7 (AZA2) and 0.5 (AZA3) (Table 23). 
Symptoms observed in mice treated with each toxin were immobility, tremors, abdominal breathing, 
hypothermia and cyanosis. Jumping was observed at doses ≥850 µg/kg of AZA3; no mouse 
developed diarrhoea. No symptoms were recorded in mice that survived for 14 days following the 
treatment. In these animals, food consumption and body weight were recorded daily and were 
similar to those of control mice. 
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Table 20. Lethality and survival times of mice treated with AZA1.
Dose
(mg/kg)
At 
24 h
After 
24 h
Total Survival times (h:min)
135 0/16 0/16 0/16 --
175 0/16 0/16 0/16 --
230 2/16 0/16 2/16 23:42-23:49
300 4/16 2/16 6/16 11:55-14:54-17:56-22:44-24:26-24:44
390 11/16 2/16 13/16 12:08-12:55-10:27-11:41-19:00-20:45-20:50-20:5121:36-
22:03-22:48-26:48-29:12
500 12/16 0/16 12/16 08:30-09:26-10:16-11:49-11:54-12:44-12:56-13:33-14:12-
20:46-20:47-22:54
650 5/8 2/8 7/8 08:22-08:38-09:47-10:26-10:57-23:24:15-24:23
850 5/8 2/8 7/8 00:23-00:30-09:21-10:44-13:19-25:59-26:31
1,100 8/8 0/8 8/8 00:56-01:19-01:35-03:19-03:36-06:39-08:33-09:01
 
Table 21. Lethality and survival times of mice treated with AZA2.
Dose
(mg/kg)
At 
24 h
After 
24 h Total Survival times (h:min)
300 0/16 0/16 0/16 --
390 0/16 0/16 0/16 --
500 3/16 0/16 3/16 09:47-21:05-21:50
650 13/16 0/16 13/16 13:20-16:20-16:30-17:23-18:55-19:23-20:43-20:47-21:00-
21:56-22:40-22:48-23:07
850 11/16 0/16 11/16 07:45-10:24-12:39-14:25-15:10-16:09-17:31-19:40-19:44-
22:10-23:11
1,100 16/16 0/16 16/16 01:38-05:03-09:15-09:45-11:03-11:40-11:58-12:40-13:17-15:05-16:10-17:20-17:22-20:37-20:55-23:42
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Table 22. Lethality and survival times of mice treated with AZA3.
Dose
(mg/kg)
At 
24 h
After 
24 h
Total Survival times (h:min)
300 0/16 0/16 0/16 --
390 0/16 0/16 0/16 --
500 0/16 0/16 0/16 --
650 1/16 0/16 1/16 01:37
850 11/16 0/16 11/16 00:54-00:58-01:09-01:23-01:44-02:05-02:10-02:23-02:23-
22:06-23:40
1,100 12/16 0/16 12/16 00:28-00:29-00:45-00:46-00:55-00:58-01:09-01:17-01:45-
11:12-14:35-19:06
 
Table 23. LD50 of AZA1, -2 and -3 in CD-1-female mice at 24 h after acute oral administration.
Compound LD50 (mg/kg) TEF
AZA1 443 1.0
AZA2 626 0.7
AZA3 875 0.5
9.3. Pathology and hematochemistry
Necropsy showed the presence of macroscopic alterations only in spontaneously dead mice or in 
those sacrificed at 24 h. Pale liver was noted in mice that died more than 5 h after the treatment, 
or sacrificed after 24 h, at the doses ≥175 µg/kg (AZA1), ≥500 µg/kg (AZA2) and ≥650 µg/kg 
(AZA3). At lethal doses, increased gas and gastric content in the stomach, sometimes associated 
with redness of the gastric wall, was observed. Furthermore, at these doses, dilation of the small 
intestine and fluid content, sometimes associated with redness of the intestinal wall and bloody 
fluid content, were also observed (Figure 54). In mice that survived after AZAs administration and 
sacrificed after 14 days, gross pathology did not reveal the presence of macroscopic alterations in 
comparison to controls. 
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Control AZA1 230 µg/kg
Figure 54. Liver and GI tract of a control mouse in comparison to those observed in a mouse 
treated with AZA1 (230 µg/kg).
Hematochemical analysis results are reported in Tables 24–29. Mice that died within 24 h or 
sacrificed at 24 h showed a marked increase in serum levels of transaminases (ALT and AST) and 
GLDH indicating hepatic damage (also evident by necropsy). This effect was recorded at all the 
administered toxin doses. 
AZA1 induced a 423% increase of ALT at the lowest dose (135 µg/kg) and up to 3,510% at the dose 
of 650 µg/kg. The increase of AST level ranged from 93% (135 µg/kg) and 1,600% (500 µg/kg), while 
GLDH ranged from 595% (135 µg/kg) and 7,263% (650 µg/kg). 
AZA2 (300–1,100 µg/kg) induced ALT serum level increases from 376% (300 µg/kg) to 2,416% 
(850 µg/kg); the increase of AST and GLDH levels were in the ranges of 314–3,498 % (390–850 µg/
kg) and 356–5,379% (300–850 µg/kg), respectively. 
AZA3 (300–1,100 µg/kg) increased serum levels of ALT, AST and GLDH up to 487% (1,100 µg/kg), 
430% (850 µg/kg) and 418% (500 µg/kg), respectively (Tables 24–26). 
In addition, a moderate to marked increase in serum levels of K+ ions was recorded in mice 
administered with all the three AZAs. In AZA1 treated mice, a significant increase (18 to 80%) was 
recorded at the dose of 500 µg/kg and above. At the same dose range, an increase from 31% to 53% 
was observed for AZA2, while AZA3 treated mice showed a slightly lower increase (from 11 to 22%). 
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No significant changes in other hematochemical parameters were recorded within 24 h after AZA 
administration (Tables 24–26). At the end of the recovery period (14 days) no significant differences 
in hematochemical parameters were recorded compared with the controls (Tables 27–29). 
In conclusion, single oral administration of AZA1, -2 and -3 to mice induced lethality, with a potency 
AZA1 > AZA2 > AZA3: from the LD50 values, the relevant TEFs were 1.0 (AZA1), 0.7 (AZA2) and 
0.5 (AZA3). Moreover, although macroscopic alterations were observed starting from the doses of 
175 µg/kg (AZA1), 500 µg/kg (AZA2) and 650 µg/kg (AZA3), hematological examination showed 
significant changes in some enzymes indicative of liver injury at the lowest administered dose of each 
toxin (135 µg/kg of AZA1 and 300 µg/kg of AZA2 or -3).   
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Table 25. Hematochemical parameters of mice within 24 h after AZA2 administration.
Parameter Controls
Mean ± S.E.
(n = 5)
AZA2 300 
mg/kg
Mean ± S.E.
(n = 5)
AZA2 390 
mg/kg
Mean ± S.E.
(n = 5)
AZA2 500 
mg/kg
Mean ± S.E.
(n = 5)
AZA2 650 
mg/kg
Mean ± S.E.
(n = 4)
AZA2 850 
mg/kg
Mean ± S.E.
(n = 4)
AZA2 1,100 
mg/kg
Mean ± S.E.
(n = 7)
ALT (IU/l) 75.6 ± 15.9 360.2 ± 118.5*
(376 %)
361.8 ± 50.3*
(379 %)
1,456.4 ± 
513.5*
(1826 %)
1,690.3 ± 
133.5*
(2136 %)
1,902.0 ± 
176.5*
(2416 %)
1,535.4 ± 132.6*
(1931 %)
AST (IU/l) 155.8 ± 28.6 723.4 ± 159.2*
(364 %)
645.6 ± 59.3*
(314 %)
1,809.2 ± 
508.3*
(1061 %)
2,763.3 ± 
386.8*
(1674 %)
5,606.0 ± 
340.9*
(3498 %)
3,201.0 ± 629.2*
(1955 %)
GLDH (IU/l) 24.6 ± 3.0 112.2 ± 37.5*
(356 %)
114.6 ± 19.5*
(366 %)
628.3 ± 211.8*
(2454 %)
470.1 ± 51.8*
(1811 %)
1,347.8 ± 
389.0*
(5379 %)
1,025.0 ± 113.6*
(4067 %)
CPK (IU/l) 2,068.8 ± 429.9 3,073.8 ± 637.3
(49 %)
3,262.0 ± 584.8
(58 %)
3,301.2 ± 616.0
(60 %)
3,659.5 ± 947.2
(77 %)
3,155.8 ± 387.7
(53 %)
3,625.7 ± 690.8
(75 %)
C r e a t i n i n e 
(mg/dl)
24.2 ± 1.2 26.4 ± 1.3
(9 %)
23.2 ± 0.4
(4 %)
22.6 ± 2.6
(- 7 %)
23.8 ± 1.3
(- 2 %)
24.3 ± 0.9
(1 %)
26.1 ± 0.7
(8 %)
Ca2+ (mM) 2.7 ± 0.1 2.9 ± 0.1
(7 %)
2.9 ± 0.1
(7 %)
2.7 ± 0.1
(0 %)
2.8 ± 0.2
(4 %)
2.8 ± 0.1
(4 %)
2.6 ± 0.1
(- 4 %)
Na+ (mM) 134.5 ± 1.6 134.1 ± 1.3
(- 1 %)
138.0 ± 1.8
(3 %)
136.5 ± 0.7
(1 %)
123.1 ± 7.1
(- 8 %)
133.1 ± 2.7
(- 1 %)
1,334.4 ± 1.5
(- 1 %)
K+ (mM) 6.8 ± 0.4 7.2 ± 1.6
(6 %)
7.6 ± 0.4
(12 %)
8.9 ± 0.8*
(31 %)
10.4 ± 0.8*
(53 %)
9.6 ± 1.0*
(41 %)
10.0 ± 0.9*
(47 %)
Cl- (mM) 102.5 ± 1.5 102.9 ± 1.7
(1 %)
105.6 ± 2.0
(3 %)
103.2 ± 1.1
(1 %)
96.3 ± 3.9
(- 6 %)
103.9 ± 0.4
(1 %)
103.5 ± 1.2
(1 %)
Pi (mM) 3.3 ± 0.1 3.8 ± 0.4
(15 %)
3.6 ± 0.2
(9 %)
3.5 ± 0.4
(6 %)
4.0 ± 0.7
(21 %)
3.9 ± 0.4
(18 %)
3.5 ± 0.3
(6 %)
*p<0.05 at the analysis of variance with respect to controls; in brackets the percent difference with respect to controls.
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Table 26. Hematochemical parameters of mice within 24 h after AZA3 administration.
Parameter
Controls
Mean ± S.E.
(n = 5)
AZA3 300 
mg/kg
Mean ± S.E.
(n = 5)
AZA3 390 
mg/kg
Mean ± S.E.
(n = 5)
AZA3 500 
mg/kg
Mean ± S.E.
(n = 5)
AZA3 650 
mg/kg
Mean ± S.E.
(n = 4)
AZA3 850 
mg/kg
Mean ± S.E.
(n = 6)
AZA3 1,100 
mg/kg
Mean ± S.E.
(n = 7)
ALT (IU/l) 124.8 ± 17.7 418.0 ± 63.2*
(235 %)
686.0 ± 86.5*
(450 %)
549.0 ± 130.2*
(340 %)
378.5 ± 69.6*
(203 %)
673.2 ± 182.9*
(439 %)
733.2 ± 172.0*
(487 %)
AST (IU/l) 202.0 ± 43.8 367.0 ± 19.4*
(82 %)
632.2 ± 105.4*
(213 %)
371.2 ± 53.7*
(84 %)
369.5 ± 36.7*
(83 %)
1071.2 ± 
332.2*
(430 %)
848.4 ± 230.1*
(320 %)
GLDH (IU/l) 47.7 ± 9.9 161.3 ± 32.7*
(238 %)
205.2 ± 51.4*
(330 %)
246.9 ± 64.3*
(418 %)
168.3 ± 12.7*
(253 %)
114.7 ± 18.3*
(140 %)
223.5 ± 70.6*
(369 %)
CPK (IU/l) 2,583.6 ± 489.9 1,947.7 ± 351.7
(- 25 %)
4,103.8 ± 707.5
(59 %)
2,990.8 ± 626.1
(16 %)
3,472.0 ± 
1134.7
(34 %)
3,357.8 ± 785.4
(30 %)
3,186.7 ± 828.1
(23 %)
C r e a t i n i n e 
(mg/dl)
25.4 ± 0.7 24.8 ± 0.4
(- 2 %)
24.4 ± 1.9
(4 %)
24.8 ± 0.8
(- 2 %)
24.3 ± 0.2
(- 4 %)
26.8 ± 1.0
(6 %)
25.4 ± 0.9
(0 %)
Ca2+ (mM) 2.4 ± 0.1 2.6 ± 0.1
(8 %)
2.6 ± 0.1
(8 %)
2.6 ± 0.1
(8 %)
2.7 ± 0.2
(12 %)
2.7 ± 0.2
(12 %)
2.6 ± 0.1
(8 %)
Na+ (mM) 132.5 ± 1.7 132.5 ± 1.3
(0 %)
131.7 ± 1.1
(- 1 %)
131.3 ± 1.5
(1 %)
133.6 ± 1.6
(1 %)
135.6 ± 1.2
(2 %)
134.7 ± 2.1
(2 %)
K+ (mM) 7.3 ± 0.2 8.8 ± 0.8
(21 %)
8.2 ± 0.5
(12 %)
8.7 ± 0.6*
(19 %)
8.9 ± 0.6*
(22 %)
8.9 ± 0.4*
(22 %)
8.1 ± 0.3*
(11 %)
Cl- (mM) 100.6 ± 1.8 102.6 ± 1.2
(2 %)
101.4 ± 0.7
(1 %)
99.7 ± 0.6
(- 1 %)
103.1 ± 1.1
(2 %)
103.9 ± 0.7
(3 %)
104.1 ± 1.0
(3 %)
Pi (mM) 3.0 ± 0.1 3.1 ± 0.1
(3 %)
3.3 ± 0.2
(10 %)
3.5 ± 0.4
(17 %)
3.2 ± 0.2
(7 %)
3.4 ± 0.3
(13 %)
3.1 ± 0.1
(3 %)
*p<0.05 at the analysis of variance with respect to controls; in brackets the percent difference with respect to controls.
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Table 27. Hematochemical parameters of mice at 14 days after AZA1 administration.
Parameter
Controls
Mean ± S.E.
(n = 3)
AZA1 135 mg/kg
Mean ± S.E.
(n = 3)
AZA1 175 mg/kg
Mean ± S.E.
( n = 3)
AZA1 230 mg/kg
Mean ± S.E.
(n = 3)
AZA1 300 mg/kg
(n = 1)
AZA1 390 mg/kg
(n = 1)
AZA1 500 mg/kg
(n = 1)
ALT (IU/l) 26.7 ± 4.6
35.3 ± 6.4
(32 %)
37.3 ± 8.1
(40 %) 43.0 ± 10.4(61 %)
32.0
(20 %)
33.0
(24 %)
51.0
(91 %)
AST (IU/l) 118.7 ± 44.8 129.0 ± 24.9(9 %)
165.3 ± 17.9
(39 %) 150.3 ± 8.2(27 %)
146.0
(23 %)
98.0
(- 17 %)
108.0
(- 9 %)
GLDH (IU/l) 20.4 ± 7.8
18.3 ± 5.3
(- 10 %)
22.5 ± 7.2
(10 %) 21.5 ± 2.0(5 %)
19.2
(- 6 %)
20.2
(- 1 %)
18.3
(- 10 %)
CPK (IU/l) 1492.7 ± 370.3
1213.7 ± 485.0
(- 19 %)
1903.3 ± 125.6
(28 %) 1547.7 ± 306.6(4 %)
1907.0
(28 %)
1235.0
(- 17 %)
1276.0
(- 15 %)
Creatinine (mg/
dl) 28.0 ± 1.2
26.7 ± 1.5
(- 5 %)
27.7 ± 0.3
(1 %) 29.0 ± 0.6(4 %)
26.0
(- 7 %)
28.0
(0 %)
24.0
(- 14 %)
Ca2+ (mM) 2.5 ± 0.1 2.4 ± 0.1(- 4 %)
2.4 ± 0.1
(4 %) 2.5 ± 0.1(0 %)
2.5
(0 %)
2.5
(0 %)
2.5
(0 %)
Na+ (mM) 128.9 ± 1.3 132.0 ± 1.2(2 %)
133.6 ± 2.0
(4 %) 133.8 ± 2.6(4 %)
128.0
(- 1 %)
128.5
(- 1 %)
134.4
(4 %)
K+ (mM) 6.0 ± 0.6 6.3 ± 0.4(5 %)
6.9 ± 0.8
(15 %) 7.2 ± 0.8(20 %)
7.3
(22 %)
6.3
(5 %)
7.1
(18 %)
Cl- (mM) 100.6 ± 1.6 104.9 ± 1.5(4 %)
102.6 ± 1.8
(2 %) 104.5 ± 1.8(4 %)
98.6
(- 2 %)
99.5
(- 1 %)
105.2
(5 %)
Pi (mM) 2.9 ± 0.3 2.8 ± 0.3(- 3 %)
2.7 ± 0.3
(- 7 %)
2.9 ± 0.1
(0 %)
3.2
(10 %)
2.9
(0 %)
2.6
(- 10 %)
In brackets: percent differences with respect to controls (no significant differences at the analysis of variance). 
NDP Marine Research Sub-Programme 2007-2013   
110
Table 28. Hematochemical parameters of mice at 14 days after AZA2 administration.
Parameter
Controls
Mean ± S.E.
(n = 3)
AZA2 300 mg/kg
Mean ± S.E.
(n = 3)
AZA2 390 mg/kg
Mean ± S.E.
( n = 3)
AZA2 500 mg/kg
Mean
(n = 2)
AZA2 650 mg/kg
Mean ± S.E.
(n = 3)
AZA2 850 mg/kg
(n = 1)
AZA2 500 mg/kg
(n = 0)
ALT (IU/l) 112.3 ± 27.4 161.0 ± 64.0(43 %)
127.7 ± 30.7
(14 %)
78.0
(- 31 %)
166.0 ± 33.7
(48 %)
165.0
(47 %) --
AST (IU/l) 184.7 ± 46.2 266.0 ± 59.2(44 %)
209.7 ± 67.8
(14 %)
114.0
(- 38 %)
221.0 ± 38.8
(20 %)
235.0
(27 %) --
GLDH (IU/l) 31.4 ± 4.0 41.6 ± 15.2(32 %)
18.7 ± 3.2
(- 40 %)
24.5
(- 22 %)
29.9 ± 4.9
(5 %)
34.6
(10 %) --
CPK (IU/l) 1,389.3 ± 351.9
1,380.0 ± 380.8
(- 1 %)
1,342.0 ± 286.7
(- 3 %)
783.0
(- 44 %)
1,717.3 ± 398.9
(24 %)
1,405.0
(1 %) --
Creatinine (mg/dl) 25.0 ± 1.2
26.0 ± 1.5
(4 %)
27.0 ± 2.1
(8 %)
26.0
(4 %)
28.0 ± 1.7
(12 %)
26.0
(4 %) --
Ca2+ (mM) 2.8 ± 0.1 2.6 ± 0.2(- 7 %)
2.6 ± 0.1
(- 7 %)
2.6
(- 7 %)
2.6 ± 0.1
(- 7 %)
2.7
(4 %) --
Na+ (mM) 141.6 ± 0.9 138.9 ± 1.1(- 2 %)
138.2 ± 2.3
(- 2 %)
140.8
(- 1 %)
138.7 ± 1.4
(- 2 %)
139.8
(- 1 %) --
K+ (mM) 6.4 ± 0.3 6.6 ± 0.4(3 %)
7.1 ± 0.5
(11 %)
6.4
(0 %)
6.5 ± 0.2
(2 %)
6.7
(5 %) --
Cl- (mM) 108.0 ± 1.2 108.7 ± 0.5(1 %)
105.1 ± 1.7
(- 3 %)
106.9
(- 1 %)
106.3 ± 0.6
(- 2 %)
106.8
(- 1 %) --
Pi (mM) 3.0 ± 0.1 2.9 ± 0.1(- 3 %)
2.9 ± 0.1
(- 3 %)
2.8
(- 7%)
2.8 ± 0.1
(- 7 %)
3.0
(0 %) --
In brackets: percent differences with respect to controls (no significant differences at the analysis of variance).
NDP Marine Research Sub-Programme 2007-2013   
111
Table 29. Hematochemical parameters of mice at 14 days after AZA3 administration.
Parameter
Controls
Mean ± S.E.
(n = 3)
AZA3 300 mg/kg
Mean ± S.E.
(n = 3)
AZA3 390 mg/kg
Mean ± S.E.
( n = 3)
AZA3 500 mg/kg
Mean ± S.E.
(n = 3)
AZA3 650 mg/kg
Mean ± S.E.
(n = 3)
AZA3 850 mg/kg
Mean ± S.E.
(n = 3)
AZA3 500 mg/kg
(n = 1)
ALT (IU/l) 112.3 ± 27.4
112.3 ± 42.9
(0 %)
187.3 ± 105.2
(67 %) 192.3 ± 79.1(71 %)
162.0 ± 38.7
(44 %)
128.5 ± 17.5
(14 %)
85.0
(- 24 %)
AST (IU/l) 184.7 ± 46.2 211.7 ± 53.1(15 %)
183.0 ± 40.3
(- 1 %) 271.0 ± 46.7(47 %)
218.7 ± 47.0
(18 %)
209.0 ± 12.0
(14 %)
147.0
(- 20 %)
GLDH (IU/l) 31.4 ± 4.0
22.2 ± 5.7
(- 29 %)
35.4 ± 10.0
(11 %) 45.3 ± 13.1(44 %)
45.9 ± 19.0
(46 %)
35.6 ± 11.9
(13 %)
23.4
(- 25 %)
CPK (IU/l) 1,389.3 ± 351.9
1,914.0 ± 589.6
(38 %)
1,491.3 ± 749.5
(7 %) 1,701.0 ± 268.2(86 %)
769.0 ± 320.8
(- 45 %)
1,310.5 ± 312.5
(- 6 %)
998.0
(- 28 %)
Creatinine (mg/dl) 25.0 ± 1.2
27.0 ± 1.5
(8 %)
27.7 ± 0.9
(11 %) 28.3 ± 2.2(13 %)
27.3 ± 2.2
(9 %)
26.0 ± 2.0
(4 %)
28.0
(12 %)
Ca2+ (mM) 2.8 ± 0.1 2.7 ± 0.1(- 4 %)
2.8 ± 0.1
(0 %) 2.7 ± 0.1(1 4 %)
2.6 ± 0.1
(- 7 %)
2.8 ± 0.1
(0 %)
2.9
(4 %)
Na+ (mM) 141.6 ± 0.9 136.3 ± 2.8(- 4 %)
140.1 ± 1.2
(- 1 %) 137.0 ± 2.5(- 3 %)
138.8 ± 1.8
(- 2 %)
138.0 ± 1.1
(- 3 %)
134.7
(- 5 %)
K+ (mM) 6.4 ± 0.3 7.4 ± 0.8(16 %)
7.9 ± 1.1
(23 %) 6.9 ± 0.1(8 %)
7.5 ± 0.7
(17 %)
7.3 ± 0.4
(14 %)
6.8
(6 %)
Cl- (mM) 108.0 ± 1.2 105.1 ± 1.7(- 3 %)
105.4 ± 0.8
(- 2 %) 105.3 ± 2.3(- 2 %)
105.4 ± 0.6
(- 2 %)
105.7 ± 0.8
(- 2 %)
102.6
(- 5 %)
Pi (mM) 3.0 ± 0.1 2.8 ± 0.3(- 7 %)
2.8 ± 0.1
(- 7 %)
2.9 ± 0.2
(- 3 %)
2.6 ± 0.2
(- 13 %)
3.1 ± 0.1
(3 %)
3.2
(7 %)
In brackets: percent differences with respect to controls (no significant differences at the analysis of variance). 
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9.4. Tissue analysis (LC-MS/MS)
AZA1, -2 and -3 mouse tissues for each dose were extracted and analysed as outlined in section 8.4. 
Preliminary results (n=2) show that AZAs were detected in all tissues with very low levels or none at 
all detected in the brain. The results for the dose of 300 µg/kg are shown in Figure 55.  A preliminary 
evaluation of the AZA distribution in the main internal organs of mice was performed 24 h after gavage 
(or at the time of death for some mice) and after 14 days of recovery. At 24 h, the highest levels of 
AZAs were found in the stomach, and in descending order, in the intestinal content, liver, small intestine, 
kidneys, lungs, large intestine, heart and brain. Recoveries ranged from ~6–23% for AZA1, ~4–19% 
for AZA2 and were lower for AZA3 (~2–8%) after 24 h (Table 30). A dose-dependency in AZAs 
absorption from the GI tract was observed. After 14 days (at doses of 300 or 500 µg/kg), only AZA1 
and -2 levels in the internal organs were still detectable, with a total recovery lower than 3% (Table 30).
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Figure 55. Distribution of AZA1, -2 and -3 in mouse tissues (n=2) after 24 h following oral 
administration at a dosage of 6 µg (300 µg/kg). 
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Table 30. LC-MS analysis (recoveries) of AZAs in mouse tissues following oral administration.
Replicate
Dose (µg/kg) 135 175 230 300 390 500
AZA1
Dose 
(µg/kg)Toxin AZA1 AZA1 AZA1 AZA1 AZA1 AZA1
Death time 24 h 24 h 24 h 24 h 20.5 h 14.2 h 14 d
1 % recovery 6.5 7.7 10.5 18.9 14.9 15.2 1.3 300
Death time 24 h 24 h 24 h 24.4 h 23.5 h 12.6 h 14 d
2 % recovery 16.3 7.2 7.0 23.1 5.8 14.3 2.2 390
Replicate
Dose (µg/kg) 300 390 500 650 850 1100
AZA2
Dose 
(µg/kg)Toxin AZA2 AZA2 AZA2 AZA2 AZA2 AZA2
Death time 24 h 24 h 24 h 24 h 22.1 h 5.03 h 14d
1 % recovery 5.8 18.5 18.7 19.3 14.8 19.5 1.6 500
Death time 24 h 24 h 24 h 20.5 h 23.1 h 20.5 h 14d
2 % recovery 5.4 4.1 8.6 15.4 11.3 14.2 0.7 300
Replicate
Dose (µg/kg) 300 390 500 650 850 1100
AZA3
Dose 
(µg/kg)Toxin AZA3 AZA3 AZA3 AZA3 AZA3 AZA3
Death time 24 h 24 h 24 h 24 h 24 h 0.5 h 14d
1 % recovery 7.3 8.1 3.5 5.2 2.3 16.3 0 500
Death time 24 h 24 h 24 h 20.5 h 1.2 h 0.5 h 14d
2 % recovery 4.1 6.3 7.2 3.6 15.9 33.8 0 300
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10. Combined toxicities (oral mouse)
10.1. Introduction
When assessing toxin profiles in shellfish, it is not uncommon to find the presence of multiple algal toxin 
classes. As such, there is increasing concern about the potential toxicological effects of mixtures of 
these various toxins towards human and environmental health - particularly if these toxin combinations 
prove to behave synergistically. Regarding the AZA class, it is not uncommon to find these toxins in 
shellfish that are also contaminated with PTX, YTX, and/or the OA group toxins. 
The first attempts to address these questions were performed in vivo using mice orally exposed to 
AZA1 and PTX2. Although combined exposures of PTX2 (5 mg/kg) and AZA1 (200 µg/kg) did not 
elicit any clinical symptoms in mice, there was a substantial increase in the absorption/distribution 
of PTX2 in mice exposed to PTX2/AZA1 versus PTX2 alone. This was particularly evident in the 
lung, blood, spleen, kidney, and liver.109 The combination also induced a slightly greater degree of 
pathological change in the small intestine (i.e., enhanced edema in the lamina propria and fusion of 
villi) but not in any other tissue/organ. 
10.2. AZA1 and OA combined study
Among the lipophilic marine algal toxins in shellfish currently regulated in the EU, toxins from the 
OA and AZA groups pose the largest threat to consumers.32,110 These toxins regularly co-occur 
in Irish shellfish.5 They cause considerable negative health effects in consumers when present in 
shellfish above certain levels. The main symptoms, dominated by diarrhoea, are caused by damage to 
the GI tract. Even though OA and AZAs exert toxicity via different mechanisms, it is important to 
find out whether they may enhance the health effects if present together, since they act on the same 
organs and are regulated individually. 
The main issue in this study was the possibility of enhanced lethality in mice upon combined oral 
exposure to OA and AZA, which had not been studied previously. The pathological effects in 
several organs and effects on absorption from the GI tract were also studied. 
The experiment was performed in two parts. The first part was designed to determine the LD10 
and LD50 of both OA and AZA1 individually. The second part focused on combined toxicity with the 
three doses 0, LD10 and LD50 for each of the two toxins OA and AZA (Table 31). 
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Table 31. Combinations of dosing and ideal number of mice needed. Bold number indicates the 
combinations that were carried out in the current study and numbers in italics indicate previously 
covered.
OA Toxin
0 LD10 LD50
AZA1 Toxin
0 3 3 3
LD10 3 4 4
LD50 3 3 3
The LD10 and LD50 for OA were determined to be ~780 mg/kg bw and 880 mg/kg bw respectively 
while for AZA1 they were ~570 mg/kg bw and 775 mg/kg bw, respectively.
No increases in pathological changes were observed in mice exposed to combinations of AZA1 
and OA. The combination influenced absorption from the GI tract; absorption was reduced 
considerably for both toxins. This may be caused by competition for the simple diffusion of weak 
organic acids across the membranes of the GI tract. The lack of pathological effects outside the 
GI tract corresponds well to the low degree of absorption observed for OA and AZA1 when 
administered separately.
Figure 56. Concentrations and distribution of AZA1 (by LC-MS/MS) in ng/g in tissues of female 
NMRI mice, after oral exposure at different dose levels of AZAs.
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Figure 57. Concentrations of AZA1 (by LC-MS/MS) in ng/g in tissues of female NMRI mice, when 
given alone at 570 µg/kg and in combination with 780 and 880 µg/kg OA.
In conclusion, the present results indicate that combined exposure to AZA1 and OA does not lead 
to enhanced acute oral toxicity compared to the toxic effects from exposure to the same toxins 
when administered separately. Consequently, regulation of toxins from these two groups, based on 
maximum tolerance levels for each group, appears to be valid.
10.3. AZA1 and YTX combined study
YTX and its analogues are produced by the dinoflagellate algae Protoceratium reticulatum111,112, 
Lingulodinium polyedrum113 and Gonyaulax spinifera.114 Although they have not been reported in Irish 
shellfish5 they have been found in shellfish from many other countries, including Japan, New Zealand, 
Australia, Canada, Italy, France, Norway and the United Kingdom.115,116 For many years, the presence 
of YTXs in shellfish has resulted in positive mouse bioassays leading to the closure of shellfisheries. 
Since YTXs do not appear to cause diarrhoea in humans and exert low oral toxicity in animal 
experiments, it has been suggested that they should be removed from regulation. Before doing so, 
it is important to determine whether the oral toxicity of YTXs is enhanced when present together 
with shellfish toxins known to cause damage to the GI tract. 
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Yessotoxin was given by gavage to mice at 1 or 5 mg/kg, either alone or in combination with AZA1 
at 200 mg/kg (a level that causes damage to the small intestine22). One group of mice received 
200 mg/kg AZA1 alone while a group of control mice were given vehicle only. Each mouse was 
dosed a volume of 250 mL per 20 g bw. The groups consisted of three mice except the control 
group which consisted of six mice. All mice were sacrificed after 24 h.
In the study YTX levels in internal organs were very low, suggesting that only a small proportion of 
YTX is transported across the intestinal barrier. The total fraction of YTX in the internal organs 
measured by LC-MS/MS accounted for less than 0.1% of the administered dose. Most of the YTX 
was recovered from the lower intestine and the faeces, while only trace amounts were found in 
blood, urine and tissues (R. Munday, AgResearch, Hamilton, New Zealand, unpublished results). The 
level of YTX in the stomach was ~2-fold higher when YTX was given in combination with AZA1, 
compared to when YTX was given alone.23 Since the stomach contents were removed before 
the toxin level was measured, a distinction between toxin levels in the stomach contents and the 
stomach wall could not be made. The observed increase in retention of the stomach contents, 
suggest an inhibitory effect of AZA1 on the motility of the stomach and duodenum, which would 
extend the period of high YTX levels in the stomach. Another possible explanation is that the 
combination induced absorption of YTX into the stomach wall, but this is less likely since such an 
absorption ought to have resulted in higher toxin levels in the liver and/or other internal organs. 
However, since the YTX concentration in the distal parts of the intestines was similar to when 
YTX was given alone (Figure 58), it seems that the motility of the stomach and intestines is not 
severely inhibited due to AZA1 but rather slowed. It may be assumed that the part of the intestine 
with pathological changes has been exposed to a substantial amount of YTX. The concentrations of 
AZA1 found in the different tissues when given in combination with YTX were similar to the levels 
when AZA1 was given alone at 200 mg/kg (Figure 59). 
These results were also similar to those obtained in Aasen et al. (2010) for AZA1 at 200 mg/
kg.22 Consequently, YTX does not seem to influence the absorption of AZA1. In mice exposed 
to a combination of AZA1 and YTX, the pathological changes in the intestine were similar to 
the changes caused by AZA1 alone. The damage to the intestine did not appear to increase the 
absorption of YTX as shown by the quantitation of YTX in blood and internal organs by LC-MS/
MS. The levels found in the blood by LC-MS/MS corresponded with the levels reported by Tubaro 
et al. (2008).117 The low YTX levels in the internal organs were consistent with the histological 
investigations by light microscopy showing normal morphology in the same organ. 
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In conclusion, 5 mg/kg YTX, either alone or together with AZA1 at 200 mg/kg does not lead to 
enhanced absorption of YTX nor to toxic effects in the heart or other internal organs.
Figure 58. Concentrations of YTX (by LC-MS/MS) in µg/kg in tissues of female NMRI mice, when 
given alone at 5 mg/kg and in combination with 200 µg/kg AZA1.
Figure 59. Concentrations of AZA1 in µg/kg in tissues of female NMRI mice after dosing of 200 µg/
kg AZA1 alone and in combination with 1 mg/kg and 5 mg/kg YTX.
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11. Cellular and molecular studies of AZA 
toxicology
11.1. Introduction
Preliminary experiments performed by Flanagan et al.118–120 using HepG2 hepatoblastoma cells and 
human bladder carcinoma cells (ECV-304) exposed to contaminated crude mussel extracts showed 
AZAs to have a cytotoxic effect. In the ASTOX project, cellular and molecular studies were 
designed to investigate the mode of action underlying the toxicity of AZAs. Studies conducted on 
seven different mammalian cell lines showed that AZAs strongly affect most cell types. A functional 
assay was developed in the ASTOX project for the specific detection of AZAs using morphological 
changes of pseudopodia in lymphocyte T cells (Jurkat). It was subsequently found to be the most 
sensitive for AZAs of all the assays tested.11
During the many cytotoxicity experiments used to assess AZA toxicity, a variety of morphological 
effects were observed. In T lymphocytes, cells initially responded to AZA1 by a reduction in 
membrane integrity, organelle protrusion concurrent with flattening of cells, and a retraction of 
their pseudopodia or lamellipodia.27 This was followed by protracted cell lysis. In leukemia cells, 
AZA2 caused DNA synthesis phase arrest.10 In neuroblastoma cells, AZA1 induced cell rounding 
and detachment from adjacent cells.26 At the subcellular level, disruption of the Golgi complex and 
an accumulation of vesicles have been reported.121 At the cellular level, AZA1, -2, and two other 
semi-synthetic analogues of AZA2 all induced gross morphological changes.122 AZA1 is a potent 
cytotoxin towards primary CGCs123, neocortical cells124, and spinal cord neurons.31 In CGCs, AZA-
induced cytotoxicity was related to the activation of the c-Jun-N-terminal (JNK) kinase125,126, whereby 
AZA1 exposure resulted in decreased neuronal volume that was protected by pre-incubation of the 
neurons with a JNK inhibitor (SP 600125), a chloride channel blocker (4,4-diisothiocyanatostilbene-
2,2-disulfonic acid; DIDS), and a Na+-K+-ATPase blocker (amiloride).125,127 The effects of AZA1 and 
-2 on cytotoxicity (and other cellular indices) appear to be irreversible.26,31,122,128 Experiments using 
human breast cancer cells and mouse fibroblasts exposed to AZA1 have also demonstrated that the 
reductions in cellular proliferation and density are not unlike the actions elicited by YTX, raising the 
possibility of similar mechanisms of action for these two phycotoxin classes.25 
Other phycotoxins such as the DSP toxins are known inducers of apoptosis.130 In vivo, there is an 
indication that mice orally exposed to AZA1 exhibited pyknosis (chromatin condensation indicative 
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of apoptosis) in dead and dying lymphocyte cells within the spleen and thymus.107 However, initial 
in vitro studies were inconclusive and suggestive of necrotic lysis. These observations were made 
based on cytotoxic morphological observations27, the absence of mitochondrial membrane potential 
changes in neuroblastoma cells129, and the absence of a sub-G1 populuation in leukemia cells exposed 
to AZA2.
There are ample data available that suggest the AZA toxins alter ion flux in various cell types. 
The AZAs have been shown to alter intracellular calcium flux124,129,131,132, proton homeostasis133, 
and membrane hyperpolarization.127 In CGCs, anion channel blockers and ouabain greatly 
ameliorated the cytotoxic effect of AZA1 in immature neurons and completely eliminated 
it in older cultures.127 Furthermore, short exposures of cultured neurons to AZA1 caused a 
significant decrease in neuronal volume that was reduced by pre-incubation of the neurons with 
4,4-diisothiocyanatostilbene-2,2-disulfonic acid (DIDS; a chloride channel blocker) or amiloride 
(Na+-K+-ATPase blocker).126 In neocortical neurons, VGSCs, NMDA, glutamate receptors, and 
L-type Ca2+ channels were ruled out as potential targets for AZA1-induced neurotoxicity, which 
is consistent with earlier reports that demonstrated AZA1 did not affect VGSC or voltage-
gated calcium channel currents.31 Although AZA1 did not alter membrane potential in SH-SY5Y 
neuroblastoma cells, a plethora of proteins related to ion/anion channels were differentially 
expressed.121 
11.2. AZA1, -2 and -3 relative potencies using the Jurkat T 
lymphocyte cell assay
The relative potencies of various AZA analogues were assessed using the Jurkat T lymphocyte cell 
assay. This cell line exhibited suitable sensitivity to AZA111,27, hence, was the natural choice for a 
model system to perform these comparative experiments. 
Results of the metabolically-based cytotoxicity assays for the Jurkat cells exposed to AZA1, -2, and 
-3 are shown in Figure 60 where all exposures were performed for 24 h, 48 h, and 72 h. AZA1, -2, 
and -3 each exhibited a cytotoxic response that was both concentration- and time- dependent, with 
EC50 values in the low or sub-nanomolar range (Table 11). Based on curve shift analysis and EC50 
comparisons, the order of in vitro potency is as follows: AZA2 > AZA3 > AZA1. Relative to AZA1, 
-2 and -3 are 8.3-fold and 4.5-fold more potent, respectively. The order of relative in vitro potencies 
is the same as the corresponding in vivo results reported by Satake et al (1998)2 and Ofuji et al 
(1999)3 (based on minimal lethal concentrations); however, the in vivo studies suggest less drastic 
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potency differences between these three AZA analogues (up to 1.5-fold). The potencies of other 
AZA analogues are detailed in Section 6.6.5, see also Table 11.
Figure 60. Effect of various AZA analogues on cell viability. Lymphocyte T cells were exposed to 
A) AZA1, B) AZA2 and C) AZA3 for 24, 48 and 72 h and viability was assessed using the MTS assay. 
All data (mean ± SE; n=3) were normalized to the control (0 M AZA1). Non-linear three parameter 
dose response (variable slope) analysis with calculated EC50 values are shown in Table 11.
The data generated by the above cytotoxicity assays effectively confirm the sensitivity of the Jurkat 
T lymphocyte cell line to AZA1, -2, and -3 at low nanomolar to sub-nanomolar concentrations. In 
order to further characterize the mechanism(s) of action of AZAs, the morphological effects of 
these three AZA analogues on Jurkat cells were assessed. 
Results of these experiments are illustrated in Figure 61. Corroborating the metabolic-based 
cytotoxicity data, these images suggest that AZA1, -2, and -3 are each cytotoxic to Jurkat T 
lymhocyte cells resulting in time-dependent cell lysis. Similar to previous findings and published 
reports for AZA127,134 time-dependent withdrawl/retraction of pseudopodia with a concurrent 
rounding of the outer cell surface was observed. However, exposure of Jurkat cells to AZA2 
and -3 did not have these same specific effects on pseudopodia. These outcomes have also been 
confirmed at higher concentrations (data not shown). For AZA2 and -3, cells appeared to expand 
in size (particularly when imaged using Nomarski differential interference contrast optics: Figure 61 
(left panel), while retaining their normal morphological characteristics (i.e., cell shape, pseudopodia 
extensions) over the duration of the exposure (72 h). These data may represent evidence for 
differences between the AZA analogues in the cell signaling pathways and the mechanism(s) of 
action involved in their induction of cytotoxicity and other downstream effects.
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Figure 61. Effects of AZA1, -2 and -3 on the morphology of Jurkat lymphocyte T cells. Cells were 
exposed to methanol (control), AZA1 (5 nM), AZA2 (0.5 nM) and AZA3 (1 nM) for 24, 48 and 72 h. 
Cells were then imaged using Nomarksi differential interference contrast (DIC).
11.3. AZA induced cell lysis via apoptosis
Experiments focusing on the mechanism of cell lysis by assessing the effects of AZA1 on caspase 
activity in Jurkat lymphocyte T cells were performed. Caspases are endonuclease suicidal enzymes 
involved in lysing DNA during PCD. The data illustrate that AZA1 up-regulates the effector caspase, 
caspase 3/7, at 48 and 72 h for all concentrations tested (Figure 63). Caspase 2 is also up-regulated 
at 48 h following treatment with 10 and 95 nM. There is also an indication that caspase 10 is slightly 
up-regulated under these same conditions. Collectively, these enzyme activity data suggest that 
apoptosis is an active process in Jurkat T lymphyocyte cells exposed to AZA1. 
To confirm the effects of AZA1 on the up-regulation of caspases, the effects of AZA1, -2, and -3 on 
DNA fragmentation were assessed. Fragmentation of DNA is a hallmark of PCD that is observed 
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towards the latter part of the process. It is clear in Figure 62 that AZA1, -2, and -3 each cause a 
laddering effect on the DNA fragementation pattern of Jurkat cells exposed to AZAs for 48 and 
72 h. Positive controls DTX2 and camptothecin also cause a similar fragmentation pattern starting 
at earlier time points. The effects of the AZAs, DTX2, and camptothecin on DNA fragmentation 
contrast the control cells (methanol control) where no DNA fragmentation was observed across all 
time points.
These data collectively support the finding that AZA-induced cell lysis is via an apoptotic 
pathway(s).135
Figure 62. Effects of AZA1, -2 and -3 on DNA fragmentation in Jurkat cells. Cells were exposed 
for A) 12 h, B) 24 h, C) 48 h and D) 72 h.
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Figure 63. Relative change in the activity of seven different caspases in Jurkat cells exposed to 1, 10, 
and 95 nM AZA1 concentrations for A) 24 h, B) 48 h, and C) 72 h. Camptothesin (1 µM) serves as 
positive control.
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11.4. Mode of action studies
The proposed mode of action for the AZAs is inhibition of the cholesterol synthesis pathway.134 
It was sought to test this mechanism by supplying extracellular cholesterol and other cholesterol 
biosynthetic substrates to Jurkat T lymphocyte cells concurrently exposed to AZA1. If the 
toxicological mechanism of AZA1 was via inhibition of this pathway, supplying cholesterol to the 
cells should rescue the cells from AZA-induced cytotoxicity. This hypothesis was extensively tested 
using various forms of cholesterol as well as four metabolic intermediates and failed to show any 
indication that the cells were being rescued (data not shown). This finding suggests that AZA1 
is not inhibiting cholesterol biosynthesis within T lymphocytes, at least to the extent of causing 
cytotoxicity. 
To further explore AZA’s mechanism(s) of action, AZAs were screened against >100 common drug 
targets. These included 40 kinases, 2 phosphatases, 76 GPCR, and 8 ion channels. To maximize 
the chances of success (in the event of different targets for the different AZA analogues), these 
targets were screened using a mixture of the AZAs (51.6% AZA1, 20.6% AZA2, 19.7% AZA3, and 
8.0% AZA6). All targets were tested in duplicate at a single AZAtotal concentration. As illustrated 
in Figure 64 the activity of all tested kinases was not altered in the presence of 348 nM AZAtotal 
and thus did not cause a response/change. Similarly, and in support of the published literature, the 
two tested phosphatases were also not altered.8,27,120 Furthermore, the AZA mixture did not have 
any major effects on the activation or inhibition of GPCRs (Figure 65). In these experiments, the 
AZAtotal concentrations were 348 nM and 436 nM, respectively. Although the IP1 GPCR appears to 
be inhibited by the AZAs, follow-up studies using pure AZA1, -2, and -3 do not support this finding 
(data not shown). 
Figure 64. Effects of AZAs on kinase and phosphatase activity.
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Finally, the AZA mixture was tested against 8 various ion channels (Figure 66) and there was some 
indication that the AZAs were inhibiting the activity of the hERG potassium ion channel by 31%. The 
hERG channel is highly important in the action potentials of cardiomyocytes by mediating the ‘rapid’ 
delayed rectifier current (IKr).
136 The hERG was then tested for channel binding and activity in the 
presence of purified AZA1, -2, and -3. 
Figure 66. Effects of AZAs on ion channel activity.
In HEK-293 cells transfected with the hERG channel, patch clamp electrophysiology data were 
collected for cells exposed to various concentrations of AZA1 (Figure 67A), -2, or -3 (Figure 67B). 
Inhibition of K+ current for each AZA analogue was concentration-dependent (IC50 value range: 
640–840 nM) and inhibited the channel while in its open state.137 
Transected Xenopus oocytes were then used for mutagenesis experiments. Using mutant hERG 
channels, AZA1 was shown to interact with phenylalanine at position 656 (F656), but not with 
tyrosine at position 652 (Y652), strongly suggesting that AZA1 interacts with the central pore of the 
hERG channel (Figure 68). 
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The interactions between AZAs and the hERG channel were further confirmed using a receptor 
binding assay and an ion flux assay.137
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Figure 67. AZAs block hERG1 channels expressed in HEK-293 cells. A) Representative patch clamp 
traces of potassium ion current through hERG channels stably expressed in HEK-293 cells in the 
presence of various concentrations of AZA1. B) Concentration dependent inhibition of potassium 
ion current through hERG channels by AZA1, -2 and -3.
Figure 68. Inhibition of hERG1 by AZA1 (10 µM) is attenuated by mutation of F656.
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11.5. Determination of toxin receptors
An AZA1/CM5 (i.e., AZA1 immobilized on a carboxymethyldextran surface) SPR chip was used in 
experiments to detect toxin receptors in subcellular fractions of Jurkat T lymphocyte cells, BE(2)-M17 
neuroblastoma cells, and Caco2 colorectal epithelial cells. Subcellular fractions, including cytoplasm 
(CE), membrane (ME), nuclear (NE), chromatin bound (CB), and pellet (PE) extracts, were reacted 
with the AZA1 sensor chip in order to assess binding activity. Specificity of binding was evaluated 
by comparing samples with and without free AZA1 added, which should reduce or eliminate binding 
to the chip surface if specific for the toxin. The PE fraction of Caco2 cells, containing cytoskeletal 
proteins, showed the highest level of specificity with ~70% of the binding activity eliminated by the 
addition of free AZA1; however, the absolute response was low indicating a weak interaction (Figure 
69). This result was consistent with the earlier report of cytoskeletal effects of AZA1 in mammalian 
cells.27 The highest absolute response was observed for the NE fraction, yet the binding activity was 
reduced by only ~15% with the addition of AZA1, which suggests a high level of non-specific binding. 
The ME fraction showed ~20% inhibition by AZA1 for all three cell lines tested, whereas similar 
specificity was noted for the CE and CB fractions of BE(2)-17 and Caco2 cells, respectively. Overall, 
all three cell lines showed fractions that bound AZA1 with a range of specificities. Selected fractions 
will be further processed using an AZA1 immunoaffinity column in order to isolate specific binding 
partner(s) for AZA1, followed by identification using LC-MS/MS and de novo sequencing.
Figure 69. SPR results for Caco 2 cell lysate samples (40 µg/mL) from subcellular fractions with and 
without AZA1 (100 ng/mL), and containing 2 mg/mL NSB (i.e., non-specific binding) reducer.
11.6. Radiolabelling
Approximately 300 µg of AZA1 was hydrogenated (cold) in a reaction using Brown’s catalyst. 
The singly and doubly hydrogenated products were subsequently purified using semi-preparative 
chromatography. The predominant product was the doubly hydrogenated AZA1 (m/z 846). 
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Table 32. Quantities of AZA1 reduced products in sample after hydrogenation reaction.
m/z 842 µg m/z 844 µg m/z 846 µg
AZA1 Hydrogenated sample 2.5 17.2 61.8
The MS spectra for both the singly (m/z 844) and doubly (m/z 846) hydrogenated compounds lacked 
the RDA cleavage products indicating that the C7–C8 double bond was reduced. NMR confirmed 
the doubly hydrogenated compound to be 4,5,7,8-tetrahydroAZA (Figure 70).
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Figure 70. Structures of AZA1 (m/z 842), 7,8-dihydroAZA1 (m/z 844) and the NMR elucidated 
structure of 4,5,7,8-tetrahydroAZA1 (m/z 846).
Using the Jurkat lymphocyte T cytotoxicity assay both hydrogenated forms of AZA1 induced 
time- and concentration-dependent cytotoxicity (Figure 71). Mean EC50 values were 0.99 nM 
(7,8-dihydroAZA1) and 4.58 nM (4,5,7,8-tetrahydroAZA1). Relative to AZA1, comparable potencies 
were 1.4 and 0.3; respectively. 
Figure 71. Cytotoxicity of two hydrogenated AZA1 analogues (Jurkat). 
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The success of the cold reaction and the fact that the products were biologically active permitted 
the progression to reacting AZA1 with tritium (hot). Purified AZA1 (1 mg) was reacted with tritium 
resulting in a radioactivity reading of ~60 mCi. However, the reaction did not go to completion 
(Figure 72).
Figure 72. MS peaks of AZA1 sample following tritium reaction.
The reaction was repeated using 1 mg of AZA1, this time reacting for longer with higher levels of 
hydrogen gas resulting in a radioactivity reading of 98 mCi (Figure 73).
Figure 73. MS peaks of AZA1 sample following 2nd tritium reaction.
The reacted samples require further analysis by LC-MS/MS using a more refined method to better 
indicate structural changes and purities. Purification will also be required prior to biological testing.
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12. Conclusions
The prevelance of AZA accumulation in shellfish appears to be increasing with greater intensity, 
not only in Ireland, but also globally. There continues to be human poisoning events associated with 
AZAs and their occurrence has been most problematic for the Irish shellfish industry.
Over the course of the ASTOX 2 project, a diverse and complex profile of the phytoplankton 
associated with this toxin group has emerged. Apart from A. spinosum, 10 additional Azadinium and 
related species were identified, some of which do not appear to produce any AZAs, while others 
are producers of novel AZAs. 
Feeding studies with A. spinosum showed that mussels will feed directly on these organisms with 
no requirement for a vector species. Mussels reached the regulatory limit after 5 days, however, 
the high concentrations observed in the wild could not be replicated under laboratory conditions. 
This may indicate: (i) that vectors are required to facilitate shellfish toxin accumulation (e.g., Favella 
ehrenbergii which has been shown to actively feed on A. spinosum); (ii) longer term feeding trials are 
required or (iii) other variables, as yet unknown, contribute to high uptake of toxins. The laboratory 
studies also showed that A. spinosum has a negative effect on shellfish in terms of mortality rates, 
feeding behaviour and physiology. Additionally, these studies showed that mussels take up AZAs 
from the dissolved phase and therefore the release of AZAs from decaying blooms may also have 
consequences for other species, not normally associated with these toxins.
From a monitoring standpoint, the development of a molecular probe capable of distinguishing 
between A. spinosum, A. obesum and A. poporum will contribute significantly to the toxin monitoring 
programme at the Marine Institute, enabling more effective observation and forecasting of blooms, 
which otherwise were difficult to detect. Further benefits for the monitoring programme arising 
from the project are the production of sustained supplies of CRMs. Bulk culturing of the producing 
organisms and improvements in isolation procedures have enabled more effective purification of 
a range of AZA analogues. The availability of these toxins has allowed the relevance of analogues 
to be established, in terms of proportions and toxicity. However, further research is still required, 
particulary for the novel analogues.
The heat-induced transformation of AZA17 and -19 into AZA3 and -6, respectively, was confirmed 
in the project. Using the RMs produced, the relevance of some of the minor and novel AZAs 
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were determined, highlighting AZA6 as a potential significant contributor to overall toxicty. The 
other purified analogues for which RMs were prepared were found to be of less significance. The 
importance of other novel AZA analogues identified in the project, such as those which lack a 
methyl group in the amino ring, have yet to be established.
The in vitro and in vivo toxicity studies performed confirmed AZA toxicity. Although the mini pigs 
were less susceptible to AZAs than humans, the studies showed that AZAs cross the intestinal 
barrier and distribute throughout the body causing internal organ damage at cellular and tissue 
levels. The results from the oral and ip mice studies correlated very well, contradicting previous 
reports and showing that AZA1 is more toxic than AZA2 and -3. These results were reflected 
in the analysis of the mini pig blood samples that showed AZA1 is most rapidly taken up into the 
blood, followed by AZA2 and then -3. Studies looking at the combined effects of AZA1 with OA 
and YTX showed that there is no increased toxicity when these groups co-occur. The in vitro studies 
were effectively used to assess the toxicity of the minor analogues and demonstrated the following 
potencies: AZA2 > AZA6 > AZA34 ≈ 37-epi-AZA1 > AZA8 ≈ AZA3 > AZA1 > AZA4 ≈ AZA9 > 
AZA5 ≈ AZA10 > AZA33 ≈ AZA36 > AZA37 > AZA26.
One of the remaining questions prior to the ASTOX 2 project concerned the mode of action of 
AZAs. Such knowledge is necessary for confirming or changing the regulatory limits, and also for 
development of treatments following exposure to AZAs. Experiments performed as part of the 
project led to the discovery that AZAs are potassium channel blockers, however the concentrations 
required to induce such effects are 2-fold those required to cause cytotoxicity and therefore 
this is not considered to be the primary mode of action. Hence other modes of action need to 
be explored and it is likely that the various analogues may exhibit unique modes of action and/
or receptors. Finally, the understanding of the main molecular mechanisms could also lead to the 
production of rapid, receptor-based toxin screening assays.
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13. Implications for monitoring programmes
 • The project yielded new knowledge regarding monitoring and forecasting
 The availability of bulk cultures of the producing organisms and isolation of sufficient 
stocks of AZA1, -2 and -3 for the preparation of CRMs will ensure that Ireland will 
maintain effective monitoring programmes.
 The development of a molecular probe to detect these organisms (A. spinosum,  
A. poporum and A. obesum) in water samples will ensure effective monitoring and 
contribute to the provision of an early warning system for Ireland’s shellfish industry. 
• Toxicity and cooking studies indicated that the current regulatory limit may be 
sufficiently low and that the EFSA recommendation to reduce the current limit may be 
unnecessary. 
 In vivo studies looking at the combined effects of AZAs with OA and YTXs have 
shown that there are no synergistic effects.
 Studies performed in ASTOX and ASTOX 2 have shown that the levels of AZAs 
can increase significantly after cooking due to a concentration effect17,18 and toxin 
conversions.74,84 As the concentrations of AZA3 and -6 are negligible in raw mussels, 
yet can increase significantly through decarboxylation of AZA17 and -19 during the 
cooking of mussels84, the overall concentrations are underestimated by methods 
used according to current legislation. However, as no cases of human intoxications 
have been reported from shellfish, which would have been over the limit had the 
shellfish been cooked prior to analysis, indicates that the current regulatory limit is 
appropriate.
 Only miminal effects were observed in pigs after feeding with high doses of AZAs. 
However, the results suggest that the pig-model may not be the most appropriate 
model in which to assess the potential impact of AZAs in humans. 
 Studies mimicking the digestive process and its effects on AZAs indicate that AZAs 
are less bioavailable when shellfish are cooked thereby rendering them ‘less toxic’.
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14. Recommendations
Based on the findings of the ASTOX 2 project, it is recommended that a review of the current 
regulatory method and limit for AZAs is undertaken. 
• This will entail the introduction of a cooking step in the method for the analysis of 
shellfish by LC-MS/MS
 The knowledge of toxin transformations (e.g., AZA17 to AZA3) suggests that 
a heating step should be introduced into the analysis of raw shellfish to more 
accurately reflect toxin profiles, thereby enhancing human health protection 
and preventing loss of valuable processed product due to rejection by importing 
countries. 
• A change in the current regulation is recommended to provide for the inclusion of AZA6 
in the legislation
 Feeding and cooking studies have shown that AZA6 (after heat induced conversion 
from AZA19) can reach concentrations more than twice that of AZA2 in some 
samples and is therefore more significant than previously thought. In vivo toxicology 
analysis indicates that this analogue is slightly less toxic than AZA1, while in vitro 
analysis indicates 5-fold greater potency.
• It is recommended that the TEFs for AZA2 and -3 be amended
 The results from both the oral and the ip mouse studies performed in ASTOX 
2 confirmed the toxicity of AZAs with very good correlation. Compared to the 
previous studies, (Satake et al2 and Ofuji et al3) on which the current TEFs are based, 
AZA1 was found to be more toxic than AZA2 and -3. 
 Analysis of blood samples taken from AZA1 dosed mini pigs showed that AZA1 is 
taken up faster into the blood, followed by AZA2 and then -3.
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15. Future research
Impact of novel AZA producers
An assessment of the relevance of the additional species/toxins to the shellfish industry and human 
health is required. Mapping of these species using gene probes at sea, and development of in situ 
biosensors for temporal studies in aquaculture areas could be performed incorporating some of the 
approaches of the ASIMUTH139 project in developing an early warning system.
Adverse effects of A. spinosum on shellfish and other species
The adverse effects of A. spinosum on mussel larvae/eggs needs to be investigated further. 
Additionally studies looking at the impact of dissolved AZAs in the water on other species should 
be performed (e.g., AZAs found in periwinkles and have been shown to have adverse effects on fish 
embryo development).
Vector/mitigation studies
It is still not fully understood how mussels may become so highly contaminated in the field. 
ASTOX 2 studies have shown only limited accumulation occurs when mussels are fed A. 
spinosum. Additionally, the shellfish are adversely affected by this species. Knowledge of feed and 
environmental factors and what additional vectors could be involved would aid in developing 
mitigation strategies.
Toxicology 
AZAs are suspected carcinogens, therefore more long term exposure studies need to be 
performed. AZA targets other than the potassium channel need to be explored. As part of the 
ASTOX 2 project a radiolabelled AZA was produced. This product now needs to be used in 
receptor binding assays which will aid in determining how these toxins interact with human cells.
Biodiscovery
There is the potential for some of the Azadinium and related species to be producers of novel 
compounds with therapeutic effects, potentially with effects antagonistic to those by AZAs. 
Metabolism studies
It is important to know how AZAs behave when consumed i.e., only accounting for less than 30% 
of what had been administered. In particular, verification of the so-called “phase II” metabolites 
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(i.e., the result of conjugation reactions generally converting lipophilic to more polar compounds 
more easily excreted as part of the detoxification process) and evaluation of their distribution and 
toxicity is required. Efforts to implement toxicokinetic/toxicodynamic (i.e., TK/TD) modeling of 
in vivo exposure data will yield a more complete conceptual framework of how organisms process 
and eliminate AZAs following exposure, with the potential for interspecies extrapolation (including 
humans). Application of ‘-omics-based strategies (i.e., genomics, transcriptomics, proteomics, 
metabolomics) in parallel with in vivo experiments (as well as in vitro models) will provide additional 
insights into the response of organisms to AZA exposure and may lead to the identification of 
biomarkers of toxin exposure, potentially useful in epidemiogical studies.
Sampling
Obtaining representative samples for analysis can be challenging and has been problematic in the 
past. There is a need to harmonise effective sampling strategies to protect consumers and limit 
losses for the shellfish industry.
Relevance of novel Azadinium species/AZA analogues for the Irish shellfish industry
The identification of new Azadinium and related species, some of which produce novel AZAs, 
warrants further research to fully assess the occurrence and impact of these additional species/AZA 
analogues in terms of prevalence and toxicity. 
Impact of Azadinium on the viability of commercial shellfish species
The exposure of mussels to A. spinosum has shown several negative effects on the viability and 
effective feeding of those mussels. Taken together with the initial studies (ASTOX) showing that 
AZAs have negative effects on the larval development of aquatic animals, these findings suggest that 
the negative impact of A. spinosum on the shellfish resource should be investigated in more depth to 
estimate the economic impact of this species on the shellfish production sector. 
Impact of AZAs on other species
The knowledge of potential uptake from the dissolved phase suggests that the impact and necessity 
for monitoring of AZAs in species, not normally associated with AZA accumulation, should be 
investigated.
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Epidemiology data
From the standpoint of risk assessment and risk management, there is a clear need for additional 
epidemiological data given that all of the information available to date is based on only seven human 
poisoning events. Additionally, it should be noted that all six risk assessments have been based on 
a single, albeit well-described, poisoning incident—the 1997 incident on Arranmore Island, Ireland. 
There is a need to have strategies in place in the event of a poisoning outbreak to acquire samples 
for analysis. Requirement for public education – to retain samples (urine, blood, etc) for analysis and 
also to retain leftover shellfish (that led to illness). 
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